var title_f37_3_37936="Nonpupil-sparing 3rd nerve palsy";
var content_f37_3_37936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nonpupil-sparing third nerve palsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right mydriasis in a patient with a right third nerve palsy secondary to a posterior communicating aneurysm. The patient also had a mild ptosis and complained of diplopia with reduced adduction, elevation, and depression of the right eye. Abduction and intorsion were normal in the right eye.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37936=[""].join("\n");
var outline_f37_3_37936=null;
var title_f37_3_37937="Alverine: International drug information";
var content_f37_3_37937=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alverine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrodog (FR);",
"     </li>",
"     <li>",
"      Spasmaverine (FR);",
"     </li>",
"     <li>",
"      Spasmine (BE);",
"     </li>",
"     <li>",
"      Spasmonal (BE, CY, GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1977655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Alverine Citrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antispasmodic Agent, Gastrointestinal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of irritable bowel syndrome and dysmenorrhea",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 60-120 mg 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule, as citrate: 60 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10515 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37937=[""].join("\n");
var outline_f37_3_37937=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303850\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977655\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977659\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977662\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977658\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821208\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977661\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10515|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37938="Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information";
var content_f37_3_37938=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate and potassium chloride (effervescent): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?21/37/22099?source=see_link\">",
"    see \"Potassium bicarbonate and potassium chloride (effervescent): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/13/23764?source=see_link\">",
"    see \"Potassium bicarbonate and potassium chloride (effervescent): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/37/22099?source=see_link\">",
"      see \"Potassium bicarbonate and potassium chloride (effervescent): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral (doses listed as mEq of",
"     <b>",
"      potassium",
"     </b>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Normal daily requirement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 40-80 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of hypokalemia during diuretic therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-2 mEq/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 25-100 mEq/day in 2-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet for solution, oral [effervescent]: Potassium chloride 25 mEq [potassium bicarbonate 0.5 g and potassium chloride 1.5 g]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1032137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dissolve tablets in 3-4 ounces cold water or juice; solution should be sipped slowly, over 5-10 minutes; administer with meals",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1032130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F211733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the potassium supplement; severe renal impairment, untreated Addison's disease, heat cramps, hyperkalemia, severe tissue trauma",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4603404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with cardiac and/or renal disease, patients receiving potassium-sparing drugs",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, glucose, chloride, pH, urine output (if indicated)",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4603405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypokalemia is highly arrhythmogenic, particularly in the setting of ischemia or digitalis toxicity. ECG evidence of hypokalemia includes flattening of the T wave. As the T wave shrinks, U waves may appear. There is no prolongation of the QT interval. Hyperkalemia may present as tall peaked symmetrical T waves. S-T elevation may present in severe hyperkalemia. QRS complex progressively widens with eventual apparent sine waves on the ECG. Hyperkalemia will also induce cardiac slowing and AV conduction abnormalities.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13035 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.150.3.100-D7E3B57AC3-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37938=[""].join("\n");
var outline_f37_3_37938=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032113\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032133\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211703\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211689\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032137\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032130\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032114\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211733\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032117\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603404\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299914\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211697\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211699\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287298\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032139\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4603405\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/37/22099?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?23/13/23764?source=related_link\">",
"      Potassium bicarbonate and potassium chloride (effervescent): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37939="Superficial spreading melanoma 4";
var content_f37_3_37939=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial spreading melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lesion is asymmetric, and presents border irregularity, color variegation, and a nodular component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37939=[""].join("\n");
var outline_f37_3_37939=null;
var title_f37_3_37940="Potassium phosphate and sodium phosphate: Pediatric drug information";
var content_f37_3_37940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium phosphate and sodium phosphate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?7/17/7444?source=see_link\">",
"    see \"Potassium phosphate and sodium phosphate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/24/24964?source=see_link\">",
"    see \"Potassium phosphate and sodium phosphate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Phos&reg; MF;",
"     </li>",
"     <li>",
"      K-Phos&reg; Neutral;",
"     </li>",
"     <li>",
"      K-Phos&reg; No. 2;",
"     </li>",
"     <li>",
"      Phos-NaK;",
"     </li>",
"     <li>",
"      Phospha 250&trade; Neutral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Phosphate Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Potassium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sodium Salt",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of potassium when determining the appropriate phosphate replacement.",
"     <b>",
"      Phosphorus Estimated Average Requirement (EAR)",
"     </b>",
"     : Oral: 3.2 mmol/day (adequate intake)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/17/7444?source=see_link\">",
"      see \"Potassium phosphate and sodium phosphate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Consider the contribution of sodium and potassium cations when determining appropriate phosphate replacement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Phosphorus-Recommended Daily Allowance (RDA) and Estimated Average Requirement (EAR)",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 3.2 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 8.9 mmol/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 14.8 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 12.3 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 16.1 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 13.1 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 40.3 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 34 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-30 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     RDA: 22.6 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     EAR: 18.7 mmol/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Maintenance:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2-3 mmol/kg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 50-150 mmol/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Supplementation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Phos&reg; Neutral, Phospha 250&trade; Neutral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &gt;4 years and Adolescents: 1 tablet 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 1-2 tablets 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-NaK:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 4-8 years: 1 packet 2 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;9 years, Adolescents, and Adults: 1 packet 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Urinary acidification:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Packets are",
"     <b>",
"      not",
"     </b>",
"     an appropriate substitution for this indication due to the higher potassium content.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     K-Phos&reg; MF: 2 tablets 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     K-Phos&reg; No. 2: 1 tablet 4 times/day; may administer 1 tablet every 2 hours (maximum: 8 tablets/24 hours) when urine is difficult to acidify",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phos-NaK: Dibasic potassium phosphate, monobasic potassium phosphate, dibasic sodium phosphate, and monobasic sodium phosphate per packet (100s) [sugar free; equivalent to elemental phosphorus 250 mg (8 mmol), sodium 160 mg (6.9 mEq), and potassium 280 mg (7.1 mEq) per packet; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Phos&reg; MF: Potassium acid phosphate 155 mg and sodium acid phosphate 350 mg [equivalent to elemental phosphorus 125.6 mg (4 mmol), sodium 67 mg (2.9 mEq), and potassium 44.5 mg (1.1 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Phos&reg; Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Phos&reg; No. 2: Potassium acid phosphate 305 mg and sodium acid phosphate 700 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 134 mg (5.8 mEq), and potassium 88 mg (2.3 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Phospha 250&trade; Neutral: Monobasic potassium phosphate 155 mg, dibasic sodium phosphate 852 mg, and monobasic sodium phosphate 130 mg [equivalent to elemental phosphorus 250 mg (8 mmol), sodium 298 mg (13 mEq), and potassium 45 mg (1.1 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1032559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Administer with food to reduce the risk of diarrhea; contents of 1 packet should be diluted in 75 mL water or juice before administration; administer tablets with a full glass of water; maintain adequate fluid intake; dilute oral solution with an equal volume of cool water",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3458484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and prevention of hypophosphatemia (FDA approved in ages &ge;4 years and adults); urinary acidification (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       K-Phos&reg; Neutral may be confused with Neutra-Phos-K&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, bradycardia, chest pain, edema, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, mental confusion, tetany (with large doses of phosphate), seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Alkalosis, hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, flatulence, nausea, stomach pain, throat pain, vomiting, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Decreased urine output",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, bone pain, muscle cramps, pain/weakness of extremities, paralysis, paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Thirst",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to phosphate (salts) or any component; hyperphosphatemia, hyperkalemia, hypocalcemia, hypomagnesemia, hypernatremia, severe renal impairment, severe tissue trauma, heat cramps, CHF, patients with phosphate kidney stones",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3458482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment, patients receiving potassium-sparing drugs (potassium salt forms), patients with adrenal insufficiency, cirrhosis",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: May enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3458483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid giving with oxalate (ie, berries, nuts, chocolate, beans, celery, tomatoes) or phytate-containing foods (ie, bran, whole wheat)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, sodium, calcium, phosphorus, renal function, reflexes",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3458487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     There is a diurnal variation with the nadir at 1100, plateau at 1600, and peak in the early evening (Gaasbeek, 2005); 1 mmol/L phosphate = 3.1 mg/dL phosphorus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Newborns: 4.2-9 mg/dL phosphorus (1.36-2.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     6 weeks to 18 months: 3.8-6.7 mg/dL phosphorus (1.23-2.16 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     18 months to 3 years: 2.9-5.9 mg/dL phosphorus (0.94-1.91 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     3-15 years: 3.6-5.6 mg/dL phosphorus (1.16-1.81 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;15 years: 2.5-5 mg/dL phosphorus (0.81-1.62 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Hypophosphatemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Moderate: 1-2 mg/dL phosphorus (0.32-0.65 mmol/L phosphate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Severe: &lt;1 mg/dL phosphorus (&lt;0.32 mmol/L phosphate)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3458485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Phosphorus is an essential mineral that is usually found in nature combined with oxygen as phosphate. It participates in bone deposition, calcium metabolism, as part of molecules that regulate many coenzymes, steps in the clotting cascade, and functions of the immune system. It is a component of the lipid  bilayer of cell membranes in the form of phospholipids and of other intracellular compounds like nucleic acids and nucleoproteins. It acts as a buffer for the maintenance of plasma and urinary pH.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F3458486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action (catharsis):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: 3-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1032552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: 1% to 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Oral forms excreted in feces",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F3458488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Each mmol of phosphate contains 31 mg elemental phosphorus; 1 mmol/L phosphate = 3.1 mg/dL phosphorus; cow&rsquo;s milk is a good source of phosphate with 1 mg elemental (0.032 mmol) phosphate per mL",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Gaasbeek A and Meinders AE, &ldquo;Hypophosphatemia: An Update on Its Etiology and Treatment,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2005, 118(10):1094-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/3/37940/abstract-text/16194637/pubmed\" id=\"16194637\" target=\"_blank\">",
"        16194637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12986 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-200.215.4.194-8300F9CC1D-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37940=[""].join("\n");
var outline_f37_3_37940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212118\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032536\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444798\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032554\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212108\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212095\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032559\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458484\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032537\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212139\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212137\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032539\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458482\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299926\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212103\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458483\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212104\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287312\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032561\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458487\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458485\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458486\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032552\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3458488\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/17/7444?source=related_link\">",
"      Potassium phosphate and sodium phosphate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/24/24964?source=related_link\">",
"      Potassium phosphate and sodium phosphate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37941="Scabies infant scalp";
var content_f37_3_37941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72616%7EPC%2F51161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72616%7EPC%2F51161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scabies, infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The rash of scabies may be more diffuse in infants, spreading to the trunk and scalp in addition to the extremities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher, GR, Ludwig, S, Baskin, MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interdigital lesions of scabies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The essential lesion is a small, erythematous, nondescript papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37941=[""].join("\n");
var outline_f37_3_37941=null;
var title_f37_3_37942="Jones fracture operative healing";
var content_f37_3_37942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Operative healing of a Jones fracture in an adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 438px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 15-year-old high-level basketball player sustained a proximal fifth metatarsal fracture at the metaphyseal-diaphyseal junction. The patient chose intramedullary screw fixation because of his desire to return to sport as promptly as possible, lessen his time in immobilization, and lessen the risk of delayed union or nonunion. A) X-ray at time of injury. B and C) After intramedullary screw fixation. (Courtesy of Keith S. Hechtman, MD.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jarvis JG, Moroz PJ. Fractures and Dislocations of the Foot. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37942=[""].join("\n");
var outline_f37_3_37942=null;
var title_f37_3_37943="Management of endometrial hyperplasia";
var content_f37_3_37943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of endometrial hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Robert L Giuntoli, II, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Howard A Zacur, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37943/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/3/37943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H364548\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia is characterized by a proliferation of endometrial glands that may progress to or coexist with endometrial cancer. Endometrial hyperplasia virtually always results from chronic estrogen stimulation unopposed by the counterbalancing effects of progesterone. Endometrial hyperplasia is treated with hysterectomy or progestin therapy.",
"   </p>",
"   <p>",
"    The classification, clinical manifestations, diagnosis, and evaluation of endometrial hyperplasia are reviewed here. Related topics can be found separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classifications, clinical manifestations, and diagnosis of endometrial hyperplasia (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link\">",
"       \"Classification and diagnosis of endometrial hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other etiologies of abnormal uterine bleeding (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/25/20887?source=see_link\">",
"       \"Initial approach to the premenopausal woman with abnormal uterine bleeding\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=see_link\">",
"       \"Postmenopausal uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Endometrial cancer (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=see_link\">",
"       \"Endometrial carcinoma: Epidemiology and risk factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610822\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of endometrial hyperplasia is guided by the risk of endometrial carcinoma. The classification system that is used most commonly is the World Health Organization system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/1\">",
"     1",
"    </a>",
"    ]. This classification system is includes four categories:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Simple without atypia",
"     </li>",
"     <li>",
"      Complex without atypia",
"     </li>",
"     <li>",
"      Simple with atypia",
"     </li>",
"     <li>",
"      Complex with atypia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The terms simple or complex refer to the",
"    <span class=\"nowrap\">",
"     glandular/stromal",
"    </span>",
"    architectural pattern. Atypia refers to nuclear atypia.",
"   </p>",
"   <p>",
"    The endometrial intraepithelial system is another classification system.",
"   </p>",
"   <p>",
"    Classification of endometrial hyperplasia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H2#H2\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Histology and classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363373\">",
"    <span class=\"h1\">",
"     MECHANISM OF PROGESTIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have consistently shown that progestins are an effective treatment of endometrial hyperplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/2-14\">",
"     2-14",
"    </a>",
"    ]. Progestins reverse endometrial hyperplasia by activation of progesterone receptors, which results in stromal decidualization and subsequent thinning of the endometrium. Progestin exposure also decreases estrogen and progesterone receptors and activates hydroxylase enzymes to convert estradiol to its less active metabolite estrone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The type of progestin, dose, and duration of treatment for endometrial hyperplasia varies widely. We recommend different treatment options depending upon the presence or absence of atypia and desire for fertility. Unlike atypia, whether the hyperplasia is described as having simple or complex architecture does not play a role in management. If regression is achieved on progestins, recurrences can be prevented by administering preventive progestin therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510482\">",
"    <span class=\"h1\">",
"     ATYPICAL HYPERPLASIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is the treatment of choice for women with endometrial hyperplasia with atypia who are not planning future pregnancy. Progestin therapy is an option for women who wish to preserve fertility or who cannot tolerate surgery.",
"   </p>",
"   <p>",
"    The recommendation for hysterectomy is based upon the high risk endometrial cancer in women with atypical endometrial hyperplasia. Many women with atypical endometrial hyperplasia diagnosed with endometrial sampling are found to have concurrent foci of endometrial cancer (17 to 52 percent) based upon data from a literature review of six studies that included 511 women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies with 19 or more years of follow-up have found that up to 29 percent of cases of atypical endometrial hyperplasia progress to endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H381678#H381678\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk of carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the high risk of coexistent endometrial cancer, prior to choosing a management approach, women with a diagnosis of atypical endometrial hyperplasia on office endometrial biopsy should undergo further evaluation with dilation and curettage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H507800#H507800\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Office endometrial biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609015\">",
"    <span class=\"h2\">",
"     Women who have completed childbearing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609148\">",
"    <span class=\"h3\">",
"     Hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with atypical endometrial hyperplasia who are postmenopausal or who are premenopausal and have completed childbearing should be treated with total extrafascial hysterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/20\">",
"     20",
"    </a>",
"    ]. Supracervical hysterectomy is not a valid option for these patients, since the potential for local extension of the endometrial neoplasia into the cervix outweighs any purported benefits of this surgical approach. During hysterectomy, intraoperative assessment of the specimen should be performed to evaluate for endometrial carcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12602?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of hysterectomy\", section on 'Total versus subtotal (supracervical)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609130\">",
"    <span class=\"h4\">",
"     Bilateral salpingo-oophorectomy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5435392\">",
"    <span class=\"h5\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;For postmenopausal women with atypical endometrial hyperplasia, we suggest hysterectomy with concomitant bilateral salpingo-oophorectomy (BSO) rather than hysterectomy alone. There are no standard recommendations regarding conserving or removing ovaries when a hysterectomy is performed for treatment of atypical endometrial hyperplasia. However, the high risk of a finding of endometrial cancer in the hysterectomy specimen in women with atypical hyperplasia (17 to 52 percent) is sufficient to make BSO a reasonable option in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/16\">",
"     16",
"    </a>",
"    ]. Endometrial cancer is associated with ovarian involvement in five percent of all cases and BSO is a standard component endometrial cancer staging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link&amp;anchor=H6#H6\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Staging and primary surgical treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, there is no reliable method of excluding endometrial malignancy intraoperatively. Gross examination and frozen section of the uterus should be performed, but these often fail to detect endometrial cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantage of performing BSO is that women who are found to have endometrial cancer in the hysterectomy specimen can potentially avoid a second procedure for removal of the ovaries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=see_link&amp;anchor=H6650537#H6650537\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Prevalence of and risk factors for nodal metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary disadvantage of routinely performing BSO in women with atypical hyperplasia is that the procedure will be unnecessary in the approximately 50 to 80 percent of women who do not have endometrial cancer. This raises a concern of whether BSO potentially exposes patients to perioperative morbidity or negative long-term health effects. These concerns are of low clinical significance, however, since BSO adds little, if any, morbidity to a hysterectomy procedure. Also, observational studies conflict regarding whether oophorectomy in postmenopausal women is associated with long-term deleterious health effects (eg, all-cause mortality, lung cancer). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=see_link&amp;anchor=H21231548#H21231548\">",
"     \"Elective oophorectomy or ovarian conservation at the time of hysterectomy\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5435400\">",
"    <span class=\"h5\">",
"     Premenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of whether the perform concomitant BSO is more challenging in premenopausal women. Compared with postmenopausal women, the risk of a synchronous primary or metastatic disease involving the ovary in premenopausal patients with endometrial cancer is significantly higher (25 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/24\">",
"     24",
"    </a>",
"    ]. However, BSO will cause premature menopause with resultant menopausal symptoms and health effects. In addition, the issue of estrogen therapy after surgical menopause remains controversial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=see_link\">",
"     \"Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women in this patient population should be counseled about the risk of endometrial cancer in the hysterectomy specimen and the potential need for BSO intraoperatively or as a subsequent procedure. If endometrial cancer is diagnosed on frozen section in a premenopausal woman, BSO should be performed as part of full surgical staging. BSO is also reasonable for women a preoperative or frozen section diagnosis of atypical hyperplasia who value avoiding reoperation (in the event the final evaluation shows endometrial cancer) more than retaining their ovaries.",
"   </p>",
"   <p>",
"    For premenopausal women with a frozen section result that is benign or shows endometrial hyperplasia without atypia, we do not perform a BSO unless there is another indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H477987\">",
"    <span class=\"h4\">",
"     Outcome and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterectomy is curative for women with endometrial hyperplasia. No further surveillance related to endometrial hyperplasia is necessary.",
"   </p>",
"   <p>",
"    Women with endometrial hyperplasia who have been treated with hysterectomy are candidates for postmenopausal hormone therapy, if there are no contraindications. This is based upon findings that post-treatment estrogen therapy is not associated with recurrence in women with endometrial cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link&amp;anchor=H25012559#H25012559\">",
"     \"Overview of endometrial carcinoma\", section on 'Postmenopausal estrogen therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H609604\">",
"    <span class=\"h2\">",
"     Women who wish to preserve fertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premenopausal women who wish to preserve fertility or women of any menopausal status who are not surgical candidates may be treated with progestin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/20\">",
"     20",
"    </a>",
"    ]. Treatment with other agents or conservative surgery is not standard clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510607\">",
"    <span class=\"h3\">",
"     Progestin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with atypical endometrial hyperplasia who wish to conserve their fertility or are not surgical candidates are treated with progestin therapy. These women must be able to comply with medical therapy and follow-up endometrial sampling. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     Megestrol acetate",
"    </a>",
"    is typically the progestin used for atypical hyperplasia because it is more potent than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA). We treat patients in this population with oral megestrol acetate 80 mg twice per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. This may be increased to 160 mg twice per day if there is no regression of the hyperplasia on follow-up endometrial sampling.",
"   </p>",
"   <p>",
"    Other options for progestin therapy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/20,25-28\">",
"     20,25-28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MPA (oral) 10 to 20 mg daily OR cyclic 12 to 14",
"      <span class=\"nowrap\">",
"       days/month",
"      </span>",
"     </li>",
"     <li>",
"      Depot medroxyprogesterone (intramuscular) 150 mg every three months",
"     </li>",
"     <li>",
"      Micronized progesterone (vaginal) 100 to 200 mg daily or cyclic 12 to 14 days per month",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       Levonorgestrel",
"      </a>",
"      -intrauterine device, duration of use one to five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H478051\">",
"    <span class=\"h4\">",
"     Outcome and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin therapy has been found to be an effective treatment for complex atypical hyperplasia in meta-analyses of observational data. One meta-analysis that included 16 studies with a total of 111 women with complex atypical hyperplasia treated with progestins found that disease was persistent in 14 percent and recurrent in 23 percent; follow-up ranged from 6 to 98 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/29\">",
"     29",
"    </a>",
"    ]. Another meta-analysis of 14 studies with a total of 151 women with complex atypical hyperplasia reported a regression rate of 86 percent, relapse rate of 26 percent, and live birth rate of 26 percent; median follow-up was 11 to 77 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometrial sampling should be repeated three months after the initiation of progestin therapy. If persistent disease is noted, the progestin dose may be increased. Sampling should be repeated again after three months. Some experts advise waiting for a withdrawal bleed before sampling, while others sample the endometrium while the patient is on progestin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study reported that the median time for regression on progestin therapy was nine months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/10\">",
"     10",
"    </a>",
"    ]. A follow-up study suggested that persistent disease at seven to nine months was predictive of treatment failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/25\">",
"     25",
"    </a>",
"    ]. Hysterectomy is recommended for treatment failures.",
"   </p>",
"   <p>",
"    Once endometrial sampling has demonstrated successful regression with no evidence of hyperplasia, we suggest that the patient actively pursue fertility options. If childbearing is delayed, we suggest maintenance progestin therapy to prevent recurrence. Various progestin preparations may be used for maintenance therapy including:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    , MPA, estrogen-progestin contraceptives, depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , or a LNG-IUD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/7-9,11,12\">",
"     7-9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients on maintenance progestin therapy, we repeat an endometrial biopsy every 6 to 12 months initially.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For premenopausal women, after one or two normal sampling results on a maintenance regimen and resumption of normal cyclic menses (or the expected menstrual pattern for depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      or the LNG-IUD), less frequent sampling is reasonable (eg, every one to two years). Hysterectomy should be performed if disease recurs or when childbearing is complete.",
"     </li>",
"     <li>",
"      For postmenopausal women, we continue sampling every 6 to 12 months indefinitely. Hysterectomy should be performed if the patient&rsquo;s health status changes and she is able to tolerate this procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510437\">",
"    <span class=\"h1\">",
"     HYPERPLASIA WITHOUT ATYPIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of progression to endometrial cancer is low for hyperplasia without atypia (&lt;1 to 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/31\">",
"     31",
"    </a>",
"    ]. The goal of treatment is to prevent progression to cancer in a small number of women and to control abnormal uterine bleeding. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=see_link&amp;anchor=H381678#H381678\">",
"     \"Classification and diagnosis of endometrial hyperplasia\", section on 'Risk of carcinoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510445\">",
"    <span class=\"h2\">",
"     Progestin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometrial hyperplasia without atypia is usually treated with progestin therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"     Medroxyprogesterone acetate",
"    </a>",
"    (MPA) is the progestin that is typically used for treatment in this patient population because there is the most clinical experience with it. We prescribe medroxyprogesterone acetate (MPA) 10 mg daily for three to six months. Most women find this continuous dosing schedule more acceptable than a cyclic regimen because they do not have cyclic vaginal bleeding during treatment.",
"   </p>",
"   <p>",
"    A cyclic regimen of MPA (eg, 10 mg daily for 12 to 14 days each month) may also be used. For cyclic progestin therapy, the schedule of therapy that is most effective is at least 12 to 14 days of therapy per month. This was reported is a series of 376 women with varying degrees of endometrial hyperplasia treated with a progestin for 7, 10, or 13 days each month for three to six months reported complete regression in 81, 98, and 100 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who experience bothersome side effects (eg, irregular vaginal bleeding, bloating, irritability, depression, headaches) from progestin therapy may require an adjustment in dose, schedule of progestin administration (continuous or cyclic), or the type of progestin.",
"   </p>",
"   <p>",
"    Other progestin preparations have also been used effectively treat endometrial hyperplasia without atypia, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Micronized progesterone (100 to 200 mg) in a vaginal cream &ndash; In one study, use of this agent from the 10th to the 25th day of the menstrual cycle for three to six months resulted in regression of endometrial hyperplasia without atypia to normal endometrium in 91 percent of women, with a relapse rate of 6 percent six months posttreatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       Levonorgestrel",
"      </a>",
"      -releasing intrauterine device (LNG-IUD) &ndash; Use of this delivery system of a progestin is especially useful for women who desire this type of contraceptive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. Endometrial biopsy can be performed with an intrauterine device in place. This was illustrated in a systematic review of 24 observational studies including 1001 women that found that treatment with device LNG-IUD compared with oral progestins had a significantly higher regression rate for complex (92 versus 66 percent) and atypical hyperplasia (90 versus 69 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Estrogen-progestin contraceptives &ndash; This is an option for women who desire these for contraception",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cannot tolerate progestins.",
"     </li>",
"     <li>",
"      Ovulation induction &ndash; In reproductive-age women, this approach will result in formation of a corpus luteum and exposure to progestins. This may be a good option for women with endometrial hyperplasia without atypia who desire pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H610857\">",
"    <span class=\"h3\">",
"     Outcome and follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression was noted in 52 of 65 patients (80 percent) with hyperplasia without atypia treated with MPA in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/5\">",
"     5",
"    </a>",
"    ]. In a cohort study of 115 women with complex hyperplasia without atypia, regression occurred in 71 percent (68 of 85) of patients treated with progestins. However, regression was also noted in 70 percent (14 of 20) women who were managed expectantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follow-up endometrial sampling should be performed to document regression to normal endometrium. We perform endometrial sampling every three to six months.",
"   </p>",
"   <p>",
"    If regression to normal endometrium does not occur after three to six months, the progestin dose may be increased or a combination of a systemic progestin and the LNG-IUD may be used.",
"   </p>",
"   <p>",
"    If atypical hyperplasia or endometrial carcinoma develops, the patient should be treated as appropriate. (See",
"    <a class=\"local\" href=\"#H510482\">",
"     'Atypical hyperplasia'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=see_link&amp;anchor=H110435224#H110435224\">",
"     \"Overview of endometrial carcinoma\", section on 'Staging and treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After treatment, we suggest initiating preventive treatment if the patient has not resumed normal cyclic menstrual function. We rebiopsy if abnormal uterine bleeding recurs.",
"   </p>",
"   <p>",
"    Preventive therapy includes regular use of a progestin. For women with chronic anovulation, such as with polycystic ovary syndrome, an estrogen-progestin contraceptive is often the best choice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Endometrial protection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative treatments for primary endometrial protection in women who cannot or prefer not to take an estrogen-progestin contraceptive include intermittent or continuous progestins. Intermittent therapy should be continued as long as chronic anovulation is present:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       Medroxyprogesterone acetate",
"      </a>",
"      (5 to 10 mg) daily for 12 to 14 days per month",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/52/16199?source=see_link\">",
"       Norethindrone acetate",
"      </a>",
"      (5 to 15 mg) daily for 12 to 14 days per month",
"     </li>",
"     <li>",
"      Micronized progesterone in a vaginal cream (200 mg) daily for 12 to 14 days per month",
"     </li>",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      (150 mg intramuscularly) every three months",
"     </li>",
"     <li>",
"      LNG-IUD, which releases 15 to 20 mcg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no strong data supporting the use of one of these regimens over another. Choice of regimen therefore depends upon patient preference, based upon factors such as cost, convenience, and side effects.",
"   </p>",
"   <p>",
"    Obese women should be encouraged to lose weight, which has multiple health benefits in addition to reduction of estradiol and estrone production by adipocytes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=see_link\">",
"     \"Health hazards associated with obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H510474\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatments other than progestins and conservative surgical treatment are under investigation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"       Danazol",
"      </a>",
"      has also been used successfully but has significant side effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/33-37\">",
"       33-37",
"      </a>",
"      ]. In a series of postmenopausal women, danazol (400 mg per day for six months) caused complete regression in only 83 percent of patients, with 8 percent relapse within four months of discontinuing therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gonadotropin-releasing hormone (GnRH) agonists or antagonists may be given to produce a pseudomenopausal state [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. In one report, approximately 86 percent of women (mean age 46 years) had regression of hyperplasia without atypia to normal endometrium after six months of GnRH agonist treatment; however, this regimen was not effective in the three women with atypia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hysteroscopic resection of endometrial hyperplasia was reported to be effective in 68 of 73 treated women, but the long term consequence of this treatment remains to be determined [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the high rate of regression, expectant management of asymptomatic women with endometrial hyperplasia without atypia has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37943/abstract/14\">",
"     14",
"    </a>",
"    ]. Reasons to use expectant management include patients with a contraindication to progestins (eg, progesterone receptor-positive breast cancer or other hormonally responsive cancer), or a patient who declines or cannot tolerate therapy. As with other women with endometrial hyperplasia, these women should undergo endometrial sampling every three to six months until normal endometrium is found. If disease persists or becomes more severe, appropriate treatment should be initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H364556\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysterectomy is the treatment of choice for women with endometrial hyperplasia with atypia who are not planning future pregnancy. (See",
"      <a class=\"local\" href=\"#H510482\">",
"       'Atypical hyperplasia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women with atypical hyperplasia, we suggest hysterectomy with concomitant bilateral salpingo-oophorectomy (BSO) rather than hysterectomy alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For premenopausal women undergoing treatment with hysterectomy, BSO is reasonable for those who value avoiding re-operation (in the event the final evaluation shows endometrial cancer) more than retaining their ovaries. (See",
"      <a class=\"local\" href=\"#H609130\">",
"       'Bilateral salpingo-oophorectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Progestin therapy is an option for women with atypical endometrial hyperplasia who wish to preserve fertility or who cannot tolerate surgery. We treat these women with oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      80 mg twice per day every day. This may be increased to 160 mg twice per day if there is no regression of the hyperplasia on follow-up endometrial sampling. Other progestin preparations may also be used. (See",
"      <a class=\"local\" href=\"#H510607\">",
"       'Progestin therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest progestins rather than surgery for treatment of endometrial hyperplasia without atypia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We treat these patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      10 mg daily for at least 12 to 14 days each month for three to six months. Other progestin preparations may also be used. (See",
"      <a class=\"local\" href=\"#H510437\">",
"       'Hyperplasia without atypia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Scully RE, Bonfiglio TA, Kurman, et al. Uterine corpus. In: Histological Typing of Female Genital Tract Tumours, 2nd ed., Springer-Verlag, New York 1994. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/2\">",
"      Eichner E, Abellera M. Endometrial hyperplasia treated by progestins. Obstet Gynecol 1971; 38:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/3\">",
"      Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983; 146:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/4\">",
"      Gambrell RD Jr. Progestogens in estrogen-replacement therapy. Clin Obstet Gynecol 1995; 38:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/5\">",
"      Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 1989; 160:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/6\">",
"      Affinito P, Di Carlo C, Di Mauro P, et al. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone. Maturitas 1994; 20:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/7\">",
"      Perino A, Quartararo P, Catinella E, et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil 1987; 18:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/8\">",
"      Wildemeersch D, Dhont M. Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003; 188:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/9\">",
"      Vereide AB, Arnes M, Straume B, et al. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003; 91:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/10\">",
"      Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/11\">",
"      Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005; 97:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/12\">",
"      Montz FJ, Bristow RE, Bovicelli A, et al. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002; 186:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/13\">",
"      Lindahl B, Will&eacute;n R. Endometrial hyperplasia. Clinico-pathological considerations of a prospective randomised study after abrasio only or high-dose gestagen treatment. Results of 2 years follow-up of 292 patients. Anticancer Res 1991; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/14\">",
"      Reed SD, Voigt LF, Newton KM, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009; 113:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/15\">",
"      Casper RF. Regulation of estrogen/progestogen receptors in the endometrium. Int J Fertil Menopausal Stud 1996; 41:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/16\">",
"      Trimble CL, Kauderer J, Zaino R, et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006; 106:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/17\">",
"      Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of \"untreated\" hyperplasia in 170 patients. Cancer 1985; 56:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/18\">",
"      Lacey JV Jr, Sherman ME, Rush BB, et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol 2010; 28:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/19\">",
"      Wentz WB. Progestin therapy in endometrial hyperplasia. Gynecol Oncol 1974; 2:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/20\">",
"      Trimble CL, Method M, Leitao M, et al. Management of endometrial precancers. Obstet Gynecol 2012; 120:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/21\">",
"      Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987; 60:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/22\">",
"      Indermaur MD, Shoup B, Tebes S, Lancaster JM. The accuracy of frozen pathology at time of hysterectomy in patients with complex atypical hyperplasia on preoperative biopsy. Am J Obstet Gynecol 2007; 196:e40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/23\">",
"      Attard Montalto S, Coutts M, Devaja O, et al. Accuracy of frozen section diagnosis at surgery in pre- malignant and malignant lesions of the endometrium. Eur J Gynaecol Oncol 2008; 29:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/24\">",
"      Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005; 106:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/25\">",
"      Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007; 31:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/26\">",
"      Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007; 25:2798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/27\">",
"      Scarselli G, Bargelli G, Taddei GL, et al. Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertil Steril 2011; 95:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/28\">",
"      Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas 2007; 57:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/29\">",
"      Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/30\">",
"      Gallos ID, Yap J, Rajkhowa M, et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207:266.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/31\">",
"      Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006; 125:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/32\">",
"      Gallos ID, Shehmar M, Thangaratinam S, et al. Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:547.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/33\">",
"      Mariani L, Sedati A, Giovinazzi R, et al. Postmenopausal endometrial hyperplasia: role of danazol therapy. Int J Gynaecol Obstet 1994; 44:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/34\">",
"      Bulletti C, Jasonni VM, Tabanelli S, et al. Danazol reverses endometrial hyperplasia to normal endometrium. Acta Eur Fertil 1987; 18:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/35\">",
"      Soh E, Sato K. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1990; 66:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/36\">",
"      Sedati A, Mariani L, Giovinazzi R, et al. The effectiveness of danazol therapy in postmenopausal women affected by endometrial hyperplasia. Clin Exp Obstet Gynecol 1992; 19:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/37\">",
"      Grio R, Piacentino R, Marchino GL, et al. Danazol in the treatment of endometrial hyperplasia. Panminerva Med 1993; 35:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/38\">",
"      Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study. Hum Reprod 1999; 14:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/39\">",
"      Colacurci N, De Placido G, Galasso M, et al. The use of GnRH agonists depot for the treatment of dysfunctional uterine bleeding. Acta Eur Fertil 1991; 22:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/40\">",
"      Pace S, Figliolini M, Grassi A, et al. Low-risk endometrial hyperplasia: hysteroscopy and histologic evaluation after treatment with LH-RH analogue. Clin Exp Obstet Gynecol 1994; 21:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37943/abstract/41\">",
"      Cianferoni L, Giannini A, Franchini M. Hysteroscopic resection of endometrial hyperplasia. J Am Assoc Gynecol Laparosc 1999; 6:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16723 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37943=[""].join("\n");
var outline_f37_3_37943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H364556\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364548\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H610822\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363373\">",
"      MECHANISM OF PROGESTIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H510482\">",
"      ATYPICAL HYPERPLASIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609015\">",
"      Women who have completed childbearing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H609148\">",
"      - Hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H609130\">",
"      Bilateral salpingo-oophorectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H5435392\">",
"      - Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H5435400\">",
"      - Premenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H477987\">",
"      Outcome and follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H609604\">",
"      Women who wish to preserve fertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H510607\">",
"      - Progestin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H478051\">",
"      Outcome and follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H510437\">",
"      HYPERPLASIA WITHOUT ATYPIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H510445\">",
"      Progestin therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H610857\">",
"      - Outcome and follow-up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H510474\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H364556\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/2/36903?source=related_link\">",
"      Clinical manifestations and evaluation of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15706?source=related_link\">",
"      Elective oophorectomy or ovarian conservation at the time of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/35/30266?source=related_link\">",
"      Health hazards associated with obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/25/20887?source=related_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/7/21624?source=related_link\">",
"      Overview of endometrial carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/41/2711?source=related_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37944="Prevention of poisoning in children";
var content_f37_3_37944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of poisoning in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Nancy R Kelly, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37944/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/3/37944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to poisons is a common problem. The Institute of Medicine estimates that the incidence of poisoning in the United States is approximately 4 million cases per year, with 300,000 cases leading to hospitalization, and approximately 30,000 deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2003-2004, poisoning accounted for 18 percent of all injury deaths and 10 percent of hospital discharges for injuries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poisoning is a significant public health issue for children. Each year in the United States, more than 1 million poison exposures among children younger than six years of age are reported to the American Association of Poison Control Centers (AAPCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, approximately 140,000 to 150,000 exposures are reported for children 6 to 12 years and 150,000 to 160,000 exposures for teenagers 13 to 19 years. Because not all poisoning exposures are reported to poison control centers, these numbers are most likely an underestimate.",
"   </p>",
"   <p>",
"    Over 90 percent of poisoning exposures occur at home [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The pattern of poisonings varies by age and sex. For preadolescents, poisoning occurs slightly more often in males than females, but this trend reverses in teenagers, with slightly more than half of all poisonings in the 13- to 19-year age group occurring in females (54 percent in 2011) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"     4",
"    </a>",
"    ]. The majority of poisonings involving young children are classified as unintentional. In contrast, more than one-half of poisoning exposures involving teenagers are intentional (3 percent in 2011) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Fatalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning exposure typically causes minor symptoms in young children; death is a relatively rare occurrence. In 2011, the AAPCC reported 20 exposure-related fatalities in children &lt;6 years old, fewer than fatalities reported over the past 10 years (eg, 32 in 2010) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, there were 6 reported deaths in the 6- to 12-year age group and 44 in the 13- to 19-year age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the fatalities in children younger than six years, 17 were reported as unintentional. One death was reported as resulting from \"malicious intent\", one as an adverse reaction, and one as unknown intention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among the six fatalities in children aged 6 to 12 years, four were reported as unintentional, one as intentional misuse, and one as intentional abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among the 44 fatalities in the 13- to 19-year age group, only one was due to unintentional exposure; 13 were associated with intentional substance abuse or misuse; and 24 were suspected suicides [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"       4",
"      </a>",
"      ]. Pharmaceutical agents commonly associated with fatalities in this age group included",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/49/22296?source=see_link\">",
"       methadone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/8/32903?source=see_link\">",
"       oxymorphone",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?38/23/39287?source=see_link\">",
"       oxycodone",
"      </a>",
"      , and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"        acetaminophen",
"       </a>",
"       /hydrocodone.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Ingested substances",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2011, as in earlier years, the substances most frequently involved in pediatric (&lt;6 years old) exposures were cosmetics and personal care products, followed by analgesics, and household cleaning products (",
"    <a class=\"graphic graphic_table graphicRef55650 \" href=\"mobipreview.htm?17/62/18411\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The categories of substances most frequently involved in fatalities in children &le;5 years of age during 2011 include analgesics,",
"    <span class=\"nowrap\">",
"     stimulants/street",
"    </span>",
"    drugs, cough and cold preparations, household cleaning substances, and hydrocarbons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"     4",
"    </a>",
"    ]. Child self-ingestion of pharmaceutical agents appears to be increasing with the rising availability of prescription medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"hazard factor\" is a measure that was devised to objectively assess the poisoning hazard of various products based upon the potential acute toxicity of individual ingredients and the frequency and extent of injuries following actual exposures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/6\">",
"     6",
"    </a>",
"    ]. It was derived through analysis of more than 3.8 million exposures that were reported to the AAPCC from 1985 through 1989 among children younger than six years. In this analysis, significant hazards were limited to a few products. These included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iron supplements (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=see_link\">",
"       \"Acute iron poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antidepressants (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=see_link\">",
"       \"Tricyclic antidepressant poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiovascular medications (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=see_link\">",
"       \"Digitalis (cardiac glycoside) poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/19/33081?source=see_link\">",
"       \"Beta blocker poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link\">",
"       \"Calcium channel blocker poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Methyl salicylate (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=see_link\">",
"       \"Salicylate poisoning in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hydrocarbons (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27736?source=see_link\">",
"       \"Hydrocarbon poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pesticides (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link\">",
"       \"Organophosphate and carbamate poisoning\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional specific products have been identified as causing severe symptoms or death in children with ingestion of only a small amount (",
"    <a class=\"graphic graphic_table graphicRef76803 \" href=\"mobipreview.htm?15/1/15389\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. These included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sulfonylureas (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=see_link\">",
"       \"Sulfonylurea agent poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Calcium channel blockers (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=see_link\">",
"       \"Calcium channel blocker poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Toxic alcohols (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23639?source=see_link\">",
"       \"Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2137?source=see_link\">",
"       \"Ethanol intoxication in children: Clinical features, evaluation, and management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=see_link\">",
"       \"Methanol and ethylene glycol poisoning\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20423?source=see_link\">",
"       \"Isopropyl alcohol poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/14/13545?source=see_link\">",
"       Clonidine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22313?source=see_link\">",
"       \"Clonidine and related imidazoline poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Opioids (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22874?source=see_link\">",
"       \"Opioid intoxication in children and adolescents\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The safety and efficacy of cough and cold medications for young children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13146?source=see_link&amp;anchor=H199065570#H199065570\">",
"     \"The common cold in children: Treatment and prevention\", section on 'Symptomatic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Site of management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of poisoning cases in children can be managed safely at home after consultation with a poison control center specialist. Of the more than 2 million poisoning exposures reported to United States poison control centers in 2011, 70 percent were managed at a non-health-care facility, which was usually the site of exposure, primarily the home of the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"     4",
"    </a>",
"    ]. For children younger than six years old, the vast majority of cases (89 percent) did not require treatment at a medical facility. Approximately 87 percent of cases involving children 6 to 12 years also were managed outside a health-care facility. In contrast, 49 percent of cases involving teenagers (13 to 19 years) and 40 percent of cases involving adults (&gt;20 years old) required management in a medical facility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cost to society",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning is a financial burden to society. Medical spending for poisoning treatment surpassed $3 billion in 1992 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/9\">",
"     9",
"    </a>",
"    ]. Numerous studies have shown that poison control centers reduce health care spending. Poison control centers provide a mechanism for safe management of most poisonings at home, expedite referral to a health-care facility when necessary, decrease unnecessary emergency department visits, and reduce hospital length of stay for patients with poison exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/10-16\">",
"     10-16",
"    </a>",
"    ]. One study estimated that the average public call to a poison control center in 1992 saved $175 in other medical spending [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/9\">",
"     9",
"    </a>",
"    ]. The authors estimated that every $1 spent on poison control center activities saved approximately $6.50 in medical costs. This is likely an underestimate of the benefits of poison control centers, in that it does not take into account decreased morbidity and mortality, or the reduction in parental anxiety and saved time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age and sex are factors to consider in evaluating a child's or adolescent's risk for poisoning. In addition, developmental and environmental factors may contribute to the risk of a poisoning event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Developmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal developmental progression of young children, including exploration of their environment, places them at risk for poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As children become mobile, they are able to maneuver through the home; they learn to open cabinets and to examine the contents",
"     </li>",
"     <li>",
"      As children begin to walk, they may be able to grab items that were previously out of reach (eg, on countertops)",
"     </li>",
"     <li>",
"      Improved fine motor skills enable toddlers to open simple screw-on caps or bottle tops",
"     </li>",
"     <li>",
"      Normal curiosity and desire for oral stimulation may cause children to place new objects directly into the mouth for tasting or swallowing",
"     </li>",
"     <li>",
"      Well-meaning preschoolers may try to \"help\" by using toxic cleaning products or by attempting to self-administer medication",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although they have the motor skills to ingest these substances and perhaps the social skills to desire to please, young children do not yet understand danger or the concept of poisoning. Preschool children, who typically understand the concept of danger and can understand and follow simple rules, may become victims of poisoning if left unsupervised. In addition, the impulsivity of some children puts them at even greater risk for poisoning.",
"   </p>",
"   <p>",
"    Developmental issues and pressures also contribute to the increased risk of poisoning among adolescents. The goal of independence and the tendency to believe that they are indestructible may cause adolescents to take undue risks in experimenting with illicit drugs or other substances of abuse. Peer pressure and desire to conform also contribute to this problem. In addition, teenagers (more commonly girls than boys) may take an overdose of medication as a suicide attempt or gesture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ]. This may be related to an acute personal crisis or a reflection of more chronic issues. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=see_link\">",
"     \"Suicidal behavior in children and adolescents: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental factors also contribute to poisoning events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ]. Most homes contain numerous potentially toxic substances, particularly in the kitchen, bathrooms, laundry room, and garage. Items used frequently, such as cleaning products, may be stored in low cabinets for easy access. Some products are so commonly used and seem so familiar that parents may not appreciate their toxicity.",
"   </p>",
"   <p>",
"    Products or medications that are used or taken frequently may be stored properly, but during use may be left momentarily within a child's reach. Child self-exposure accounted for 95 percent of visits to a health care facility for evaluation of exposure to a potentially toxic dose of a pharmaceutical agent reported to the American Association of Poison Control Centers between 2001 and 2008 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Look-alikes also pose a problem for small children. Some medications look identical to candy. Similarly, some cleaning products may look like or be stored in containers that resemble those of food or juice. The availability of medications, drugs, or other substances of abuse at school or home may put vulnerable teenagers at further risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most poisonings that occur in young children are unintentional. Though sometimes referred to as \"accidental,\" the preferred term in the injury prevention literature is &ldquo;unintentional&rdquo; because the term \"accident\" implies a random, uncontrollable act of fate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/18\">",
"     18",
"    </a>",
"    ]. Poisonings, like other types of injuries, are understandable, predictable, and preventable events. Active areas of research include better understanding of poisoning events, strategies to reduce the frequency of poisonings, and improvement of services and treatment when poisonings occur.",
"   </p>",
"   <p>",
"    Prevention strategies for poisonings, as for other types of injury, can be divided into primary (pre-event), secondary (event), and tertiary (post-event) prevention strategies. As a general rule, primary passive intervention strategies (eg, legislation that limits the dose of baby",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    per container) are more effective than active intervention strategies (educating parents to keep baby aspirin out of the reach of children). Educational efforts have been shown to change safety-related knowledge and behavior (eg, displaying the poison control telephone number) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. However, direct evidence that educational counseling results in lower injury rates is lacking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11767?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of pediatric injury prevention: Epidemiology; history; application\", section on 'Principles of injury prevention and control'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion below will focus on primary prevention. Secondary prevention strategies are mentioned briefly and discussed in detail elsewhere. Tertiary prevention strategies depend upon the individual exposure and are discussed in the specific topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=see_link\">",
"     \"Management of acetaminophen (paracetamol) poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=see_link\">",
"     \"Acute iron poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention encompasses all of the activities that prevent a poisoning event from occurring. Activities such as legislation, product engineering, and educational efforts are included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Legislation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, legislation and regulatory means were implemented to protect children, adolescents, and adults from toxic exposures beginning in 1906. Significant reductions in poisoning events and child deaths may be attributed to these regulations and legislation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1906, the Pure Food and Drug Act (\"Wiley Act\") created the Food, Drug and Insecticide Administration, which became the Food and Drug Administration (FDA) in 1930 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/30\">",
"       30",
"      </a>",
"      ]. This act required federal approval for foods and drugs meant for human consumption.",
"     </li>",
"     <li>",
"      In 1927, the Caustic Poison Act required labels to warn parents of the dangers of lye (used to make soap) and 10 other caustic substances.",
"     </li>",
"     <li>",
"      In 1951, the FDA defined and restricted certain medications to prescription status.",
"     </li>",
"     <li>",
"      In 1961, Public Law 87-319, which designates the third week of March each year as National Poison Prevention Week, was signed into effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/31\">",
"       31",
"      </a>",
"      ]. National Poison Prevention Week provides national recognition of this serious health issue and entails widespread public education about poison prevention.",
"     </li>",
"     <li>",
"      In 1966, packaging of baby",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      was regulated to limit the number of tablets (81 mg) per single container to 36 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/30\">",
"       30",
"      </a>",
"      ]. This occurred in response to the recognition that unintentional aspirin ingestion was a significant cause of morbidity and mortality in young children. Between 1960 and 1980, deaths from aspirin dropped from 144 to 12 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1970, the Poison Prevention Packaging Act (PPPA) required child-resistant packaging for certain types of opiates and other dangerous drugs, drain cleaners and oven cleaners, lighter fluid, turpentine, and a variety of solvents and other household products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/33\">",
"       33",
"      </a>",
"      ]. Child-resistant containers separate the child from the toxic product by imposing a physical barrier [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/34\">",
"       34",
"      </a>",
"      ]. The particular physical barrier is not necessarily childproof but is designed to delay the child's ability to open the container long enough for an adult to discover the child before ingestion can occur.",
"      <br/>",
"      <br/>",
"      The PPPA has been one of the most important achievements in poisoning prevention. Analysis of data from the National Electronic Injury Surveillance System and the National Center for Health Statistics indicated that the ingestion rate of substances regulated by the PPPA declined from",
"      <span class=\"nowrap\">",
"       5.7/1000",
"      </span>",
"      children in 1973 to",
"      <span class=\"nowrap\">",
"       3.4/1000",
"      </span>",
"      children in 1978 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/29\">",
"       29",
"      </a>",
"      ]. The PPPA is further credited with preventing an estimated 86,000 ingestions between 1974 and 1981 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/35\">",
"       35",
"      </a>",
"      ]. One study estimated that child-resistant packaging reduced childhood deaths from",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      by 34 percent, resulting in approximately 90 fewer child deaths from 1973 to 1990 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/36\">",
"       36",
"      </a>",
"      ]. In 2011 there were no reported deaths in young children due to aspirin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1997, the FDA passed a regulation requiring unit-dose packaging for iron-containing products with 30 mg or more of iron per unit dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/30\">",
"       30",
"      </a>",
"      ]. In the five years after this intervention was introduced, there was a decrease in the number of calls to poison centers regarding iron ingestion in children younger than six years and a decrease in the number of deaths due to iron poisoning compared with the 10 years before the introduction of this intervention [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/37\">",
"       37",
"      </a>",
"      ]. In 2007, there were no deaths in children younger than six years of age due to iron ingestion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/38\">",
"       38",
"      </a>",
"      ]. Unfortunately, this regulation was withdrawn in 2003 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=see_link\">",
"       \"Acute iron poisoning\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In 2011, the FDA issued guidance to improve the consistency between dosing instructions and dosing devices for orally ingested liquid over-the-counter medications, as well as the clarity of the markings on dosing devices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Product engineering",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to unit dose packaging and child-resistant containers, other products have been engineered to prevent poisoning events. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Storage and locking devices designed to prevent access of children to toxic materials. Examples include boxes that permit easy access for adults but prevent access by children (eg, a tackle or tool box with an external latch and lock), devices that secure cabinet doors, and door locks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The addition of bittering agents to make dangerous substances unpalatable, potentially reducing the amount of substance that is ingested or forcing it to be expelled [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/25,41,42\">",
"       25,41,42",
"      </a>",
"      ]. Although this would seem to be an effective poison prevention strategy, the ability of bittering agents to reduce the incidence or severity of childhood poisoning is unproven [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/43,44\">",
"       43,44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of poison warning labels or stickers that may alert adults and older children to the toxic hazard of various substances. However, they do not deter young children from playing with medication containers, nor do they reduce the rate of poisoning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/45,46\">",
"       45,46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Due to the increase in fatalities related to ingestion of button batteries some researchers have called for product manufacturers to 1) secure the battery compartment of household products that use button batteries so that children cannot remove the battery and the battery will not be released if the product is dropped, 2) develop child-resistant, unit-of-use battery packaging, and 3) provide warnings on products and battery packaging to inform consumers that ingestion of button batteries can cause serious injury or death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/47\">",
"       47",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=see_link&amp;anchor=H23#H23\">",
"       \"Button and cylindrical battery ingestion\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary prevention also includes educational efforts targeted toward avoidance of poisoning exposure. As an example, clinicians should consider the risk of poisoning when they prescribe medications and use less toxic therapies when appropriate. Particular precautions should be taken with medications that are commonly involved in fatal ingestions and those that are toxic in small doses (",
"    <a class=\"graphic graphic_table graphicRef76803 \" href=\"mobipreview.htm?15/1/15389\">",
"     table 2",
"    </a>",
"    ). Other educational efforts may involve community outreach projects, mass media campaigns, or education in a clinical setting. Emergency department visits for poisoning provide another important opportunity for preventive education; unfortunately, this opportunity is often missed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H376519128\">",
"    <span class=\"h4\">",
"     Anticipatory guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periodic anticipatory guidance for poisoning prevention is recommended by the American Academy of Pediatrics (AAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17,37,49\">",
"     17,37,49",
"    </a>",
"    ] and the United States Preventive Services Task Force (USPSTF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/25\">",
"     25",
"    </a>",
"    ]. In addition, the USPSTF recommends against the use of poison-warning stickers that are intended to deter children from playing with containers of medicine and other poisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/25\">",
"     25",
"    </a>",
"    ]. These stickers neither deter young children from playing with medication containers nor reduce the rate of poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anticipatory guidance for poisoning prevention should begin near the six-month visit and continue throughout childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ]. Parents should be encouraged to survey the home periodically to evaluate all injury hazards, not just those related to poisoning (",
"    <a class=\"graphic graphic_table graphicRef66415 \" href=\"mobipreview.htm?1/54/1901\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ]. In each room, parents should consider whether toxic or poisonous substances are necessary; those that are deemed necessary should be safely stored, and those that are not should be appropriately discarded. Homes that the child visits, particularly grandparents' homes, also should be surveyed by the parents at the time the child arrives for a visit.",
"   </p>",
"   <p>",
"    Parents should be encouraged to buy the least toxic product that will accomplish the desired task. Toxic products should be purchased in small quantities and disposed of when they are no longer needed. Home use of certain products with high or irreversible toxicity (eg, crystal drain cleaner) should be avoided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The universal poison control telephone number for the United States (1-800-222-1222) should be posted near the phone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    added to the telephone&rsquo;s",
"    <span class=\"nowrap\">",
"     memory/speed",
"    </span>",
"    dial. The poison control center should be the first source of information about poisons in an emergency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should provide seasonally and geographically appropriate information when indicated. Examples include the risk of carbon monoxide poisoning in cold areas during the winter and the risk of insect repellents in temperate climates or during the temperate season.",
"   </p>",
"   <p>",
"    Specific \"safety rules\" for parents from Healthy Children webpage of the AAP include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/50\">",
"     50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Keep harmful products locked up and out of your child's sight and reach.",
"     </li>",
"     <li>",
"      Use safety latches or locks on drawers and cabinets where you keep dangerous items.",
"     </li>",
"     <li>",
"      Take extra care during stressful times.",
"     </li>",
"     <li>",
"      Call medicine by its correct name. You do not want to confuse the child by calling medicine \"candy.\"",
"     </li>",
"     <li>",
"      Always replace the safety caps immediately after product use.",
"     </li>",
"     <li>",
"      Never leave containers of alcohol within a child's reach.",
"     </li>",
"     <li>",
"      Keep products in their original containers. Never put nonfood products in food or drink containers.",
"     </li>",
"     <li>",
"      Read labels with care before using any product.",
"     </li>",
"     <li>",
"      Teach children not to drink or eat anything unless it is given to them by an adult.",
"     </li>",
"     <li>",
"      Do not take medicine in view of small children. Children tend to copy adult behavior.",
"     </li>",
"     <li>",
"      Check your home often for old medications and get rid of them; the FDA provides guidelines for drug disposal (",
"      <a class=\"external\" href=\"file://www.fda.gov/forconsumers/consumerupdates/ucm101653.htm\">",
"       www.fda.gov/forconsumers/consumerupdates/ucm101653.htm",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Get rid of substances used for old-fashioned treatments such as oil of wintergreen, boric acid, ammoniated mercury, oil of turpentine, and camphorated oil.",
"     </li>",
"     <li>",
"      Remember that there is more danger of poisoning when a child is away from home, especially at a grandparent's home.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prevention of button battery ingestion is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=see_link&amp;anchor=H23#H23\">",
"     \"Button and cylindrical battery ingestion\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary prevention involves interventions that prevent injury or illness once a poisoning exposure has occurred. Examples of secondary prevention strategies include the development of poison control centers and various methods of decontamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Poison centers",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2011, there are 60 poison control centers in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/51\">",
"     51",
"    </a>",
"    ]. These centers serve the 50 states, Puerto Rico, the Federated States of Micronesia, American Samoa, and Guam. Poison control centers provide 24-hour poison information, telephone management, advice, and consultation about toxic exposures. They also provide professional and public education on poison prevention, diagnosis, and treatment. &nbsp;",
"   </p>",
"   <p>",
"    Poison control centers provide information on a wide variety of potential exposures including chemicals, medications, herbs, plants, and even snake and spider bites. Consultation with the local poison control center should be the first action for the caregiver of a child who may have ingested a toxic substance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/49\">",
"     49",
"    </a>",
"    ]. The national toll-free number for poison control centers is (1-800-222-1222). More information about poison control centers can be obtained by visiting the American Association of Poison Control Centers&rsquo; (AAPCC) website at",
"    <a class=\"external\" href=\"file://www.aapcc.org/\">",
"     www.aapcc.org",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order for poison control centers to be helpful as secondary prevention strategies, it is crucial that parents and other caretakers know about poison centers, the services that poison centers provide, and the circumstances under which the poison center should be called.",
"   </p>",
"   <p>",
"    In one report, 210 caretakers of children evaluated for unintentional poisoning in an emergency center were interviewed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/52\">",
"     52",
"    </a>",
"    ]. Only 46 percent had contacted the poison center before the emergency department visit. Poison center use was higher among whites than blacks (adjusted odds ratio 2.7, 95% CI 1.2-5.8) and parents educated outside the United States (adjusted OR 8.2, 95% CI 1.7-38.4). Similar results were reported in a retrospective review comparing sociodemographic characteristics between counties with high and low utilization of regional poison control centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons accounting for these differences include lack of knowledge about the poison center, as well as perceived barriers and misconceptions about poison centers, such as uncertainty about poison center staff qualifications, fear of being reported for neglect, and fear of inability to carry out recommendations made by poison center staff [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/54\">",
"     54",
"    </a>",
"    ]. Educational programs designed to increase parental use of poison centers, especially among minorities, have had promising results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37944/abstract/22,55\">",
"     22,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Decontamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decontamination is another method of modulating poisoning injury after poisoning exposure has occurred. Various methods of decontamination in children, including syrup of ipecac and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/47/33525?source=see_link\">",
"     activated charcoal",
"    </a>",
"    , are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=see_link\">",
"     \"Decontamination of poisoned children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Tertiary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tertiary prevention involves interventions that minimize injury or toxic effects once symptoms have appeared. Examples of tertiary prevention strategies include emergency medical services, inpatient care, and the administration of antidotes. Tertiary prevention strategies, particularly the administration of antidotes, vary depending upon the particular exposure (eg, N-acetylcysteine for",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    exposure). These strategies are discussed in detail separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poisoning, like other injuries, is a predictable and preventable event. Prevention strategies include legislation, product engineering, and education. Of these, education is most relevant to the pediatric health-care provider.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When less toxic alternatives are available, clinicians should avoid prescribing medications that are commonly involved in fatal ingestions or are toxic in small doses (",
"      <a class=\"graphic graphic_table graphicRef76803 \" href=\"mobipreview.htm?15/1/15389\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Education'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticipatory guidance for poisoning prevention should begin near the six-month visit and continue throughout childhood. Important components of anticipatory guidance include (see",
"      <a class=\"local\" href=\"#H376519128\">",
"       'Anticipatory guidance'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Encouraging parents to survey the home periodically to identify and remove potential poisoning hazards (",
"      <a class=\"graphic graphic_table graphicRef66415 \" href=\"mobipreview.htm?1/54/1901\">",
"       table 3",
"      </a>",
"      ). Homes that the child visits also should be surveyed for poisoning hazards.",
"     </li>",
"     <li>",
"      Encouraging parents to avoid home use of products with high or irreversible toxicity; toxic products should be purchased in small quantities and disposed of when no longer needed.",
"     </li>",
"     <li>",
"      Provision of the universal poison control telephone number for the United States (1-800-222-1222) and encouraging parents to post the number near the phone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      add it to their telephone&rsquo;s",
"      <span class=\"nowrap\">",
"       memory/speed",
"      </span>",
"      dial; the poison control center is the best source of information about poisons in an emergency.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Committee on Poison Prevention and Control, Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies. Magnitude of the problem. In: Forging a Poison Prevention and Control System, National Academies Press, Washington, DC 2004. p.43.",
"    </li>",
"    <li>",
"     Bergen G, Chen LH, Warner M, Fingerhut LA. Injury in the United States: 2007 Chartbook, National Center for Health Statistics, Hyattsville, MD 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/3\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2010 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 28th Annual Report. Clin Toxicol (Phila) 2011; 49:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/4\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2011 Annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol (Phila) 2012; 50:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/5\">",
"      Bond GR, Woodward RW, Ho M. The growing impact of pediatric pharmaceutical poisoning. J Pediatr 2012; 160:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/6\">",
"      Litovitz T, Manoguerra A. Comparison of pediatric poisoning hazards: an analysis of 3.8 million exposure incidents. A report from the American Association of Poison Control Centers. Pediatrics 1992; 89:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/7\">",
"      Henry K, Harris CR. Deadly ingestions. Pediatr Clin North Am 2006; 53:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/8\">",
"      Michael JB, Sztajnkrycer MD. Deadly pediatric poisons: nine common agents that kill at low doses. Emerg Med Clin North Am 2004; 22:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/9\">",
"      Miller TR, Lestina DC. Costs of poisoning in the United States and savings from poison control centers: a benefit-cost analysis. Ann Emerg Med 1997; 29:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/10\">",
"      King WD, Palmisano PA. Poison control centers: can their value be measured? South Med J 1991; 84:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/11\">",
"      Chafee-Bahamon C, Lovejoy FH Jr. Effectiveness of a regional poison center in reducing excess emergency room visits for children's poisonings. Pediatrics 1983; 72:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/12\">",
"      Litovitz T, Kearney TE, Holm K, et al. Poison Control Centers: is there an antidote for budget cuts? Am J Emerg Med 1994; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/13\">",
"      Blizzard JC, Michels JE, Richardson WH, et al. Cost-benefit analysis of a regional poison center. Clin Toxicol (Phila) 2008; 46:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/14\">",
"      Zaloshnja E, Miller T, Jones P, et al. The potential impact of poison control centers on rural hospitalization rates for poisoning. Pediatrics 2006; 118:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/15\">",
"      Zaloshnja E, Miller T, Jones P, et al. The impact of poison control centers on poisoning-related visits to EDs--United States, 2003. Am J Emerg Med 2008; 26:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/16\">",
"      Vassilev ZP, Marcus SM. The impact of a poison control center on the length of hospital stay for patients with poisoning. J Toxicol Environ Health A 2007; 70:107.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Injury and Poison Prevention, American Academy of Pediatrics. Injury prevention in and around the home. In: Injury Prevention and Control for Children and Youth, American Academy of Pediatrics, Elk Grove Village, IL 1997. p.47.",
"    </li>",
"    <li>",
"     Committee on Injury and Poison Prevention, American Academy of Pediatrics. The science of injury prevention. In: Injury Prevention and Control for Children and Youth, American Academy of Pediatrics, Elk Grove Village, IL 1997. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/19\">",
"      Dershewitz RA, Posner MK, Paichel W. The effectiveness of health education on home use of ipecac. Clin Pediatr (Phila) 1983; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/20\">",
"      Woolf A, Lewander W, Filippone G, Lovejoy F. Prevention of childhood poisoning: efficacy of an educational program carried out in an emergency clinic. Pediatrics 1987; 80:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/21\">",
"      Watson M, Kendrick D, Coupland C, et al. Providing child safety equipment to prevent injuries: randomised controlled trial. BMJ 2005; 330:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/22\">",
"      Kelly NR, Huffman LC, Mendoza FS, Robinson TN. Effects of a videotape to increase use of poison control centers by low-income and Spanish-speaking families: a randomized, controlled trial. Pediatrics 2003; 111:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/23\">",
"      Polivka BJ, Casavant MJ, Malis E, Baker D. Evaluation of the Be Poison Smart! poison prevention intervention. Clin Toxicol (Phila) 2006; 44:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/24\">",
"      Kendrick D, Smith S, Sutton A, et al. Effect of education and safety equipment on poisoning-prevention practices and poisoning: systematic review, meta-analysis and meta-regression. Arch Dis Child 2008; 93:599.",
"     </a>",
"    </li>",
"    <li>",
"     DiGuiseppi C. Preventing household and recreational injuries. In: U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed, Williams &amp; Wilkins, Baltimore 1996. p.659.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/26\">",
"      Centers for Disease Control (CDC). Unintentional poisoning among young children--United States. MMWR Morb Mortal Wkly Rep 1983; 32:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/27\">",
"      Palmisano PA. Targeted intervention in the control of accidental drug overdoses by children. Public Health Rep 1981; 96:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/28\">",
"      Clarke A, Walton WW. Effect of safety packaging on aspirin ingestion by children. Pediatrics 1979; 63:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/29\">",
"      Walton WW. An evaluation of the Poison Prevention Packaging Act. Pediatrics 1982; 69:363.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Poison Prevention and Control, Board on Health Promotion and Disease Prevention, Institute of Medicine of the National Academies. Historical context of poison control. In: Forging a Poison Prevention and Control System, The National Academies Press, Washington, DC 2004. p.20.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/31\">",
"      Liegey M. Accidental poisonings drop in the U.S. Prevention efforts cited. Chemical Times and Trends 1991; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     Baker S, O'Neill B, Karpf R. Poisonings. In: The Injury Fact Book, Lexington Books, Lexington, MA 1984. p.191.",
"    </li>",
"    <li>",
"     Consumer Product Safety Commission. Poison Prevention Packaging Act of 1970. www.cpsc.gov/businfo/pppa.html (Accessed on April 20, 2006).",
"    </li>",
"    <li>",
"     Woolf AD, Lovejoy FH Jr. Prevention of childhood poisonings. In: Clinical Management of Poisoning and Drug Overdose, Haddad LM, Shanon MW, Windchester JF III (Eds), WB Saunders, Philadelphia 1998. p.300.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/35\">",
"      Centers for Disease Control (CDC). Update: childhood poisonings--United States. MMWR Morb Mortal Wkly Rep 1985; 34:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/36\">",
"      Rodgers GB. The effectiveness of child-resistant packaging for aspirin. Arch Pediatr Adolesc Med 2002; 156:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/37\">",
"      Tenenbein M. Unit-dose packaging of iron supplements and reduction of iron poisoning in young children. Arch Pediatr Adolesc Med 2005; 159:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/38\">",
"      Bronstein AC, Spyker DA, Cantilena LR Jr, et al. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila) 2008; 46:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/39\">",
"      Food and Drug Administration, HHS. Iron-containing supplements and drugs; label warning statements and unit-dose packaging requirements; removal of regulations for unit-dose packaging requirements for dietary supplements and drugs. Final rule; removal of regulatory provisions in response to court order. Fed Regist 2003; 68:59714.",
"     </a>",
"    </li>",
"    <li>",
"     US FDA Center for Drug Evaluation and Research. Guidance for industry. Dosage delivery devices for orally ingested OTC liquid drug products. May 2011. file://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM188992.pdf (Accessed on May 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/41\">",
"      Sibert JR, Frude N. Bittering agents in the prevention of accidental poisoning: children's reactions to denatonium benzoate (Bitrex). Arch Emerg Med 1991; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/42\">",
"      Berning CK, Griffith JF, Wild JE. Research on the effectiveness of denatonium benzoate as a deterrent to liquid detergent ingestion by children. Fundam Appl Toxicol 1982; 2:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/43\">",
"      Rodgers GC Jr, Tenenbein M. The role of aversive bittering agents in the prevention of pediatric poisonings. Pediatrics 1994; 93:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/44\">",
"      White NC, Litovitz T, Benson BE, et al. The impact of bittering agents on pediatric ingestions of antifreeze. Clin Pediatr (Phila) 2009; 48:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/45\">",
"      Vernberg K, Culver-Dickinson P, Spyker DA. The deterrent effect of poison-warning stickers. Am J Dis Child 1984; 138:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/46\">",
"      Fergusson DM, Horwood LJ, Beautrais AL, Shannon FT. A controlled field trial of a poisoning prevention method. Pediatrics 1982; 69:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/47\">",
"      Litovitz T, Whitaker N, Clark L. Preventing battery ingestions: an analysis of 8648 cases. Pediatrics 2010; 125:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/48\">",
"      Demorest RA, Posner JC, Osterhoudt KC, Henretig FM. Poisoning prevention education during emergency department visits for childhood poisoning. Pediatr Emerg Care 2004; 20:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/49\">",
"      American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Poison treatment in the home. American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Pediatrics 2003; 112:1182.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Keep your home safe from poisons. Available at: file://www.healthychildren.org/English/safety-prevention/all-around/pages/Keep-Your-Home-Safe-From-Poisons.aspx (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     American Association of Poison Control Centers. Available at: file://www.aapcc.org/dnn/AAPCC/AboutAAPCC.aspx (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/52\">",
"      Kelly NR, Kirkland RT, Holmes SE, et al. Assessing parental utilization of the poison center: an emergency center-based survey. Clin Pediatr (Phila) 1997; 36:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/53\">",
"      Vassilev ZP, Marcus S, Jennis T, et al. Rapid communication: sociodemographic differences between counties with high and low utilization of a regional poison control center. J Toxicol Environ Health A 2003; 66:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/54\">",
"      Kelly NR, Groff JY. Exploring barriers to utilization of poison centers: a qualitative study of mothers attending an urban Women, Infants, and Children (WIC) Clinic. Pediatrics 2000; 106:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37944/abstract/55\">",
"      Gardner HG, American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. Office-based counseling for unintentional injury prevention. Pediatrics 2007; 119:202.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2873 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37944=[""].join("\n");
var outline_f37_3_37944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Fatalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Ingested substances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Site of management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cost to society",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Developmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Environmental factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Legislation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Product engineering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H376519128\">",
"      Anticipatory guidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Poison centers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Decontamination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Tertiary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2873\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2873|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/62/18411\" title=\"table 1\">",
"      Agents most commonly ingested by children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/1/15389\" title=\"table 2\">",
"      Medications and toxins fatal in small doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/54/1901\" title=\"table 3\">",
"      Poisoning home survey",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/19/33081?source=related_link\">",
"      Beta blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/62/15337?source=related_link\">",
"      Button and cylindrical battery ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31736?source=related_link\">",
"      Calcium channel blocker poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22313?source=related_link\">",
"      Clonidine and related imidazoline poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/13/25817?source=related_link\">",
"      Digitalis (cardiac glycoside) poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/5/2137?source=related_link\">",
"      Ethanol intoxication in children: Clinical features, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23639?source=related_link\">",
"      Ethanol intoxication in children: Epidemiology, estimation of toxicity, and toxic effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/5/27736?source=related_link\">",
"      Hydrocarbon poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20423?source=related_link\">",
"      Isopropyl alcohol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/51/13114?source=related_link\">",
"      Management of acetaminophen (paracetamol) poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4154?source=related_link\">",
"      Methanol and ethylene glycol poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/21/22874?source=related_link\">",
"      Opioid intoxication in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/31/11767?source=related_link\">",
"      Overview of pediatric injury prevention: Epidemiology; history; application",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23834?source=related_link\">",
"      Suicidal behavior in children and adolescents: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/23/13687?source=related_link\">",
"      Sulfonylurea agent poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/53/13146?source=related_link\">",
"      The common cold in children: Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/24/36231?source=related_link\">",
"      Tricyclic antidepressant poisoning",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37945="Refractoriness to platelet transfusion therapy";
var content_f37_3_37945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Refractoriness to platelet transfusion therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Dennis Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Alyssa Ziman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37945/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/3/37945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets play a vital role in the maintenance of normal hemostatic activity. Accordingly, for patients with low platelet counts (thrombocytopenia) or impaired platelet function, platelet transfusion can be of significant value in preventing and treating hemorrhage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although many patients respond appropriately when transfused with platelets, less than adequate results tend to be the rule rather than the exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/1\">",
"     1",
"    </a>",
"    ], leading to an increased risk of morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/2\">",
"     2",
"    </a>",
"    ]. Published reports have cited an incidence of refractoriness to platelet transfusion of 15 to 25 percent in the",
"    <span class=\"nowrap\">",
"     hematology/oncology",
"    </span>",
"    patient population utilizing leukocyte-reduced blood products and even higher rates during the pre-leukocyte-reduction era [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The numerous factors associated with poor recovery and survival of transfused platelets, and the diagnosis, management, and prevention of alloimmune refractoriness to platelet transfusion will be reviewed here. General issues related to platelet transfusion are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695439\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractoriness to platelet transfusion can be separated into non-immune and immune causes (",
"    <a class=\"graphic graphic_table graphicRef67416 \" href=\"mobipreview.htm?5/43/5819\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately two-thirds of refractory episodes are due to non-immune causes, such as sepsis, fever, bleeding, splenomegaly, disseminated intravascular coagulation (DIC), hepatic sinusoidal obstruction syndrome (hepatic veno-occlusive disease), graft-versus-host disease (GVHD) and medications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/3,7\">",
"       3,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Twenty percent of cases have a combination of both immune and non-immune causes.",
"     </li>",
"     <li>",
"      Immune causes account for the remaining minority of cases and include alloimmunization to HLA",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      platelet-specific antigens.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Characteristics of the platelet component, such as ABO compatibility and the age of the unit, can also affect post-transfusion platelet increments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/3,5,8\">",
"     3,5,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695446\">",
"    <span class=\"h1\">",
"     NON-IMMUNE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the most frequently cited causes of refractoriness to platelet transfusion, fever is likely not an independent cause and probably reflects underlying infection, which is clearly associated with shortened platelet survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/9\">",
"     9",
"    </a>",
"    ]. Clinical bleeding is also often listed as a cause of platelet refractoriness, however it is more likely that bleeding, as well as poor overall patient survival, is a consequence rather than a cause of the reduced survival of platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sepsis and its association with thrombocytopenia is a well known cause; however the mechanisms are not completely understood. Several hypotheses have focused on immune and non-immune consumption and sequestration, as well as decreased platelet production. In addition, consumptive processes such as disseminated intravascular coagulation (DIC) and hemophagocytosis may contribute to thrombocytopenia in some septic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/10-12\">",
"     10-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DIC results in an increased rate of platelet consumption and refractoriness to platelet transfusion. This is a particular problem in cases of acute promyelocytic leukemia where DIC may result in an increased risk of fatal hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Platelet transfusion and fresh frozen plasma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=see_link&amp;anchor=H18#H18\">",
"     \"Initial treatment of acute promyelocytic leukemia in adults\", section on 'Control of coagulopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenomegaly is well established as a cause of poor responses to platelet transfusion. Under normal conditions, approximately one-third of an individual's platelets are sequestered in the spleen where they are in equilibrium with the circulating platelet pool. In cases of extreme splenomegaly, splenic sequestration can be increased to 90 percent (",
"    <a class=\"graphic graphic_figure graphicRef52400 \" href=\"mobipreview.htm?7/24/7566\">",
"     figure 1",
"    </a>",
"    ). As a result, when administering platelet transfusions to patients with massive splenomegaly, it can be expected that a large fraction of the transfused platelets will be sequestered in the spleen, resulting in poor post-transfusion platelet increments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Normal splenic function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634026\">",
"    <span class=\"h2\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT), both allogeneic and autologous, is clearly associated with an impaired response to platelet transfusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. In one series, for example, 310 of 484 (64 percent) evaluable post-transplant platelet transfusions resulted in an inadequate response. Additionally, hepatic sinusoidal obstruction syndrome associated with intrahepatic thrombosis and platelet deposition in hepatic venules, which occurs in 22 percent of patients undergoing HCT, may contribute to platelet refractoriness.",
"   </p>",
"   <p>",
"    However, one set of investigators found no difference in the incidence of platelet refractoriness between HCT patients with and without hepatic sinusoidal obstruction syndrome (56 percent and 60 percent respectively). These authors also found that 80 percent of patients who died from any cause were refractory to platelets, suggesting that platelet refractoriness may be an indicator of clinical deterioration in patients with this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=see_link&amp;anchor=H4#H4\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634033\">",
"    <span class=\"h3\">",
"     Graft-versus-host disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graft-versus-host disease (GVHD) is also a risk factor for refractoriness to platelet transfusion in the HCT patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition to the thrombotic microangiopathy associated with GVHD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/21\">",
"     21",
"    </a>",
"    ], there is an increased incidence of platelet autoantibodies in patients with acute or chronic GVHD, suggesting a possible immune component to increased platelet destruction in this setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20950016\">",
"    <span class=\"h3\">",
"     Donor cell production of HLA antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two patients who received allogeneic HCT from their mothers, who were mismatched at one HLA antigen, developed platelet transfusion refractoriness post-HCT due to the development of HLA antibodies arising from the donor&rsquo;s cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/23\">",
"     23",
"    </a>",
"    ]. Each donor had probably been immunized during pregnancy by their partner&rsquo;s HLA antigens expressed in the fetus. These results suggest that, if mothers are selected as HCT donors for their children, they should be tested for the presence of HLA antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634040\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia caused by medications is relatively common, with hundreds of drugs implicated in this process. For example, administration of amphotericin has been associated with a reduced corrected count increment (CCI) following platelet transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/9\">",
"     9",
"    </a>",
"    ]. Drug-induced thrombocytopenia is usually immune-mediated and therefore transfused platelets, which are subject to the same immune-mediated destruction, can have a shortened lifespan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695453\">",
"    <span class=\"h1\">",
"     IMMUNE CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the various causes for platelet refractoriness, alloimmunization is the one for which there is the greatest potential for prevention and management. Platelet antigens causing alloimmunization can be separated into two groups, those that are shared with other blood cells and tissues, such as the human leukocyte antigen (HLA) system, and those that are specific to platelets, such as the human platelet antigen (HPA) system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/24\">",
"     24",
"    </a>",
"    ]. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695460\">",
"    <span class=\"h2\">",
"     Human leukocyte antigen (HLA) system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization to HLA antigens is a major risk factor for refractoriness to platelet transfusions. Although platelets express only HLA Class I antigens, HLA Class II antigens present on leukocytes may be essential for the development of alloimmunization to HLA Class I antigens. Exposure to foreign HLA Class II antigens can occur through prior transfusion or from maternal-fetal incompatibility during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/5,25\">",
"     5,25",
"    </a>",
"    ]. The importance of leukocytes in platelet refractoriness is illustrated by the findings in the TRAP study, which demonstrated a decrease in the rate of alloimmunization when leukocyte-reduced blood components were transfused [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prevention of alloimmunization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    While HLA-A and HLA-B antibodies are typically implicated, antibodies to HLA-C locus antigens have also been reported as a cause for platelet refractoriness. However, for practical purposes, in the United States at the present time, lists of",
"    <span class=\"nowrap\">",
"     blood/platelet",
"    </span>",
"    donors typed for the HLA-C locus antigen are not available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695467\">",
"    <span class=\"h2\">",
"     Human platelet antigen (HPA) system",
"    </span>",
"    &nbsp;&mdash;&nbsp;While alloimmune platelet refractoriness almost always results from the production of antibodies to HLA Class I antigens on the platelet surface, antibodies to platelet specific antigens (HPA) have been described as a cause for refractoriness to platelet transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Red cell antigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interestingly, some studies show that patients who have developed red blood cell (RBC) alloantibodies appear more likely to also have HLA antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. In one report, 53 surgical patients with RBC alloantibodies were compared with a control group of 69 similar patients with a history of previous transfusions but who had not developed RBC antibodies. HLA antibodies were found significantly more often in the group of patients who had developed RBC alloantibodies (23 versus 10 percent). This may be a reflection of the degree of immunocompetency in these patients. In other words, patients who develop RBC antibodies are probably more immunocompetent and more likely to become HLA alloimmunized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695474\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF PLATELET COMPONENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20949939\">",
"    <span class=\"h2\">",
"     Leukocyte reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of refractoriness to transfusion has been dramatically reduced given the widespread use of leukocyte-reduced blood components. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H4#H4\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'HLA alloimmunization and platelet refractoriness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The TRAP study demonstrated a significant decrease in the rate of alloimmunization in patients receiving leukocyte-reduced platelets when compared with non-leukocyte-reduced components (7 to 8 versus 16 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634115\">",
"    <span class=\"h2\">",
"     ABO compatibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is common and acceptable practice to transfuse ABO-non-identical platelets to patients, especially when ABO identical platelets are not available. Platelet increments following transfusion of ABO non-identical platelets demonstrate a blunted response compared with transfusion of ABO-identical platelets with decreased recovery but adequate survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. This blunted response should not be confused with alloimmunization. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'ABO matched platelets'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Another issue relates to infusion of ABO-incompatible plasma (eg, transfusion of a platelet unit from a group O donor that contains anti-A to an A recipient) with which there is a 1:2500 to 1:9000 risk of hemolysis. In general, transfusion services have policies dictating the transfusion of ABO-identical or plasma compatible platelets when available. However, when these products are unavailable, the patient&rsquo;s indication for transfusion will outweigh the potential risk of hemolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634122\">",
"    <span class=\"h2\">",
"     Age of the platelet product",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors not only define platelet refractoriness as an inadequate platelet increment, but also include certain requirements for the transfused platelet product (ie, use ABO-identical fresh platelets less than 72 hours old) in order to make the diagnosis of refractoriness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ]. It would be ideal when attempting to determine the cause of inadequate response to platelet transfusion, to limit the number of confounding variables by transfusing the freshest ABO-identical platelets available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prevention of alloimmunization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695481\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractoriness to platelet transfusion is defined in this review as a platelet count response significantly less than expected to",
"    <strong>",
"     two or more",
"    </strong>",
"    platelet transfusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695488\">",
"    <span class=\"h2\">",
"     Measuring response to platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following formula has been used to measure the response to platelet transfusion based on a platelet count obtained 10 minutes to one hour post-transfusion:",
"   </p>",
"   <p>",
"    Corrected count increment (CCI) = [PPI x BSA (m",
"    <sup>",
"     2",
"    </sup>",
"    )] x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      11",
"     </sup>",
"     /",
"    </span>",
"    number of platelets transfused",
"   </p>",
"   <p>",
"    PPI represents the post-transfusion platelet increment (ie, post-transfusion platelet count minus pre-transfusion platelet count) and BSA is body surface area measured in square meters.",
"   </p>",
"   <p>",
"    In the non-refractory patient, the value of the CCI most often seen in practice is",
"    <span class=\"nowrap\">",
"     &ge;10,000/microL.",
"    </span>",
"    This is roughly equivalent to a rise in platelet count of",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    in the average adult patient based on a BSA of 2.0 m",
"    <sup>",
"     2",
"    </sup>",
"    and transfusion of one unit of single donor apheresis platelets (or an equivalent pool of whole-blood derived platelet concentrates) containing approximately 4 to 5 x 10",
"    <sup>",
"     11",
"    </sup>",
"    platelets.",
"   </p>",
"   <p>",
"    Refractoriness to platelet transfusion according to the American Society of Clinical Oncology is defined as a CCI of",
"    <span class=\"nowrap\">",
"     &lt;5000/microL",
"    </span>",
"    on at least two sequential occasions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ]. This is roughly equivalent to an absolute platelet count increment of less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    after administration of an apheresis unit given to an average-sized adult. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H382870688#H382870688\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet count increment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695495\">",
"    <span class=\"h2\">",
"     Making the diagnosis of refractoriness to platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the CCI can be used, it may not be the most practical means of assessing response to transfusion, as the number of platelets transfused is not always available. Therefore, we recommend the use of two measurements of platelet response when evaluating the refractory patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Platelet recovery",
"      </strong>",
"      - Defined as the increment in platelet count measured 10 minutes to one hour following transfusion. (See",
"      <a class=\"local\" href=\"#H16695488\">",
"       'Measuring response to platelet transfusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Platelet survival",
"      </strong>",
"      - Evaluated by a platelet count obtained 18 to 24 hours post-transfusion. Platelet survival should be sufficient to permit a gradual fall in the platelet count to pre-transfusion levels in approximately three days (",
"      <a class=\"graphic graphic_figure graphicRef82283 \" href=\"mobipreview.htm?3/29/3550\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both platelet recovery and platelet survival should be evaluated. Platelet refractoriness is considered to be present if there is a substantially smaller rise in the platelet count",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a substantially more rapid return to pre-transfusion levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ]. The patterns of response seen in various conditions are shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef82283 \" href=\"mobipreview.htm?3/29/3550\">",
"     figure 2",
"    </a>",
"    ). Two patterns can be seen in refractory patients:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1653725\">",
"    <span class=\"h3\">",
"     Pattern for non-immune causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal increment at one hour following transfusion (normal platelet recovery), with return to the baseline count within 24 hours (reduced platelet survival), is typical of the shortening of platelet survival seen with sepsis, following hematopoietic cell transplantation, disseminated intravascular coagulation (DIC), and possibly in bleeding patients and those taking medications that interfere with platelet survival. This type of pattern is not consistent with alloimmunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1653732\">",
"    <span class=\"h3\">",
"     Pattern for immune causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little or no increment in platelet count (reduced platelet recovery), even within one hour of transfusion, is seen with alloimmunization. In general, a poor platelet increment should be demonstrated after at least two transfusions before entertaining the diagnosis of refractoriness secondary to alloimmunization.",
"   </p>",
"   <p>",
"    When the first pattern is present, little can be done to improve the platelet transfusion response other than appropriate therapy for the underlying disease. In contrast, effective modalities are available if the second pattern is present, which suggests alloimmunization as a cause of refractoriness to platelet transfusion (",
"    <a class=\"graphic graphic_algorithm graphicRef73873 \" href=\"mobipreview.htm?42/16/43264\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For patients who appear to be alloimmunized, we recommend that a sample of the patient's plasma be tested for the presence of antibodies to the human leukocyte antigen system (ie, anti-HLA antibodies). The presence of HLA antibodies is demonstrated by testing patient plasma against a panel of lymphocytes (or synthetic beads bearing Class I antigens) that represent most of the HLA Class I specificities in the population. If the antibody screen is negative, testing for antibodies to the human platelet antigen system (ie, anti-HPA antibodies) should be performed (",
"    <a class=\"graphic graphic_algorithm graphicRef73873 \" href=\"mobipreview.htm?42/16/43264\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    At our institution, we do not routinely obtain HLA typing on refractory patients as our approach is to provide HLA-antigen negative &ldquo;compatible&rdquo; platelets (ie, platelets that do not contain the HLA antigens to which the patient has developed antibodies). However, if an HLA typing has been obtained for transplantation purposes, these results are used to find HLA-matched platelet units. (See",
"    <a class=\"local\" href=\"#H16695502\">",
"     'HLA-antigen negative &ldquo;compatible&rdquo; platelets'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A modification of the technique using synthetic beads bearing Class I antigens is to detect only those HLA antibodies capable of binding the first component of complement (C1q) in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/37\">",
"     37",
"    </a>",
"    ]. If confirmed in other studies, this method may be better able to identify clinically relevant antibodies and to select acceptable platelet units. Currently, this technique is not widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20950169\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NON-ALLOIMMUNIZED PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A normal platelet count increment at one hour following transfusion (normal platelet recovery), with return to the baseline count within 24 hours (reduced platelet survival), is typical of the shortening of platelet survival seen in the non-immunized patient. The most common causes of this pattern are sepsis, hematopoietic cell transplantation, disseminated intravascular coagulation (DIC), and the taking of medications that interfere with platelet survival (",
"    <a class=\"graphic graphic_algorithm graphicRef73873 \" href=\"mobipreview.htm?42/16/43264\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    When this pattern is present, little can be done to improve the transfusion response other than appropriate therapy for the underlying disease condition (eg, sepsis, DIC, malignancy, drug-related) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE ALLOIMMUNIZED PATIENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to suggest that the transfusion trigger for patients refractory to platelet transfusion should be any different from that for non-refractory patients. In cases of non-immune platelet refractoriness, the underlying illness or condition (eg, sepsis, DIC, drug) must be treated. In cases of immune-mediated refractoriness, there are several strategies to consider when selecting platelets for these patients: provision of HLA-matched platelets or HLA &ldquo;compatible&rdquo; (antigen-negative) platelets; platelets selected by crossmatch tests; and maneuvers to reduce alloimmunization. Furthermore, given the transient nature of antibody production, patients diagnosed with refractoriness need to be regularly reassessed for the",
"    <span class=\"nowrap\">",
"     presence/specificity",
"    </span>",
"    of antibodies in order to assure provision of compatible platelet units and avoid unnecessary use of more expensive and difficult to obtain compatible units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16699776\">",
"    <span class=\"h2\">",
"     Platelet selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once antibodies to HLA or HPA antigens are identified, the Transfusion Service will work with the clinical team and community blood center to find compatible platelet products.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     HLA antibodies against platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available approaches are listed below when HLA antibodies against platelets have been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     HLA-matched platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional management of patients with HLA antibodies is to provide platelets from donors HLA-matched for the HLA-A and HLA-B loci. Although platelets express HLA-C antigens on their surface, and antibodies against HLA-C antigens have been demonstrated as a cause for immune-mediated refractoriness, platelets are not routinely matched for HLA-C antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of HLA matching was first described in a study published in 1969 in which it was demonstrated that administration of platelets from HLA-matched family members improved both platelet recovery and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HLA-matched donors can be found either among family members or via a registry of HLA typed unrelated individuals typically maintained by the community blood center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/38,40,41\">",
"     38,40,41",
"    </a>",
"    ]. The degree of match, based on the traditional classification system in the table, can predict the success of post-transfusion platelet count increments:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade A and BU (B1U or B2U) HLA-matched platelets are associated with the best increases in platelet count.",
"     </li>",
"     <li>",
"      Selection of platelet donors with antigens in the same &ldquo;cross-reactive groups&rdquo; (CREGs) as the patient&rsquo;s antigens, has been demonstrated to be nearly as successful in supporting alloimmune platelet refractoriness as HLA-matched transfusions (Grade B1X or B2UX) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/42\">",
"       42",
"      </a>",
"      ]. This appears to be due to the inability of the patient&rsquo;s immune system to recognize these CREGs as different. Expanding the available number of units with use of CREGs can significantly increase the pool of potential &ldquo;compatible&rdquo; donors.",
"     </li>",
"     <li>",
"      B2X, C, and D matches give post-transfusion responses similar to that of randomly selected platelet products.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unfortunately, for many patients, HLA-matched donors, despite the use of selection algorithms that included CREGs, are frequently unavailable. Under these circumstances, transfusion of platelets from partially mismatched donors may provide adequate responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative computerized matching techniques are now emerging and may further improve the ability of blood banks to provide apheresis platelets for HLA-alloimmunized patients. As an example, the HLAMatchmaker is a software algorithm that predicts HLA compatibility including acceptable mismatched options. This method takes into account CREGs, HLA matching on a DNA rather than a serological level, and matching for highly immunogenic HLA epitopes, as well as HLA-C antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients in whom HLA alloimmunization alone is responsible for platelet refractoriness generally respond well to HLA-matched donor platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/38-40,49\">",
"     38-40,49",
"    </a>",
"    ]. Whenever HLA-matched platelets are provided to patients, such components should be irradiated to prevent transfusion-associated graft-versus-host disease. Furthermore, it is essential to obtain a 10-minute to one-hour post-transfusion count to monitor the response to these units. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=see_link&amp;anchor=H4#H4\">",
"     \"Transfusion-associated graft-versus-host disease\", section on 'Partial HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An HLA-matched donor can usually safely donate as often as twice a week for several weeks without becoming thrombocytopenic. However, for patients requiring longer periods of transfusion support (eg, aplastic anemia), it is preferable to locate several donors to support the patient&rsquo;s platelet needs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H558381883#H558381883\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'ABO, Rh, and HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695502\">",
"    <span class=\"h4\">",
"     HLA-antigen negative &ldquo;compatible&rdquo; platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another approach to further increase the available donor pool is to choose apheresis platelet units that lack HLA antigens reacting specifically with the patient&rsquo;s antibodies. This is a similar approach to the technique used to provide compatible RBCs for patients who have RBC antibodies. With this method, the laboratory does not intend to provide units that match for every antigen present, but rather finds units lacking only those antigens to which the patient has antibodies. At our institution, this is our standard approach, given the greater likelihood of finding a compatible unit.",
"   </p>",
"   <p>",
"    This approach was described in 29 HLA-alloimmunized patients refractory to transfusion with random-donor platelets. In this study, a regional blood center was able to find a mean of only six donors per patient who were a four-antigen HLA match, and 33 donors who were identical at two or three loci, while they could identify over 1400 donors who were potentially safe by the antibody specificity method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695509\">",
"    <span class=\"h4\">",
"     Crossmatch-compatible platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach is to identify compatible units of apheresis platelets by crossmatching the units with the patient's plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/40,50\">",
"     40,50",
"    </a>",
"    ]. These serologic techniques are typically available through community blood centers with commercially available automated kits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/51\">",
"     51",
"    </a>",
"    ]. The solid-phase red cell adherence test (SPRCA) is the most widely used method for platelet cross-matching.",
"   </p>",
"   <p>",
"    Compared with HLA matching, crossmatching can be both more convenient and economical. Crossmatching allows for a quick and effective selection of units from the available inventory and can be performed in a few hours as opposed to the days it may take to identify, recruit, collect, and test an appropriate HLA-matched donor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/52\">",
"     52",
"    </a>",
"    ]. It is also of benefit to patients with uncommon HLA types where it would be very difficult to find an HLA-matched donor. Additionally, it avoids exclusion of HLA-mismatched but otherwise compatible donors thereby increasing the number of potentially compatible units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695516\">",
"    <span class=\"h3\">",
"     HPA antibodies against platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crossmatching may be beneficial in the infrequent patient in whom refractoriness to platelet transfusion is due to the presence of antibodies to the human platelet antigen (HPA) system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/27,53\">",
"     27,53",
"    </a>",
"    ]. As an example, in one study of 293 multiply-transfused thrombocytopenic patients, the rate of alloimmunization to HPA antigens was 2 percent, whereas the rate of alloimmunization to HLA antigens was 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of this method was demonstrated in a patient with antibodies directed against the HPA-1a antigen (PLA1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/27\">",
"     27",
"    </a>",
"    ]. This patient, who had life-threatening bleeding and no response to transfusion of HLA-matched platelets, had excellent platelet increments and cessation of bleeding following transfusion of HPA-1a negative platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     ABO matched platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have recommended that the initial approach to managing refractory patients should be to select fresher platelet units as well as those from ABO identical donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ]. Such a strategy has anecdotally improved recovery and survival in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/40,55-58\">",
"     40,55-58",
"    </a>",
"    ] and, as stated in a recent systematic review of the available literature, has been associated with a definite higher platelet count increment over the use of ABO-non identical transfusions, although the clinical significance of the greater platelet count increments was minimal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/4,59,60\">",
"     4,59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H558381883#H558381883\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'ABO, Rh, and HLA matching'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of ABO-identical, non-HLA compatible platelets is unlikely to be effective in patients who have true alloimmune refractoriness. Provision of fresh or ABO-matched platelets should not delay efforts to secure HLA-matched or crossmatch-compatible platelets. However, when available, extending the match for both HLA and ABO may provide additional benefit in some patients over HLA matching alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/61\">",
"     61",
"    </a>",
"    ]. This was shown in a study of 50 pediatric patients with beta thalassemia major and platelet transfusion refractoriness following hematopoietic stem cell transplantation. Transfusion outcome depended upon both the degree of HLA matching and ABO compatibility, as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/62\">",
"     62",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Matched at HLA and ABO compatible: 76 percent successful platelet transfusions",
"     </li>",
"     <li>",
"      Matched at HLA and ABO incompatible or mismatched at HLA and ABO compatible: 67 percent successful",
"     </li>",
"     <li>",
"      Mismatched at HLA and ABO incompatible: 46 percent successful",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment of active bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute management of bleeding in patients who have alloimmune platelet refractoriness can be difficult. The most dangerous complications are intrapulmonary or intracranial hemorrhage resulting in significant morbidity and mortality. Thus, aggressive intervention must begin before these complications have occurred (eg, when extensive mucous membrane bleeding [&ldquo;wet purpura&rdquo;] is observed, a generally accepted prognostic sign for potentially life-threatening hemorrhage). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult patient with thrombocytopenia\", section on 'Purpura'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most effective therapy, as noted above, is transfusion of either HLA-compatible (matched or antigen-negative) or crossmatch-compatible platelets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ]. If these cannot be obtained, repeated infusions of random apheresis platelets should be attempted, although there is little evidence that this strategy is beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of drug therapies have been attempted based, at least in part, upon their efficacy in autoimmune thrombocytopenia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Antifibrinolytic agents",
"      </strong>",
"      (eg, epsilon",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30311?source=see_link\">",
"       aminocaproic acid",
"      </a>",
"      ) have been utilized to reduce bleeding in thrombocytopenic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/63\">",
"       63",
"      </a>",
"      ], and are probably safe in patients who are not at risk for increased intravascular coagulation.",
"     </li>",
"     <li>",
"      <strong>",
"       Intravenous immune globulin",
"      </strong>",
"      (IVIG) has been proposed as a strategy for immune modulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/64\">",
"       64",
"      </a>",
"      ], but the results have generally been unimpressive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. In a controlled trial, IVIG (400",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      for five days) provided platelet transfusion response benefit in five of seven patients at one and six hours post-transfusion, but not at 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/67\">",
"       67",
"      </a>",
"      ]. However, this short-term response may be sufficient in patients who are actively bleeding.",
"     </li>",
"     <li>",
"      <strong>",
"       Splenectomy",
"      </strong>",
"      appears to be of no value in the alloimmunized patient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/67\">",
"       67",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Splenomegaly'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/42/30373?source=see_link\">",
"       Recombinant human factor VIIa",
"      </a>",
"      <strong>",
"      </strong>",
"      -",
"      <strong>",
"      </strong>",
"      Anecdotal success has been reported using recombinant factor VIIa to arrest bleeding in an HLA alloimmunized thrombocytopenic patient refractory to transfusion with cross-match compatible platelets [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/68\">",
"       68",
"      </a>",
"      ]. While this represents an off-label use of this product, it may be a reasonable option as a temporary measure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      last resort, considering the specific institutional protocols and availability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=see_link&amp;anchor=H9#H9\">",
"       \"Therapeutic uses of recombinant coagulation factor VIIa\", section on 'Glanzmann thrombasthenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Glucocorticoids",
"      </strong>",
"      have not been useful when given in standard doses; we are not aware of studies using very high doses of these agents.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevention of alloimmunization",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695523\">",
"    <span class=\"h3\">",
"     Leukoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;It may be possible to decrease the incidence of alloimmunization to HLA Class I antigens and subsequent platelet refractoriness by utilizing leukocyte-reduced blood components for transfusion. This effort relies on the role of HLA Class II antigens on transfused leukocytes in initiating the primary immune response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H4#H4\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'HLA alloimmunization and platelet refractoriness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several randomized platelet transfusion trials have clearly documented the effectiveness of transfusing leukoreduced blood products compared with non-leukocyte-reduced products in preventing the development of HLA antibodies. The TRAP trial is the largest study to date that has addressed this issue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"     25",
"    </a>",
"    ]. This randomized, multicenter trial included 530 patients who received induction chemotherapy for acute myeloid leukemia and who had no alloantibodies at baseline. The use of platelet transfusions that were modified by leukocyte reduction compared with the transfusion of unmodified platelets significantly lowered the rate of development of lymphocytotoxic antibodies (17 to 18 versus 45 percent), as well as the incidence of alloimmune platelet refractoriness (3 to 4 versus 13 percent). Interestingly, the rates of antibody production were considerably higher than the rate of platelet refractoriness, reinforcing that alloimmune platelet refractoriness is a clinical, rather than a laboratory, diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16695530\">",
"    <span class=\"h3\">",
"     Use of ABO compatible platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets express ABH antigens on their surface. These antigens are intrinsic to the platelet membrane and passively adsorbed from plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/70\">",
"     70",
"    </a>",
"    ]. Studies have demonstrated that ABO-incompatible platelet transfusions are associated with a reduced post-transfusion increment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/4,55\">",
"     4,55",
"    </a>",
"    ]. In a systematic review of the available literature, the authors concluded that ABO-identical platelet transfusion appears to reduce the frequency of platelet refractoriness compared with ABO-non-identical transfusion, but it has yet to be determined whether this is true when comparing ABO-identical (matched) with ABO-compatible platelet transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/59,71\">",
"     59,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above-mentioned strategies may not be effective for all patients. For example, there is a higher incidence of platelet transfusion refractoriness in women who have been pregnant, and it may be impossible to prevent the secondary immune response and refractoriness in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8634211\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"      ��� Refractoriness to platelet transfusion is present when there is a platelet count response significantly less than expected following",
"      <strong>",
"       two or more",
"      </strong>",
"      platelet transfusions. A normal response in an average adult given one unit of single donor apheresis platelets is a rise in platelet count of approximately",
"      <span class=\"nowrap\">",
"       30,000/microL",
"      </span>",
"      in 10 to 60 minutes (corrected count increment",
"      <span class=\"nowrap\">",
"       &ge;10,000/microL),",
"      </span>",
"      with a return to baseline at three days (",
"      <a class=\"graphic graphic_figure graphicRef82283 \" href=\"mobipreview.htm?3/29/3550\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16695481\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A normal increment at one hour with return to the baseline count within 24 hours is typical of the pattern seen with sepsis, following hematopoietic cell transplantation, disseminated intravascular coagulation, and use of medications that interfere with platelet survival. When this pattern is present, little can be done to improve the transfusion response other than therapy for the underlying disease condition (",
"      <a class=\"graphic graphic_algorithm graphicRef73873 \" href=\"mobipreview.htm?42/16/43264\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16695446\">",
"       'Non-immune causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Little or no increment in platelet count within one hour of transfusion (a rise in platelet count of less than 10,000 to",
"      <span class=\"nowrap\">",
"       15,000/microL",
"      </span>",
"      or corrected count increment",
"      <span class=\"nowrap\">",
"       &lt;5000/microL),",
"      </span>",
"      is seen in patients with antibodies to antigens of the HLA or HPA system (ie, immune-mediated), and may be seen in patients with massive splenomegaly. (See",
"      <a class=\"local\" href=\"#H16695453\">",
"       'Immune causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Splenomegaly'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Management",
"      </strong>",
"      ��� In cases of immune-mediated refractoriness, there are several strategies to consider when selecting platelets: HLA-matched platelets, HLA &ldquo;compatible&rdquo; (antigen-negative) platelets, platelets selected by crossmatch tests, and HPA compatible platelets when HPA antibodies are present (",
"      <a class=\"graphic graphic_algorithm graphicRef73873 \" href=\"mobipreview.htm?42/16/43264\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Management of the alloimmunized patient'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16699776\">",
"       'Platelet selection'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment of active bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Prevention ���",
"      </strong>",
"      There are two available methods for reducing platelet alloimmunization:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that leukoreduced platelets be administered whenever possible (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This is routine practice in most blood banks. (See",
"      <a class=\"local\" href=\"#H16695523\">",
"       'Leukoreduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=see_link&amp;anchor=H4#H4\">",
"       \"Leukoreduction to prevent complications of blood transfusion\", section on 'HLA alloimmunization and platelet refractoriness'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that ABO-identical (preferred) or ABO-compatible platelets be administered whenever this is logistically possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Those at greatest risk for platelet refractoriness (ie,",
"      <span class=\"nowrap\">",
"       hematology/oncology",
"      </span>",
"      patients undergoing hematopoietic cell transplantation) should be given preference for ABO-identical or ABO-compatible products. (See",
"      <a class=\"local\" href=\"#H16695530\">",
"       'Use of ABO compatible platelets'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Petz L. Platelet transfusions. In: Clinical Practice of Transfusion Medicine, 3rd ed, Petz L, Swisher SN, Kleinman S, et al. (Eds), Churchill Livingston, New York 1996. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/2\">",
"      Kerkhoffs JL, Eikenboom JC, van de Watering LM, et al. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion 2008; 48:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/3\">",
"      Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol 2008; 142:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/4\">",
"      Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105:4106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/5\">",
"      Legler TJ, Fischer I, Dittmann J, et al. Frequency and causes of refractoriness in multiply transfused patients. Ann Hematol 1997; 74:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/6\">",
"      Klingemann HG, Self S, Banaji M, et al. Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. Br J Haematol 1987; 66:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/7\">",
"      Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988; 71:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/8\">",
"      Novotny VM. Prevention and management of platelet transfusion refractoriness. Vox Sang 1999; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/9\">",
"      B&ouml;ck M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion 1996; 36:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/10\">",
"      St&eacute;phan F, Cheffi MA, Kaplan C, et al. Autoantibodies against platelet glycoproteins in critically ill patients with thrombocytopenia. Am J Med 2000; 108:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/11\">",
"      Bogdonoff DL, Williams ME, Stone DJ. Thrombocytopenia in the critically ill patient. J Crit Care 1990; 5:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/12\">",
"      George MR, Herman JH, Holdbrook T, et al. Platelet refractoriness in acquired hemophagocytic syndrome. Transfusion 2011; 51:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/13\">",
"      Ventura GJ, Hester JP, Dixon DO, et al. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol 1989; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/14\">",
"      Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia. J Clin Invest 1966; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/15\">",
"      Klumpp TR, Herman JH, Innis S, et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant 1996; 17:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/16\">",
"      Benson K, Fields K, Hiemenz J, et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. Semin Oncol 1993; 20:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/17\">",
"      Ishida A, Handa M, Wakui M, et al. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation--a prospective analysis. Transfusion 1998; 38:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/18\">",
"      Li G, Liu F, Mao X, Hu L. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation. Transfus Apher Sci 2011; 45:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/19\">",
"      Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/20\">",
"      Rio B, Andreu G, Nicod A, et al. Thrombocytopenia in venocclusive disease after bone marrow transplantation or chemotherapy. Blood 1986; 67:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/21\">",
"      Daly AS, Hasegawa WS, Lipton JH, et al. Transplantation-associated thrombotic microangiopathy is associated with transplantation from unrelated donors, acute graft-versus-host disease and venoocclusive disease of the liver. Transfus Apher Sci 2002; 27:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/22\">",
"      Anasetti C, Rybka W, Sullivan KM, et al. Graft-v-host disease is associated with autoimmune-like thrombocytopenia. Blood 1989; 73:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/23\">",
"      Hatakeyama N, Hori T, Yamamoto M, et al. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother. Pediatr Transplant 2011; 15:E177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/24\">",
"      Tinmouth AT, Semple E, Shehata N, Branch DR. Platelet immunopathology and therapy: a Canadian Blood Services Research and Development Symposium. Transfus Med Rev 2006; 20:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/25\">",
"      Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/26\">",
"      Saito S, Ota S, Seshimo H, et al. Platelet transfusion refractoriness caused by a mismatch in HLA-C antigens. Transfusion 2002; 42:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/27\">",
"      Pappalardo PA, Secord AR, Quitevis P, et al. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001; 41:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/28\">",
"      Vassallo RR. Recognition and management of antibodies to human platelet antigens in platelet transfusion-refractory patients. Immunohematology 2009; 25:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/29\">",
"      Brantley SG, Ramsey G. Red cell alloimmunization in multitransfused HLA-typed patients. Transfusion 1988; 28:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/30\">",
"      Buetens O, Shirey RS, Goble-Lee M, et al. Prevalence of HLA antibodies in transfused patients with and without red cell antibodies. Transfusion 2006; 46:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/31\">",
"      Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/32\">",
"      Josephson CD, Mullis NC, Van Demark C, Hillyer CD. Significant numbers of apheresis-derived group O platelet units have \"high-titer\" anti-A/A,B: implications for transfusion policy. Transfusion 2004; 44:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/33\">",
"      Julmy F, Ammann RA, Taleghani BM, et al. Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs. Transfusion 2009; 49:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/34\">",
"      Kaufman RM. Platelet ABO matters. Transfusion 2009; 49:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/35\">",
"      Quillen K, Sheldon SL, Daniel-Johnson JA, et al. A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies. Transfusion 2011; 51:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/36\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/37\">",
"      Fontaine MJ, Kuo J, Chen G, et al. Complement (C1q) fixing solid-phase screening for HLA antibodies increases the availability of compatible platelet components for refractory patients. Transfusion 2011; 51:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/38\">",
"      McFarland JG, Anderson AJ, Slichter SJ. Factors influencing the transfusion response to HLA-selected apheresis donor platelets in patients refractory to random platelet concentrates. Br J Haematol 1989; 73:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/39\">",
"      Yankee RA, Grumet FC, Rogentine GN. Platelet transfusion The selection of compatible platelet donors for refractory patients by lymphocyte HL-A typing. N Engl J Med 1969; 281:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/40\">",
"      Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987; 70:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/41\">",
"      Yankee RA, Graff KS, Dowling R, Henderson ES. Selection of unrelated compatible platelet donors by lymphocyte HL-A matching. N Engl J Med 1973; 288:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/42\">",
"      Duquesnoy RJ, Filip DJ, Rodey GE, et al. Successful transfusion of platelets \"mismatched\" for HLA antigens to alloimmunized thrombocytopenic patients. Am J Hematol 1977; 2:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/43\">",
"      Schiffer CA, O'Connell B, Lee EJ. Platelet transfusion therapy for alloimmunized patients: selective mismatching for HLA B12, an antigen with variable expression on platelets. Blood 1989; 74:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/44\">",
"      Hussein MA, Lee EJ, Fletcher R, Schiffer CA. The effect of lymphocytotoxic antibody reactivity on the results of single antigen mismatched platelet transfusions to alloimmunized patients. Blood 1996; 87:3959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/45\">",
"      Nambiar A, Duquesnoy RJ, Adams S, et al. HLAMatchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. Blood 2006; 107:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/46\">",
"      Duquesnoy RJ. Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008; 48:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/47\">",
"      Brooks EG, MacPherson BR, Fung MK. Validation of HLAMatchmaker algorithm in identifying acceptable HLA mismatches for thrombocytopenic patients refractory to platelet transfusions. Transfusion 2008; 48:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/48\">",
"      Pai SC, Lo SC, Lin Tsai SJ, et al. Epitope-based matching for HLA-alloimmunized platelet refractoriness in patients with hematologic diseases. Transfusion 2010; 50:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/49\">",
"      Levin MD, Kappers-Klunne M, Sintnicolaas K, et al. The value of alloantibody detection in predicting response to HLA-matched platelet transfusions. Br J Haematol 2004; 124:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/50\">",
"      Petz LD, Garratty G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion 2000; 40:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/51\">",
"      Rebulla P, Morelati F, Revelli N, et al. Outcomes of an automated procedure for the selection of effective platelets for patients refractory to random donors based on cross-matching locally available platelet products. Br J Haematol 2004; 125:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/52\">",
"      Sacher RA, Kickler TS, Schiffer CA, et al. Management of patients refractory to platelet transfusion. Arch Pathol Lab Med 2003; 127:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/53\">",
"      Arber C, Bertrand G, Halter J, et al. Platelet refractoriness due to combined anti-HLA and anti-HPA-5a alloantibodies: clinical management during myeloablative allogeneic HSCT and development of a quantitative MAIPA assay. Br J Haematol 2007; 139:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/54\">",
"      Kickler T, Kennedy SD, Braine HG. Alloimmunization to platelet-specific antigens on glycoproteins IIb-IIIa and Ib/IX in multiply transfused thrombocytopenic patients. Transfusion 1990; 30:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/55\">",
"      Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood 1965; 26:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/56\">",
"      Brand A, Sintnicolaas K, Claas FH, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986; 26:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/57\">",
"      Jim&eacute;nez TM, Patel SB, Pineda AA, et al. Factors that influence platelet recovery after transfusion: resolving donor quality from ABO compatibility. Transfusion 2003; 43:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/58\">",
"      Julmy F, Achermann F, Schulzki T, et al. PLTs of blood group A1 donors express increased surface A antigen owing to apheresis and prolonged storage. Transfusion 2003; 43:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/59\">",
"      Shehata N, Tinmouth A, Naglie G, et al. ABO-identical versus nonidentical platelet transfusion: a systematic review. Transfusion 2009; 49:2442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/60\">",
"      Pavenski K, Warkentin TE, Shen H, et al. Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study. Transfusion 2010; 50:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/61\">",
"      McVey M, Cserti-Gazdewich CM. Platelet transfusion refractoriness responding preferentially to single donor aphaeresis platelets compatible for both ABO and HLA. Transfus Med 2010; 20:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/62\">",
"      Marktel S, Napolitano S, Zino E, et al. Platelet transfusion refractoriness in highly immunized beta thalassemia children undergoing stem cell transplantation. Pediatr Transplant 2010; 14:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/63\">",
"      Kalmadi S, Tiu R, Lowe C, et al. Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. Cancer 2006; 107:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/64\">",
"      Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991; 38:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/65\">",
"      Schiffer CA, Hogge DE, Aisner J, et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984; 64:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/66\">",
"      Kickler T, Braine HG, Piantadosi S, et al. A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. Blood 1990; 75:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/67\">",
"      Hogge DE, Dutcher JP, Aisner J, Schiffer CA. The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients. Blood 1984; 64:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/68\">",
"      Heuer L, Blumenberg D. Management of bleeding in a multi-transfused patient with positive HLA class I alloantibodies and thrombocytopenia associated with platelet dysfunction refractory to transfusion of cross-matched platelets. Blood Coagul Fibrinolysis 2005; 16:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/69\">",
"      Goldfinger D, Lowe C. Prevention of adverse reactions to blood transfusion by the administration of saline-washed red blood cells. Transfusion 1981; 21:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/70\">",
"      Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABH antigens on human platelets. Blood 1985; 65:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37945/abstract/71\">",
"      Carr R, Hutton JL, Jenkins JA, et al. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990; 75:408.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7922 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37945=[""].join("\n");
var outline_f37_3_37945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8634211\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16695439\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16695446\">",
"      NON-IMMUNE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8634026\">",
"      Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8634033\">",
"      - Graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20950016\">",
"      - Donor cell production of HLA antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8634040\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16695453\">",
"      IMMUNE CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16695460\">",
"      Human leukocyte antigen (HLA) system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16695467\">",
"      Human platelet antigen (HPA) system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Red cell antigens",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16695474\">",
"      CHARACTERISTICS OF PLATELET COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20949939\">",
"      Leukocyte reduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8634115\">",
"      ABO compatibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8634122\">",
"      Age of the platelet product",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16695481\">",
"      DIAGNOSTIC APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16695488\">",
"      Measuring response to platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16695495\">",
"      Making the diagnosis of refractoriness to platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1653725\">",
"      - Pattern for non-immune causes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1653732\">",
"      - Pattern for immune causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20950169\">",
"      MANAGEMENT OF THE NON-ALLOIMMUNIZED PATIENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      MANAGEMENT OF THE ALLOIMMUNIZED PATIENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16699776\">",
"      Platelet selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - HLA antibodies against platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      HLA-matched platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16695502\">",
"      HLA-antigen negative &ldquo;compatible&rdquo; platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H16695509\">",
"      Crossmatch-compatible platelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16695516\">",
"      - HPA antibodies against platelets",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - ABO matched platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment of active bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevention of alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16695523\">",
"      - Leukoreduction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16695530\">",
"      - Use of ABO compatible platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8634211\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7922\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7922|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/16/43264\" title=\"algorithm 1\">",
"      Diagnosis and management of platelet refractoriness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7922|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/24/7566\" title=\"figure 1\">",
"      Splenic platelet pooling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/29/3550\" title=\"figure 2\">",
"      Patterns of response to platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7922|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/43/5819\" title=\"table 1\">",
"      Causes platelet transfusion refractoriness",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15674?source=related_link\">",
"      Approach to the adult patient with thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/12/200?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31962?source=related_link\">",
"      Therapeutic uses of recombinant coagulation factor VIIa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/35/6710?source=related_link\">",
"      Transfusion-associated graft-versus-host disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37946="Clinical manifestations and diagnosis of celiac disease in children";
var content_f37_3_37946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of celiac disease in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     Ivor D Hill, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/3/37946/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/3/37946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease (also known as gluten-sensitive enteropathy or nontropical sprue) is an immune-mediated inflammation of the small intestine caused by sensitivity to dietary gluten and related proteins in genetically sensitive individuals. The disorder is common, occurring in 0.5 to 1 percent of the general population in most countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The grains that contain the triggering proteins are wheat, barley, and rye; there is some controversy as to whether oats also can cause the disease. The small intestinal mucosa improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced. In a study from an era in which celiac disease was not treated, mortality was 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/2\">",
"     2",
"    </a>",
"    ]. The appropriate treatment is a gluten-free diet for life, and this results in complete resolution of symptoms for most individuals.",
"   </p>",
"   <p>",
"    The diagnosis and clinical manifestations of celiac disease are reviewed here. Its management and the use of antibodies for diagnosis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic is discussed in an official position statement issued by the American Gastroenterological Association [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/3\">",
"     3",
"    </a>",
"    ] and a consensus statement from the National Institutes of Health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/4\">",
"     4",
"    </a>",
"    ]. The discussion below also reflects guidelines developed by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ] and the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5\">",
"     5",
"    </a>",
"    ]. The pediatric guidelines are available on the NASPGHAN Web site (",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of celiac disease was unexplained until the Dutch pediatrician Willem K Dicke recognized an association between the consumption of bread and cereals and relapsing diarrhea. This observation was corroborated when, during periods of food shortage in the Second World War, the symptoms of his patients improved once bread was replaced by non-cereal-containing foods; this finding confirmed the benefit of earlier, empirical diets that used pure fruit, potatoes, banana, milk, or meat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because symptoms reoccurred when bread was reintroduced after the war, Dicke and van de Kamer initiated controlled experiments exposing children with celiac disease to defined diets and then determined fecal weight and fecal fat as a measure of malabsorption. Wheat, barley, rye, and (to a minor degree) oats triggered malabsorption, which could be reversed after exclusion of these \"toxic\" cereals from the diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/9\">",
"     9",
"    </a>",
"    ]. Shortly thereafter, the toxic agents were found to be present in gluten, the primary protein found in wheat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The celiac lesion in the proximal small intestine was first described in 1954. The primary findings were mucosal inflammation, crypt hyperplasia, and villous atrophy (",
"    <a class=\"graphic graphic_picture graphicRef76680 \" href=\"mobipreview.htm?23/30/24041\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/11\">",
"     11",
"    </a>",
"    ]. With the development of peroral biopsy, it became apparent that celiac disease and adult nontropical sprue shared the same features and pathogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is an immune disorder that is triggered by an environmental agent (gluten) in genetically predisposed individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The genetic basis of the disease is shown by the frequent intrafamilial occurrence and the remarkably close association with the HLA-DQ2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DQ8 gene locus. More than 99 percent of individuals with celiac disease have HLA DQ2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    DQ8, compared with 40 percent of the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/15\">",
"     15",
"    </a>",
"    ]. While the presence of either the HLA DQ2 or DQ8 genotype is essential to confer disease, it is not sufficient, and another gene or genes at a non-HLA locus must also participate. Non-HLA genes are likely to be a stronger determinant of disease susceptibility than the HLA locus.",
"   </p>",
"   <p>",
"    Because of common genetic contributors, several groups are at increased risk for celiac disease. The genetic contributors to celiac disease are discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk groups'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Genetic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated with a number of autoimmune disorders including type 1 diabetes mellitus and autoimmune thyroid disease. In addition, the intestinal lesion of celiac disease is associated with several different autoantibodies that are useful for diagnostic purposes. IgA-antibodies against endomysium and the endomysial autoantigen tissue transglutaminase are highly sensitive and specific. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Associated conditions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Diagnostic approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is possible that immunologic similarities between gliadin protein motifs and enteral pathogens may be involved in pathogenesis of an immunologic response to antigens in gluten. This hypothesis was supported in one study, in which analysis of alpha gliadin demonstrated an amino acid region that was homologous to the 54KDa E1b protein coat of adenovirus 12, suggesting that exposure to the virus in a susceptible person could be involved in the pathogenesis of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the pathogenetic role of these antibodies remains to be clarified. Both humoral and cell-mediated immune mechanisms are involved, and the range of gluten peptides triggering the reaction may vary with the age of the patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Autoantibodies and intraepithelial lymphocytes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Infant feeding practices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of celiac disease at any age requires exposure to gluten. However, there is emerging evidence that the timing and manner of gluten exposure may affect the risk for or clinical expression of celiac disease. Observational studies suggest that the risk for celiac disease might be reduced by continuing breast feeding while introducing gluten into an infant's diet, and by introducing gluten gradually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These factors are thought to be implicated in an epidemic of celiac disease that occurred in Sweden between 1984 and 1996, in which the frequency of symptomatic celiac disease in children younger than two years increased four-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/20\">",
"     20",
"    </a>",
"    ]. The onset and end of this epidemic were abrupt, and coincided with specific changes in infant feeding practices; this suggests but does not prove a causal association between infant feeding practices and celiac disease risk. Rates of celiac disease among children born during this epidemic are as high as 3 percent by age 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/21\">",
"     21",
"    </a>",
"    ]. One third of these cases came to attention because of symptoms, and the remaining cases were diagnosed by population screening. Currently, infant feeding practices in Sweden emphasize gradual introduction of gluten while breast-feeding is ongoing, and the prevalence of celiac disease in young children has returned to pre-epidemic levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/22\">",
"     22",
"    </a>",
"    ]. Future studies are needed to determine whether these measures decrease the lifetime risk for celiac disease, or merely delay onset of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many years, celiac disease was defined by a set of classic clinical manifestations. However, the combination of serologic, genetic, and histologic data has led to an appreciation of the highly variable clinical manifestations of the condition and the description of other categories of celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Classic celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic description of celiac disease, or gluten-sensitive enteropathy, includes the following three features:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms of malabsorption such as steatorrhea, weight loss, or other signs of nutrient or vitamin deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of characteristic histologic changes (including villous atrophy) on small intestinal biopsy.",
"     </li>",
"     <li>",
"      Resolution of the mucosal lesions and symptoms upon withdrawal of gluten-containing foods, usually within a few weeks to months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The degree of the villous atrophy does not necessarily correlate with the severity of clinical symptoms. Although there is a gradient of decreasing severity from the proximal to the distal small intestine, correlating with the higher proximal concentration of dietary gluten, sampling error can occur due to some inhomogeneity of mucosal inflammation.",
"   </p>",
"   <p>",
"    The histologic features range from a mild alteration characterized only by increased intraepithelial lymphocytes (Marsh type 1 lesion) to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis, and crypt hyperplasia (Marsh type 3 lesion) (",
"    <a class=\"graphic graphic_figure graphicRef60343 \" href=\"mobipreview.htm?30/17/30994\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76680 \" href=\"mobipreview.htm?23/30/24041\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/12,23-27\">",
"     12,23-27",
"    </a>",
"    ]. The Marsh type 4 lesion has the same histologic features seen in the type 3 lesion except that the crypts are hypoplastic.",
"   </p>",
"   <p>",
"    Failure to improve on a gluten-free diet is usually due to poor dietary compliance or other underlying malabsorptive disorders. However, in rare cases, diet-refractory celiac disease may be related to sprue-associated lymphoma or to collagenous sprue, a related but little-understood disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of celiac disease in adults\", section on 'Refractory sprue'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Atypical celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, the extraintestinal manifestations are predominant, and there are few or no gastrointestinal symptoms. As for patients with classical disease, the diagnosis requires serologic testing, biopsy evidence of villous atrophy, and improvement of symptoms on a gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Silent/subclinical celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;These patients have no discernible symptoms of celiac disease, but have a positive specific serologic test for celiac disease and biopsy evidence of villous atrophy. These cases are usually detected by screening of high-risk groups. The term \"silent\" may be a misnomer; after treatment with a gluten-free diet, many of these patients retrospectively recognize symptoms that they had not previously considered to be abnormal. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Subclinical disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Latent celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with celiac disease, but who have normal jejunal mucosa and no or minor symptoms at least at one time point while on a normal, gluten-containing diet, are said to have \"latent\" celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/27\">",
"     27",
"    </a>",
"    ]. Two variants of latent celiac disease have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac disease was present before, usually in childhood; the patient recovered completely with a gluten-free diet, remaining quiescent even when a normal diet is adopted.",
"     </li>",
"     <li>",
"      A normal mucosa was diagnosed at an earlier occasion while ingesting a normal diet, but celiac disease developed later.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27351026\">",
"    <span class=\"h2\">",
"     Potential celiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have never had a biopsy consistent with celiac disease but show immunologic abnormalities characteristic for the disorder (eg, positive IgA to endomysium, a \"celiac intestinal antibody pattern,\" and increased intraepithelial lymphocytes) are said to have \"potential\" celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/28\">",
"     28",
"    </a>",
"    ]. These patients often have a genetic predisposition, especially HLA-DQ2, and a first-degree relative with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'High-risk groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The short-term outcome of potential celiac disease in young children was described in a cohort study that prospectively followed children from birth if they had a first-degree relative with celiac disease; by a mean age of 29 &plusmn; 12 months, 96 of the children had developed serologic evidence of celiac disease and underwent intestinal biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/29\">",
"     29",
"    </a>",
"    ]. Seventy-two of the children could be diagnosed with overt celiac disease on the basis of abnormal intestinal biopsies. Twenty-four children had potential celiac disease, defined as positive antibody tests but normal intestinal biopsies. These children with potential celiac disease continued a gluten-containing diet, and 86 percent became antibody negative during the two-year follow-up period. Five percent developed overt celiac disease, and 9 percent had fluctuating antibody levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     General population",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease occurs primarily in Caucasians. In Europe and the United States, prevalence estimates range from 1:80 to 1:300 children (3 to 13 per 1000 children) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ]. Females are affected approximately twice as often as males, although the ratio varies depending on the strategy used to find cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevalence estimates have increased with the advent of highly sensitive and specific screening tests, which identified many patients with minimal or no symptoms. Epidemiological studies using these tests with biopsy verification established prevalences of 1:300 to 1:500 in most countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/31\">",
"     31",
"    </a>",
"    ]. A large screening study in the United States suggested a prevalence of 1:133 among patients with no risk factors or symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/32\">",
"     32",
"    </a>",
"    ]. These estimates are similar to those found in European studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/33-36\">",
"     33-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even those not ethnically derived from European populations can develop celiac disease if they have an appropriate genetic background. Punjabis from India living in England and eating a gluten-rich diet developed this disorder 2.9 times more often than Europeans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/37\">",
"     37",
"    </a>",
"    ]. A disorder named \"summer diarrhea\" had long been known in their indigenous country, when wheat replaced maize during the summer season. Furthermore, a very high prevalence rate of 5 percent was documented for the Saharawi population of Northern Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/38\">",
"     38",
"    </a>",
"    ]. It is also common in Egypt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/39\">",
"     39",
"    </a>",
"    ], Tunisia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/40\">",
"     40",
"    </a>",
"    ], and other populations in North Africa, the Middle East, and Southern Asia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/41\">",
"     41",
"    </a>",
"    ]. Celiac disease appears to be less common in China, but a few cases have now been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/42\">",
"     42",
"    </a>",
"    ]. The prevalence in some developing countries is probably underestimated due to limited access to diagnostic facilities and confounding of the disease with other causes of small intestinal damage. Overall, the global distribution of the disease seems to parallel the distribution of HLA genotypes that predispose to celiac disease, provided that the population is also exposed to gluten [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the largest screening investigations of celiac disease was performed in 17,201 school children, aged 6 to 15 years, who were recruited from several regions of Italy and represented 69 percent of the eligible population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/44\">",
"     44",
"    </a>",
"    ]. The prevalence was 1:184 and the ratio of asymptomatic to symptomatic cases was a remarkable 7:1 (",
"    <a class=\"graphic graphic_table graphicRef57975 \" href=\"mobipreview.htm?21/31/22011\">",
"     table 1",
"    </a>",
"    ). Based upon these data, it was estimated that the number of affected persons in Italy alone was 220,000, three-quarters of whom were unidentified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings indicate that the number of so-called silent celiacs (a misnomer because most of these patients suffer from nonspecific symptoms) is much higher than the number of patients with classic celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     High-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of celiac disease as detected by screening programs using specific antibodies is substantially increased in the following groups as compared to the general population (",
"    <a class=\"graphic graphic_table graphicRef50751 \" href=\"mobipreview.htm?41/53/42844\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First- and second-degree relatives of patients with celiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,32\">",
"       1,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Down syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,46\">",
"       1,46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Type 1 diabetes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IgA deficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,50\">",
"       1,50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Turner syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Williams syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Autoimmune thyroiditis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,53,54\">",
"       1,53,54",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals with Down syndrome appear to have the highest risk, as up to 16 percent are affected (a 20-fold increase in risk over the general population). For the other groups, between 2 and 7 percent are affected, representing a 3- to 10-fold increase in risk as compared to the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,32,47-49,51,52\">",
"     1,32,47-49,51,52",
"    </a>",
"    ]. For autoimmune thyroiditis, the association is weak during childhood and appears to increase with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for these associations is discussed in detail separately. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Diabetes mellitus'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Associated conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although originally recognized largely as a disease of infants, celiac disease most often presents later, between the ages of 10 and 40. Thus, the classical description of a child with life-threatening malabsorption often is replaced by atypical presentation of celiac disease in older children or adults. This changing presentation of the disease may be due to longer periods of breast-feeding and the later introduction of gluten into the infant diet, and increasing recognition of subclinical disease due to advances in serological screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classically, celiac disease presented between 6 and 24 months of age, after the introduction of gluten into the diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ]. The children have chronic diarrhea, anorexia, abdominal distension and pain, and failure to thrive or weight loss; some may also have vomiting. If the diagnosis is delayed, children may present with signs of severe malnutrition. Severely affected infants may present with a celiac crisis and the hemodynamic and metabolic consequences of dehydration.",
"   </p>",
"   <p>",
"    Gastrointestinal symptoms in older children and adults are similar, but usually less dramatic. Paradoxically, the disease may cause either constipation or diarrhea. When diarrhea is present, the stools are often bulky and foul-smelling, and may float because of steatorrhea. Flatulence and abdominal distension (caused by colonic bacterial digestion of malabsorbed nutrients) are common. These symptoms may be accompanied by the consequences of malabsorption, such as growth failure, weight loss, severe anemia, neurologic disorders from deficiencies of B vitamins, and osteopenia from deficiency of vitamin D and calcium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Nongastrointestinal manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous non-gastrointestinal manifestations of celiac disease have been described (",
"    <a class=\"graphic graphic_table graphicRef76474 \" href=\"mobipreview.htm?25/6/25707\">",
"     table 3",
"    </a>",
"    ). Conditions associated with celiac disease in adults are described in detail separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/56\">",
"     56",
"    </a>",
"    ]. In many patients, non-gastrointestinal symptoms are the presenting complaint and should prompt the consideration of serologic testing. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Growth and development",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 8 and 10 percent of children with apparent \"idiopathic\" short stature have serologic evidence of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients with gastrointestinal symptoms have slightly attenuated adult height unless treated prior to puberty [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/57\">",
"     57",
"    </a>",
"    ]. Delay in linear growth may occur even when weight for height is relatively normal, and in the absence of significant gastrointestinal symptoms. Thus, the process is probably not entirely attributable to undernutrition.",
"   </p>",
"   <p>",
"    Studies from the United States, Europe, and Australia report that a substantial number of children are overweight or obese at the time that celiac disease is diagnosed, although the rate of obesity is somewhat lower than in the local population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. In one of these series, 75 percent of patients who were overweight or obese at diagnosis had a decrease in their degree of obesity (decrease in BMI z-score) after beginning a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/58\">",
"     58",
"    </a>",
"    ]. Among patients who were underweight at diagnosis, 80 percent grew into a healthy weight after beginning a gluten-free diet, and 20 percent remained underweight.",
"   </p>",
"   <p>",
"    Boys with untreated celiac disease have reduced levels of serum dihydrotestosterone in a pattern suggesting androgen resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,62\">",
"     1,62",
"    </a>",
"    ]. Adolescent girls may have an increased frequency of menstrual abnormalities such as delayed menarche, and later may have problems with infertility and experience an early menopause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. Treatment with a gluten-free diet appears to prevent these problems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H33#H33\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Menstrual and reproductive issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Neurologic disease and behavioral symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease may have as its primary manifestation neurologic or behavioral symptoms. Several reports in adults have described an association between celiac disease and neuropsychiatric symptoms such as ataxia, peripheral neuropathy, depression, anxiety, or epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/67-73\">",
"     67-73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H18#H18\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Neuropsychiatric disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children with celiac disease, clinically apparent neurologic disorders are uncommon, and the evidence supporting the association with celiac disease is weak. Disorders that may be associated with celiac disease include hypotonia, developmental delay, learning disorders and ADHD, headache, and cerebellar ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Epileptic disorders are only slightly more common among children with celiac disease, and there is no increase in the frequency of tic disorders. A population-based study in Italy found that clinically diagnosed neurologic or psychiatric disorders among children with celiac disease were only slightly increased as compared to healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/76\">",
"     76",
"    </a>",
"    ]. In the same report, children with known or cryptogenic neurologic disorders did not have a higher prevalence of celiac disease as compared to the general population. Similarly, celiac disease was not overrepresented in a population of adolescent psychiatric outpatients in Finland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/77\">",
"     77",
"    </a>",
"    ], but depression and disruptive behavioral disorders were nonetheless more common among children with celiac disease than in matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although clinically apparent neurologic disorders are unusual in children with celiac disease, subclinical neurologic abnormalities are common, and may affect the central and peripheral nervous systems. In a study of children with newly diagnosed celiac disease, almost 20 percent had subclinical neurologic abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/79\">",
"     79",
"    </a>",
"    ]. Among 27 children, two had peripheral polyneuropathy documented with electromyography, one had prolonged latencies in somatosensory evoked potential, and two had MRI abnormalities consisting of pontine demyelinization or cortical atrophy. Similarly, there is some evidence of regional hypoperfusion of the cerebrum in adult patients with untreated celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/77\">",
"     77",
"    </a>",
"    ]. In most, but not all such conditions, improvement is observed after treatment with a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/72,74,80,81\">",
"     72,74,80,81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of the neurologic symptoms is unclear. Some of the disorders, such as infantile hypotonia and developmental delay, may be caused by malnutrition, including specific micronutrient deficiencies; these problems tend to resolve on a gluten-free diet. However, there is increasing evidence that some or all of these neurologic abnormalities are caused by autoimmune mechanisms. As an example, widespread IgA tissue transglutaminase deposition around vessels in the cerebellum has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/82\">",
"     82",
"    </a>",
"    ]. In particular, anti-ganglioside antibodies may be involved in the pathogenesis of neurologic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/83\">",
"     83",
"    </a>",
"    ], although studies examining this possibility have had somewhat conflicting results. These findings suggest that an immune-mediated process may lead to gluten ataxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dermatitis herpetiformis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of skin manifestations of celiac disease. Dermatitis herpetiformis is the most common (",
"    <a class=\"graphic graphic_table graphicRef71271 \" href=\"mobipreview.htm?3/19/3387\">",
"     table 4",
"    </a>",
"    ), occurring in up to 24 percent of adult patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. A few reports have suggested an association between psoriasis and elevated levels of antibodies to gliadin, reticulin, or tissue transglutaminase, but a strong association between psoriasis and celiac disease has not been documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. Similar to celiac disease, anti-tTG antibodies are elevated in patients with dermatitis herpetiformis, confirming the pathogenetic relation of the diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 85 percent of adult patients with dermatitis herpetiformis have the characteristic changes of celiac disease on intestinal biopsy, although most have no gastrointestinal symptoms. Dermatitis herpetiformis is less common prior to puberty, but has been reported in patients as young as 8 months old [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. It is commonly misdiagnosed as atopic dermatitis, scabies, or linear IgA dermatosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dermatitis herpetiformis is characterized by an itchy papular vesicular eruption usually located symmetrically on the extensor surfaces of the elbows, knees, buttocks, sacrum, face, neck, trunk, and occasionally within the mouth (",
"    <a class=\"graphic graphic_picture graphicRef74915 graphicRef70783 \" href=\"mobipreview.htm?4/63/5111\">",
"     picture 2A-B",
"    </a>",
"    ). The predominant symptoms are itching and burning that is rapidly relieved with rupture of the blisters. The earliest abnormality comprises a small erythematous macule 2 to 3 mm in diameter that quickly develops into a papule. Small vesicles then appear to coalesce. Scratching causes them to rupture, dry up, and leave an area of pigmentation and scarring. The diagnosis can be confirmed by the demonstration of granular IgA deposition in an area of the skin not affected by blistering, along the subepidermal membrane. The results of the skin biopsy are sufficient to make the diagnosis of dermatitis herpetiformis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H1643384077#H1643384077\">",
"     \"Dermatitis herpetiformis\", section on 'Clinical findings'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many experts recommend a lifelong gluten-free diet based on the results of the skin biopsy alone, and an intestinal biopsy is not required. Although patients with dermatitis herpetiformis may have a symptomatic response to medications such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/31/34288?source=see_link\">",
"     dapsone",
"    </a>",
"    , complete resolution of the skin lesions in most patients will not occur without gluten withdrawal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=see_link&amp;anchor=H1643384165#H1643384165\">",
"     \"Dermatitis herpetiformis\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dental enamel defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dental enamel defects involving the secondary dentition are more common among children and adults with celiac disease, and may occur in the absence of gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/93\">",
"     93",
"    </a>",
"    ]. The enamel defects considered to be specific to celiac disease are symmetrically distributed and detectable in all four quadrants of the dentition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/94\">",
"     94",
"    </a>",
"    ]. Defects may consist of cream, yellow, or brown opacities, loss of enamel glaze, horizontal grooves, or shallow pits (",
"    <a class=\"graphic graphic_picture graphicRef56066 \" href=\"mobipreview.htm?27/23/28031\">",
"     picture 3",
"    </a>",
"    ). The incisors are most commonly affected. The prevalence of enamel defects in children with celiac disease varies from 38 to 96 percent, as compared to 0.6 to 17 percent in control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. There is some evidence that these defects are mediated by immunologic mechanisms (associated with the HLA allele DR3), and not by malabsorption of nutrients such as calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/96\">",
"     96",
"    </a>",
"    ]. Early identification and treatment of celiac disease may prevent the development of the enamel defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Metabolic bone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone loss (usually osteomalacia) occurs commonly in celiac disease and can occur in patients without gastrointestinal symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/98-101\">",
"     98-101",
"    </a>",
"    ]. These patients have secondary hyperparathyroidism that probably is caused by vitamin D deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In children, metabolic bone disease generally resolves with a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. In a study of 30 children and adolescents maintained on a long-term gluten-free diet (average 10.7 years), bone mineral density and serum markers of bone metabolism completely normalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, metabolic bone disease generally improves on a gluten-free diet, including in those with clinically silent celiac disease. However, the abnormalities may not resolve entirely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/100,102\">",
"     100,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Metabolic bone disease'",
"    </a>",
"    .) The American Gastroenterological Association (AGA) guideline for osteoporosis in gastrointestinal diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/106\">",
"     106",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA Web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 25 percent of adults with celiac disease have arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/107\">",
"     107",
"    </a>",
"    ]. In children, celiac disease is reported in 2 to 3 percent of those presenting with juvenile idiopathic arthritis or juvenile chronic arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/108,109\">",
"     108,109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild elevations in serum aminotransferases (AST and ALT) were seen in 42 percent of adult patients with celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/110\">",
"     110",
"    </a>",
"    ]. Conversely, celiac disease is found in 5 to 10 percent of adults with chronic elevations of aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/111\">",
"     111",
"    </a>",
"    ]. Studies of children with celiac disease suggest that aminotransferase elevations are also common at diagnosis (32 to 54 percent), particularly in patients presenting with the classical symptoms of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In most patients the aminotransferases normalize with a gluten-free diet.",
"   </p>",
"   <p>",
"    Patients with celiac disease also appear to have increased risks for a broad spectrum of liver diseases, including acute hepatitis, primary biliary cirrhosis, and chronic hepatitis including autoimmune hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/114-117\">",
"     114-117",
"    </a>",
"    ]. Several cases of severe liver disease with cirrhosis in children with celiac disease have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/118\">",
"     118",
"    </a>",
"    ], but celiac disease is not established as a causative factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is a frequent cause of iron deficiency anemia in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. Consequently, iron deficiency anemia is an indication for celiac screening in adults. Although anemia is common among children with celiac disease, there is not good evidence that the prevalence of celiac disease is significantly increased among children with iron deficiency anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Subclinical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and widespread availability of serologic screening has led to the understanding that celiac disease can exist in a very mild form and may go largely undetected because most patients have mild and nonspecific symptoms, such as fatigue, borderline iron deficiency, or otherwise unexplained elevations in serum aminotransferases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/121,122\">",
"     121,122",
"    </a>",
"    ], or no symptoms at all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/101\">",
"     101",
"    </a>",
"    ]. Sometimes the child's only overt problem may be short stature. Monosymptomatic forms of celiac disease have been reported such as severe constipation, anemia, dental enamel hypoplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/123\">",
"     123",
"    </a>",
"    ], delayed puberty, and sterility in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/124\">",
"     124",
"    </a>",
"    ]. The most common type of anemia in celiac disease is caused by iron deficiency; megaloblastic anemia is rare. Serum iron, serum folate, and red cell folate are usually all reduced in patients older than 1 year. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Iron deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The range of symptoms in children with subclinical disease is illustrated by a study of children whose celiac disease was diagnosed through a screening program [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/44\">",
"     44",
"    </a>",
"    ]. Most of these children had minimal gastrointestinal symptoms. However, there were numerous important clinical and laboratory findings, such as iron deficiency, recurrent abdominal pain, and mood changes (",
"    <a class=\"graphic graphic_table graphicRef77895 \" href=\"mobipreview.htm?40/38/41579\">",
"     table 5",
"    </a>",
"    ). In another study, 31 percent of patients with subclinical disease (versus 67 percent with classic symptoms) were malnourished [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/125\">",
"     125",
"    </a>",
"    ]. Once on a gluten-free diet, all reported objective and subjective improvement of well-being, as they recognized symptoms they had not previously considered to be abnormal.",
"   </p>",
"   <p>",
"    Even in individuals with minimal symptoms, establishing and treating subclinical celiac disease may help to identify and treat unsuspected nutritional deficiencies, and to reduce the risk of low-birth-weight infants born to affected mothers. It is less clear whether these individuals have increased risk for malignancies or autoimmune diseases that might be reduced by treatment with a gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Risk of malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested increased risk for some malignancies, particularly non-Hodgkin lymphoma and gastrointestinal cancers, in adults with celiac disease compared to the general population. The incidence of cancers does not appear to be increased during childhood or adolescence.",
"   </p>",
"   <p>",
"    At least one study suggests that the risk for malignancy is reduced by long-term treatment with a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/126\">",
"     126",
"    </a>",
"    ]. Although this has not been fully established, it is one of the rationales for recommending lifelong treatment for all patients with celiac disease, even for those with minimal gastrointestinal symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H25#H25\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Risk of malignancy and mortality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease frequently is associated with Down syndrome, Williams syndrome, Turner syndrome, selective IgA deficiency, and several autoimmune conditions such as type 1 diabetes mellitus, and thyroid disease (",
"    <a class=\"graphic graphic_table graphicRef50751 \" href=\"mobipreview.htm?41/53/42844\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease is associated closely with type 1 diabetes mellitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/127-130\">",
"     127-130",
"    </a>",
"    ]. In several reports, between 2.6 and 7.8 percent of adults with type 1 diabetes had IgA autoantibodies to endomysium or to tissue transglutaminase; most such patients were proven to have celiac disease with small bowel biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/85,131\">",
"     85,131",
"    </a>",
"    ]. Many such patients had no overt clinical manifestations of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/85\">",
"     85",
"    </a>",
"    ]. Other reports have demonstrated that as many as 3.5 percent of children of parents with type 1 diabetes have celiac disease, the prevalence of which increases with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A causal relationship between celiac disease and diabetes mellitus has been suggested, but not established. A few studies in humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/132\">",
"     132",
"    </a>",
"    ] and animals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/133,134\">",
"     133,134",
"    </a>",
"    ] suggest that celiac disease may trigger autoimmune processes leading to diabetes. One study noted that the prevalence of autoimmune diseases, including Type 1 diabetes mellitus, may be related to the duration of exposure to gluten, and may reach more than 30 percent in patients diagnosed with celiac disease after age 20 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/135\">",
"     135",
"    </a>",
"    ]. However, other observations suggest that celiac disease does not trigger diabetes: the age of onset and the severity of diabetes do not appear to be influenced by the presence of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/85\">",
"     85",
"    </a>",
"    ] and celiac autoantibodies usually develop after the onset of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/136\">",
"     136",
"    </a>",
"    ]. Thus, larger and prospective clinical studies are required to clarify the relationship between celiac disease, type 1 diabetes, and other autoimmune disorders.",
"   </p>",
"   <p>",
"    Whether a gluten-free diet improves diabetes in diabetic patients with celiac disease is unclear. Only a few small studies have investigated the effect of a strict gluten-free diet on type 1 diabetics with silent celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/128,137,138\">",
"     128,137,138",
"    </a>",
"    ]. Patients showed at best a trend toward an increased body mass index and bone health, but no change in folate or hemoglobin levels or insulin requirements. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H28#H28\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Autoimmune thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 2 to 5 percent of individuals with autoimmune thyroiditis develop celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/139,140\">",
"     139,140",
"    </a>",
"    ]. Conversely, 10 to 20 percent of individuals with celiac disease have autoimmune thyroiditis, and its clinical course does not appear to be affected by a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'Chronic autoimmune thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this association, the presence of antithyroid antibodies at diagnosis has a low predictive value for the development of thyroid hypofunction. In a series of 135 children with celiac disease, 23 percent had positive antithyroid antibody titers at diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/141\">",
"     141",
"    </a>",
"    ]. Approximately 12 percent of the patients had elevated thyroid stimulating hormone levels, suggesting subclinical hypothyroidism, regardless of whether the antithyroid antibody titers were positive. In most of these patients, the subclinical hypothyroidism normalized during the follow up period (8.9 &plusmn; 4 years on a gluten-free diet). Among patients with persistently positive antithyroid antibodies during the follow up period, subclinical hypothyroidism developed in 25 percent. Thus, this study does not suggest that treatment with a gluten-free diet alters the clinical course of autoimmune thyroiditis in patients with celiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Celiac disease occurs in up to 16 percent of individuals with Down syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/46\">",
"     46",
"    </a>",
"    ] and up to 10 percent of individuals with selective IgA deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/50\">",
"     50",
"    </a>",
"    ]; the prevalence of celiac disease is also increased in Williams and Turner syndromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weaker associations with primary biliary cirrhosis, as well as a variety of other liver diseases, have been described in adults. Evidence for these associations is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Associated conditions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The steps to establishing a diagnosis of celiac disease are summarized here, and discussed in detail separately. The following guidelines are recommended by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of celiac disease typically requires both of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of characteristic histologic changes on small intestinal biopsy in a symptomatic individual.",
"     </li>",
"     <li>",
"      Complete symptom resolution on a gluten free diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Serological tests that revert from positive to negative on a gluten-free diet may be used as supportive evidence of the diagnosis, and are particularly valuable in individuals with minimal symptoms. &nbsp;",
"   </p>",
"   <p>",
"    The diagnosis is presumptively established when there is concordance between the serologic results and the biopsy findings. It is confirmed when symptoms resolve subsequently on a gluten-free diet. Demonstration of histologic normalization while on a gluten-free diet is no longer required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Whom to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of screening for asymptomatic celiac disease has not yet been established by evidence-based criteria. Such a strategy could possibly result in recognition and correction of subclinical nutritional deficiency states, resolution of mild symptoms, and potentially decrease the risk for malignancy. However, there are few data to support these beneficial effects and the strategy would require many asymptomatic individuals to adhere to a difficult dietary regimen.",
"   </p>",
"   <p>",
"    We agree with the NASPGHAN and international recommendations that serologic screening for celiac disease be performed in the following groups of children, provided they are on a gluten-containing diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,5,41\">",
"     1,5,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the following clinical signs and symptoms, if not otherwise explained:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to thrive",
"     </li>",
"     <li>",
"      Persistent diarrhea",
"     </li>",
"     <li>",
"      Chronic constipation, recurrent abdominal pain, or vomiting",
"     </li>",
"     <li>",
"      Dental enamel hypoplasia of permanent teeth (symmetric distribution)",
"     </li>",
"     <li>",
"      Idiopathic short stature",
"     </li>",
"     <li>",
"      Significant pubertal delay",
"     </li>",
"     <li>",
"      Iron deficiency anemia not responsive to supplementation",
"     </li>",
"     <li>",
"      Dermatitis herpetiformis-like rash (",
"      <a class=\"graphic graphic_picture graphicRef74915 graphicRef70783 \" href=\"mobipreview.htm?4/63/5111\">",
"       picture 2A-B",
"      </a>",
"      ) &nbsp;",
"     </li>",
"     <li>",
"      Recurrent aphthous stomatitis",
"     </li>",
"     <li>",
"      Fracture not explained by the level of trauma",
"     </li>",
"     <li>",
"      Abnormal liver biochemical tests",
"     </li>",
"     <li>",
"      Chronic fatigue &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All members of the following high-risk groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      First-degree relatives of patients with celiac disease",
"     </li>",
"     <li>",
"      Autoimmune thyroiditis",
"     </li>",
"     <li>",
"      Type 1 diabetes",
"     </li>",
"     <li>",
"      Down syndrome",
"     </li>",
"     <li>",
"      Turner syndrome",
"     </li>",
"     <li>",
"      Williams syndrome",
"     </li>",
"     <li>",
"      Selective IgA deficiency",
"     </li>",
"     <li>",
"      Autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/116,117\">",
"       116,117",
"      </a>",
"      ] &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In suggesting screening for asymptomatic individuals in these high-risk groups, these guidelines differ from those used for adults in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/4\">",
"     4",
"    </a>",
"    ]. This difference in recommendations reflects a debate about the utility of screening for celiac disease among truly asymptomatic individuals belonging to a high-risk group, because the benefit of treating such individuals has not been proven. Guidelines from the United Kingdom encourage testing for the first three of these high-risk groups, and suggest consideration of testing for the other groups on this list, as well as for individuals with a variety of nonspecific symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/142\">",
"     142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis of celiac disease\", section on 'Who should be tested'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The debate continues about whether asymptomatic individuals in these high-risk groups should be screened, and recommendations may change as new information arises about the potential risks and benefits of screening. As an example, a study of a celiac screening program for children with type 1 diabetes mellitus compared clinical characteristics of 71 children with asymptomatic celiac disease with matched controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/143\">",
"     143",
"    </a>",
"    ]. The children with celiac disease were slightly thinner (as indicated by a lower body mass index z-score), but height, bone mineral density and diabetes control were similar. Thus, it is reasonable to question the need for celiac screening and the added burden of a gluten-free diet for patients with type 1 diabetes and no symptoms of celiac disease, and to make treatment decisions on a case-by-case basis, based on a discussion of estimated risks, symptoms, and treatment burden. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=see_link\">",
"     \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If screening is undertaken for asymptomatic individuals in these high-risk groups, testing should be performed at three years of age or older and on a gluten-containing diet for at least one year. If initial results are negative, screening tests should be repeated at intervals, or if symptoms develop. The optimal time interval for subsequent screening has not been studied, but in our practice, we screen asymptomatic members of these groups every three to five years during childhood.",
"   </p>",
"   <p>",
"    An alternative strategy for asymptomatic individuals in these high-risk groups is to assess for the HLA types DQ2 and DQ8 as the initial screening test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5,144\">",
"     5,144",
"    </a>",
"    ]. Those who test positive for HLA DQ2 or DQ8 should then undergo serial screening for celiac-associated antibodies every three to five years as described above. Those who test negative for HLA DQ2 and DQ8 do not require additional screening because they have a very low risk for developing celiac disease. Of note, HLA testing is substantially more costly than serologic screening for celiac disease but does not require serial testing. The cost-effectiveness of this strategy has not been established and depends on the pre-test risk for celiac disease in the population tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/145\">",
"     145",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetic factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients with dermatitis herpetiformis established by skin biopsy are presumed to have celiac disease and treated without other diagnostic studies. A baseline measurement of tTG-antibodies is valuable to monitor improvement after institution of a gluten free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     How to test",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, a presumptive diagnosis of celiac disease requires positive results of a specific antibody test and characteristic histologic changes of the intestinal mucosa. The diagnosis is confirmed if there is normalization of antibodies and symptoms (if any) when the patient is on a gluten-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15390478\">",
"    <span class=\"h3\">",
"     Antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic tests for celiac disease are useful for screening and are an important step in the diagnosis of the disease (",
"    <a class=\"graphic graphic_table graphicRef75505 \" href=\"mobipreview.htm?22/38/23148\">",
"     table 6",
"    </a>",
"    ). Currently, the most valuable test is for antibodies against tissue transglutaminase (anti-tTG), which is highly sensitive, specific, and more cost-effective than other antibody tests. The diagnostic accuracy of IgA anti-tTG immunoassays has been optimized by the use of human tTG in place of the non-human tTG preparations used in earlier immunoassay kits. Using second-generation ELISA technology, the sensitivity and specificity of anti-tTG antibodies for biopsy-proven celiac disease are generally above 96 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1,146,147\">",
"     1,146,147",
"    </a>",
"    ]. Sensitivities are somewhat lower in children younger than two years, but are still near 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. Rapid office-based test kits have somewhat lower sensitivity and specificity, so a laboratory-based assay should be performed in patients with positive results of the rapid test, or those with negative results of the rapid test but strong clinical suspicion of celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/15,150\">",
"     15,150",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Immunofluorescence test for IgA antibodies to endomysium, a structure of the smooth muscle connective tissue, is also highly sensitive and specific [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/33\">",
"     33",
"    </a>",
"    ]. However, this test is generally more expensive than anti-tTG, and its accuracy is more dependent on interpretation by laboratory personnel. Tests measuring IgG and IgA antibodies to gliadin are considerably less reliable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/151,152\">",
"     151,152",
"    </a>",
"    ], although a second generation anti-gliadin antibody test (Deamidated Gliadin Peptide, DGP) yields far higher diagnostic accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/153-155\">",
"     153-155",
"    </a>",
"    ]. Tests of antireticulin antibodies have reasonably high specificity, but lower sensitivity, and are no longer commonly used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/156\">",
"     156",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H4#H4\">",
"     \"Diagnosis of celiac disease\", section on 'Serologic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For most patients, we recommend measuring IgA antibodies to human recombinant tissue transglutaminase (tTG). This test is highly specific and sensitive, although false-positive and false-negative results may still occur with some frequency in populations with a low risk for celiac disease. Measurements of IgA antibodies to endomysium are equally accurate, but this test is more expensive and somewhat dependent on operator interpretation. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Autoimmunity'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link\">",
"     \"Diagnosis of celiac disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For individuals with known selective IgA deficiency, testing should be performed with IgG antibodies to tTG instead of the usual IgA-based antibody test. Because the IgG antibodies to tTG have limited specificity, concurrent measurement of a second IgG-based antibody such as DGP is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 2 percent of children with celiac disease will have previously unrecognized IgA deficiency. Therefore, total IgA should be measured in children with negative results of IgA-tTG but a high clinical suspicion of celiac disease.",
"   </p>",
"   <p>",
"    In children younger than two years, both the tTG and EMA tests are less sensitive for detecting celiac disease, so concurrent assessment of more than one celiac-specific antibody (eg, tTG with antibodies to DGP) is suggested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5\">",
"     5",
"    </a>",
"    ]. Preliminary evidence suggests DGP may be more sensitive than tTG in this age group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/157,158\">",
"     157,158",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15390455\">",
"    <span class=\"h3\">",
"     Intestinal biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All individuals with positive tTG antibodies or antiendomysial antibodies should have an intestinal biopsy to establish the diagnosis of celiac disease. The biopsy should be performed with the patient on a gluten-containing diet. Multiple biopsies should be taken from the distal duodenum and duodenal bulb and interpreted by an expert pathologist; the disease may have a patchy distribution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/159-162\">",
"     159-162",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnosis of celiac disease\", section on 'Diagnostic approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One case series suggests that celiac disease can be reliably diagnosed without the need for histologic confirmation in",
"    <strong>",
"     symptomatic",
"    </strong>",
"    patients with very high results of serologic tests (tTG &gt;100",
"    <span class=\"nowrap\">",
"     U/mL,",
"    </span>",
"    or about 10 times the upper limit of normal), providing that there is also a clear clinical response to a gluten-free diet [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/163\">",
"     163",
"    </a>",
"    ]. If this strategy is chosen, some expert groups suggest HLA typing to add strength to the diagnosis (because celiac disease would be effectively excluded in any patient that does not have HLA types DQ2 or DQ8), but the additional diagnostic value of HLA typing in this setting is probably modest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5,164\">",
"     5,164",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetic factors'",
"    </a>",
"    above). However, until this finding is confirmed in larger populations of patients with celiac disease, we do not advocate this approach. We feel that histologic confirmation is required for maximal diagnostic certainty, because of the life-long burden of a gluten-free diet. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Whom to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with a gluten-free diet is recommended for both diagnostic and therapeutic purposes for all children in one of the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with characteristic findings on intestinal biopsy and symptoms consistent with celiac disease (including nonspecific symptoms such as constipation or abdominal pain).",
"     </li>",
"     <li>",
"      Children with characteristic findings on intestinal biopsy and belonging to one of the above high-risk groups (eg, relatives of patients with established celiac disease, or patients with type 1 diabetes), whether or not there are associated symptoms.",
"     </li>",
"     <li>",
"      Patients with dermatitis herpetiformis confirmed by skin biopsy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We do NOT recommend beginning a gluten-free diet prior to evaluating an intestinal biopsy, because the symptoms of celiac disease are nonspecific and the biopsy is essential to making the diagnosis.",
"   </p>",
"   <p>",
"    For patients who are already on a gluten-free diet at the time of evaluation, we suggest serologic testing for tTG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endomysial antibodies. If these are elevated, an intestinal biopsy should be obtained to confirm the diagnosis of celiac disease. If these antibodies are not elevated, celiac disease is not excluded. In this case, we suggest HLA",
"    <span class=\"nowrap\">",
"     DQ2/DQ8",
"    </span>",
"    testing to determine whether the patient is genetically susceptible to celiac disease. If these results are negative, celiac disease is essentially excluded (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetic factors'",
"    </a>",
"    above). If the patient tests positive for HLA",
"    <span class=\"nowrap\">",
"     DQ2/DQ8,",
"    </span>",
"    then a gluten challenge should be performed by reintroducing moderate amounts of wheat into the diet, and retesting for tTG antibodies when symptoms recur or after six months if the patient remains asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/144\">",
"     144",
"    </a>",
"    ]. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Patients with positive tests for tissue transglutaminase or anti-endomysial antibodies, but normal results of small bowel biopsies, are considered to have latent or potential celiac disease (see",
"    <a class=\"local\" href=\"#H27351026\">",
"     'Potential celiac disease'",
"    </a>",
"    above). We suggest NOT treating such patients with a gluten-free diet if they do not have symptoms. However, it is important that the evaluation of such patients include expert review of multiple intestinal biopsies since the histologic abnormalities can be patchy. Furthermore, these patients should be carefully monitored for growth failure and other symptoms that might suggest active celiac disease, and should be rebiopsied if symptoms develop.",
"   </p>",
"   <p>",
"    There is some evidence that symptomatic children with positive serologic tests for celiac disease but apparently normal biopsies are very likely to have celiac disease, as illustrated by the following observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report followed eight children with some gastrointestinal symptoms and positive serologic tests (anti endomysial antibodies) but normal intestinal histology who continued to consume a gluten-containing diet. Within two years, seven of these eight children had developed marked mucosal atrophy and were diagnosed with celiac disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/165\">",
"       165",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another series, 86 asymptomatic children with positive serologic tests and normal biopsies continued to consume a gluten-containing diet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/3/37946/abstract/166\">",
"       166",
"      </a>",
"      ]. Antibody testing had been performed in these children because of risk factors (having an autoimmune disease or first-degree relative with celiac disease). After three years, antibodies disappeared in 15 percent and villous atrophy developed in about 30 percent. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Therefore, a substantial number of children with positive serologic tests but normal biopsies will develop celiac disease within a few years, while in a smaller number the antibodies disappear completely; the likelihood of this progression is not well established, but may vary depending on whether symptoms are present. Decisions about whether to begin a gluten-free diet for patients with positive serologic tests but normal biopsy results should be made on a case-by-case basis with the family, after consideration of the patient&rsquo;s level of symptoms, appropriate exclusion of other causes of the symptoms, the burden of maintaining a gluten-free diet, and the adequacy of the biopsied tissue samples. &nbsp;",
"   </p>",
"   <p>",
"    Treatment of individuals with confirmed celiac disease consists of a lifelong gluten-free diet. Details of treatment and monitoring are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"     \"Management of celiac disease in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/14/11492?source=see_link\">",
"       \"Patient information: Celiac disease in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6912852\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Celiac disease is an immune-mediated inflammation of the small intestine caused by sensitivity to dietary gluten and related proteins in genetically sensitive individuals. The disorder is common, occurring in 0.5 to 1 percent of the general population in most countries. The grains that contain the triggering proteins are wheat, barley, and rye; there is some controversy as to whether oats also can cause the disease. The small intestinal mucosa improves morphologically when treated with a gluten-free diet and relapses when gluten is reintroduced. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Classic clinical features of patients with celiac disease include symptoms of malabsorption such as diarrhea, steatorrhea, weight loss, or other signs of nutrient or vitamin deficiency, the presence of characteristic histologic changes (including villous atrophy) on small intestinal biopsy, and resolution of the mucosal lesions and symptoms upon withdrawal of gluten-containing foods, usually within a few weeks to months. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classic celiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with celiac disease have extraintestinal manifestations, in addition to or instead of gastrointestinal symptoms. The most specific extraintestinal manifestation is dermatitis herpetiformis, which is uncommon prior to puberty (",
"      <a class=\"graphic graphic_picture graphicRef74915 graphicRef70783 \" href=\"mobipreview.htm?4/63/5111\">",
"       picture 2A-B",
"      </a>",
"      ). Other extraintestinal manifestations include delayed growth and pubertal development, neurologic disease and behavioral symptoms, arthritis, dental enamel defects, liver disease, and iron deficiency. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Nongastrointestinal manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is now recognized that some patients with celiac disease have mild or minimal symptoms, but positive celiac serologies. If these patients have abnormal intestinal biopsies they are said to have &ldquo;silent&rdquo; celiac disease, and if their biopsies are normal they are said to have &ldquo;potential&rdquo; celiac disease. Many of these patients will develop symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      worsening intestinal lesions if they continue on a gluten-containing diet. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Silent/subclinical celiac disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27351026\">",
"       'Potential celiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest serologic screening for celiac disease in patients with failure to thrive, persistent diarrhea, chronic constipation, recurrent abdominal pain, dental enamel hypoplasia of permanent teeth, idiopathic short stature, significant pubertal delay, or iron deficiency anemia not responsive to supplementation. In addition, we suggest screening individuals with the following disorders which are associated with an increased risk for celiac disease: first-degree relatives of patients with celiac disease, autoimmune thyroiditis, type 1 diabetes, Down syndrome, Turner syndrome, Williams syndrome, and selective IgA deficiency and autoimmune hepatitis. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Whom to test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serologic screening is performed by measuring one of several antibodies that are specific for celiac disease (",
"      <a class=\"graphic graphic_table graphicRef75505 \" href=\"mobipreview.htm?22/38/23148\">",
"       table 6",
"      </a>",
"      ). Currently, the most clinically useful test is for antibodies against tissue transglutaminase (anti-tTG), which is highly sensitive, specific, and more cost-effective than other antibody tests. (See",
"      <a class=\"local\" href=\"#H34\">",
"       'How to test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with positive results of the serologic screen should undergo endoscopy, with biopsies from several areas of the duodenum including the duodenal bulb. The histologic features of celiac disease range from a mild alteration characterized only by increased intraepithelial lymphocytes (Marsh type 1 lesion) to a flat mucosa with total mucosal atrophy, complete loss of villi, enhanced epithelial apoptosis, and crypt hyperplasia (Marsh type 3 lesion) (",
"      <a class=\"graphic graphic_figure graphicRef60343 \" href=\"mobipreview.htm?30/17/30994\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef76680 \" href=\"mobipreview.htm?23/30/24041\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Classic celiac disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Diagnostic approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with positive results of the serologic screen and histologic changes consistent with celiac disease should be given the presumptive diagnosis of celiac disease, and should be treated with a gluten-free diet. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Whom to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A gluten-free diet should NOT be started prior to a full evaluation for celiac disease, including intestinal biopsy. This is because the symptoms of celiac disease are nonspecific, and an intestinal biopsy is essential to making the diagnosis. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Whom to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with positive results of the serologic screen but normal intestinal biopsies probably have latent celiac disease, and may not require treatment with a gluten-free diet if they are asymptomatic. However, because many of these patients will go on to develop intestinal lesions and symptoms, they should be monitored closely, and treatment should be considered if they develop symptoms. In patients who have symptoms but a normal intestinal biopsy, it is also reasonable to consider treatment with a gluten-free diet, after exclusion of other conditions and careful consideration of the potential benefits and treatment burden with the family. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Whom to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients treated with a gluten-free diet should be monitored for changes in symptoms (including growth parameters) and serologies. A decrease in symptoms and normalization of antibodies confirms the diagnosis of celiac disease. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Diagnostic approach'",
"      </a>",
"      above.) Details of treatment and monitoring are discussed in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=see_link\">",
"       \"Management of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/1\">",
"      Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/2\">",
"      Hardwick C. Prognosis in coeliac disease: A Review of Seventy-Three Cases. Arch Dis Child 1939; 14:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/3\">",
"      AGA Institute. AGA Institute Medical Position Statement on the Diagnosis and Management of Celiac Disease. Gastroenterology 2006; 131:1977.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Consensus Development Conference Statement. Celiac Disease 2004. Available at: file://consensus.nih.gov/ (Accessed on March 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/5\">",
"      Husby S, Koletzko S, Korponay-Szab&oacute; IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 2012; 54:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/6\">",
"      Smits BJ. History of coeliac disease. BMJ 1989; 298:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/7\">",
"      Haas SV. Celiac disease, its specific treatment and cure without nutritional relapse. JAMA 1932; 99:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/8\">",
"      Dicke WK. Simple dietary treatment for the syndrome of GheeHerter. Ned Tijdschr Geneeskd 1941; 85:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/9\">",
"      DICKE WK, WEIJERS HA, VAN DE KAMER JH. Coeliac disease. II. The presence in wheat of a factor having a deleterious effect in cases of coeliac disease. Acta Paediatr 1953; 42:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/10\">",
"      VAN DE KAMER JH, WEIJERS HA, DICKE WK. Coeliac disease. IV. An investigation into the injurious constituents of wheat in connection with their action on patients with coeliac disease. Acta Paediatr 1953; 42:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/11\">",
"      PAULLEY JW. Observation on the aetiology of idiopathic steatorrhoea; jejunal and lymph-node biopsies. Br Med J 1954; 2:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/12\">",
"      RUBIN CE, BRANDBORG LL, PHELPS PC, TAYLOR HC Jr. Studies of celiac disease. I. The apparent identical and specific nature of the duodenal and proximal jejunal lesion in celiac disease and idiopathic sprue. Gastroenterology 1960; 38:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/13\">",
"      Kagnoff MF. Celiac disease. A gastrointestinal disease with environmental, genetic, and immunologic components. Gastroenterol Clin North Am 1992; 21:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/14\">",
"      Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000; 119:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/15\">",
"      Hadithi M, von Blomberg BM, Crusius JB, et al. Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med 2007; 147:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/16\">",
"      Kagnoff MF, Paterson YJ, Kumar PJ, et al. Evidence for the role of a human intestinal adenovirus in the pathogenesis of coeliac disease. Gut 1987; 28:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/17\">",
"      Ivarsson A, Hernell O, Stenlund H, Persson LA. Breast-feeding protects against celiac disease. Am J Clin Nutr 2002; 75:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/18\">",
"      Akobeng AK, Ramanan AV, Buchan I, Heller RF. Effect of breast feeding on risk of coeliac disease: a systematic review and meta-analysis of observational studies. Arch Dis Child 2006; 91:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/19\">",
"      Szajewska H, Chmielewska A, Pie��cik-Lech M, et al. Systematic review: early infant feeding and the prevention of coeliac disease. Aliment Pharmacol Ther 2012; 36:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/20\">",
"      Ivarsson A, Persson LA, Nystr&ouml;m L, et al. Epidemic of coeliac disease in Swedish children. Acta Paediatr 2000; 89:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/21\">",
"      Myl&eacute;us A, Ivarsson A, Webb C, et al. Celiac disease revealed in 3% of Swedish 12-year-olds born during an epidemic. J Pediatr Gastroenterol Nutr 2009; 49:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/22\">",
"      Ivarsson A, Myl&eacute;us A, Norstr&ouml;m F, et al. Prevalence of childhood celiac disease and changes in infant feeding. Pediatrics 2013; 131:e687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/23\">",
"      Fry L, Seah PP, McMinn RM, Hoffbrand AV. Lymphocytic infiltration of epithelium in diagnosis of gluten-sensitive enteropathy. Br Med J 1972; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/24\">",
"      Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 1992; 102:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/25\">",
"      Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995; 9:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/26\">",
"      Ferguson A, Arranz E, O'Mahony S. Clinical and pathological spectrum of coeliac disease--active, silent, latent, potential. Gut 1993; 34:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/27\">",
"      Troncone R, Greco L, Mayer M, et al. Latent and potential coeliac disease. Acta Paediatr Suppl 1996; 412:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/28\">",
"      Arranz E, Ferguson A. Intestinal antibody pattern of celiac disease: occurrence in patients with normal jejunal biopsy histology. Gastroenterology 1993; 104:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/29\">",
"      Lionetti E, Castellaneta S, Pulvirenti A, et al. Prevalence and natural history of potential celiac disease in at-family-risk infants prospectively investigated from birth. J Pediatr 2012; 161:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/30\">",
"      Lanzini A, Villanacci V, Apillan N, et al. Epidemiological, clinical and histopathologic characteristics of celiac disease: results of a case-finding population-based program in an Italian community. Scand J Gastroenterol 2005; 40:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/31\">",
"      Fasano A. Where have all the American celiacs gone? Acta Paediatr Suppl 1996; 412:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/32\">",
"      Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med 2003; 163:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/33\">",
"      Pittschieler K, Ladinser B. Coeliac disease: screened by a new strategy. Acta Paediatr Suppl 1996; 412:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/34\">",
"      Ascher H, Kristiansson B. Childhood coeliac disease in Sweden. Lancet 1994; 344:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/35\">",
"      Johnston SD, Watson RG, McMillan SA, et al. Preliminary results from follow-up of a large-scale population survey of antibodies to gliadin, reticulin and endomysium. Acta Paediatr Suppl 1996; 412:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/36\">",
"      Grodzinsky E. Screening for coeliac disease in apparently healthy blood donors. Acta Paediatr Suppl 1996; 412:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/37\">",
"      Sher KS, Fraser RC, Wicks AC, Mayberry JF. High risk of coeliac disease in Punjabis. Epidemiological study in the south Asian and European populations of Leicestershire. Digestion 1993; 54:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/38\">",
"      R&auml;tsch IM, Catassi C. Coeliac disease: a potentially treatable health problem of Saharawi refugee children. Bull World Health Organ 2001; 79:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/39\">",
"      Abu-Zekry M, Kryszak D, Diab M, et al. Prevalence of celiac disease in Egyptian children disputes the east-west agriculture-dependent spread of the disease. J Pediatr Gastroenterol Nutr 2008; 47:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/40\">",
"      Ben Hariz M, Kallel-Sellami M, Kallel L, et al. Prevalence of celiac disease in Tunisia: mass-screening study in schoolchildren. Eur J Gastroenterol Hepatol 2007; 19:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/41\">",
"      Fasano A, Araya M, Bhatnagar S, et al. Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition consensus report on celiac disease. J Pediatr Gastroenterol Nutr 2008; 47:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/42\">",
"      Wang XQ, Liu W, Xu CD, et al. Celiac disease in children with diarrhea in 4 cities in China. J Pediatr Gastroenterol Nutr 2011; 53:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/43\">",
"      Cataldo F, Montalto G. Celiac disease in the developing countries: a new and challenging public health problem. World J Gastroenterol 2007; 13:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/44\">",
"      Catassi C, Fabiani E, R&auml;tsch IM, et al. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl 1996; 412:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/45\">",
"      Greco L, Percopo S. The coeliac disease task force \" Free from Gluten,\" \" Improved knowledge to cure coeliac disease\". Acta Paediatr Suppl 1996; 412:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/46\">",
"      Carlsson A, Axelsson I, Borulf S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antiendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics 1998; 101:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/47\">",
"      Hoffenberg EJ, Bao F, Eisenbarth GS, et al. Transglutaminase antibodies in children with a genetic risk for celiac disease. J Pediatr 2000; 137:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/48\">",
"      Hummel M, Bonifacio E, Stern M, et al. Development of celiac disease-associated antibodies in offspring of parents with type I diabetes. Diabetologia 2000; 43:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/49\">",
"      Crone J, Rami B, Huber WD, et al. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003; 37:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/50\">",
"      Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/51\">",
"      Bonamico M, Pasquino AM, Mariani P, et al. Prevalence and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab 2002; 87:5495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/52\">",
"      Giannotti A, Tiberio G, Castro M, et al. Coeliac disease in Williams syndrome. J Med Genet 2001; 38:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/53\">",
"      Ch'ng CL, Biswas M, Benton A, et al. Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf) 2005; 62:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/54\">",
"      Meloni A, Mandas C, Jores RD, Congia M. Prevalence of autoimmune thyroiditis in children with celiac disease and effect of gluten withdrawal. J Pediatr 2009; 155:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/55\">",
"      McGowan KE, Castiglione DA, Butzner JD. The changing face of childhood celiac disease in north america: impact of serological testing. Pediatrics 2009; 124:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/56\">",
"      Holmes GK. Non-malignant complications of coeliac disease. Acta Paediatr Suppl 1996; 412:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/57\">",
"      Cacciari E, Corazza GR, Salardi S, et al. What will be the adult height of coeliac patients? Eur J Pediatr 1991; 150:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/58\">",
"      Reilly NR, Aguilar K, Hassid BG, et al. Celiac disease in normal-weight and overweight children: clinical features and growth outcomes following a gluten-free diet. J Pediatr Gastroenterol Nutr 2011; 53:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/59\">",
"      Brambilla P, Picca M, Dilillo D, et al. Changes of body mass index in celiac children on a gluten-free diet. Nutr Metab Cardiovasc Dis 2013; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/60\">",
"      Venkatasubramani N, Telega G, Werlin SL. Obesity in pediatric celiac disease. J Pediatr Gastroenterol Nutr 2010; 51:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/61\">",
"      Moscheo C, Vieni G, Pellegrino S, et al. The changing face of celiac disease: a girl with obesity and celiac disease. J Paediatr Child Health 2010; 46:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/62\">",
"      Bona G, Marinello D, Oderda G. Mechanisms of abnormal puberty in coeliac disease. Horm Res 2002; 57 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/63\">",
"      Sher KS, Mayberry JF. Female fertility, obstetric and gynaecological history in coeliac disease: a case control study. Acta Paediatr Suppl 1996; 412:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/64\">",
"      Meloni GF, Dessole S, Vargiu N, et al. The prevalence of coeliac disease in infertility. Hum Reprod 1999; 14:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/65\">",
"      Collin P, Vilska S, Heinonen PK, et al. Infertility and coeliac disease. Gut 1996; 39:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/66\">",
"      Kolho KL, Tiitinen A, Tulppala M, et al. Screening for coeliac disease in women with a history of recurrent miscarriage or infertility. Br J Obstet Gynaecol 1999; 106:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/67\">",
"      Addolorato G, Stefanini GF, Capristo E, et al. Anxiety and depression in adult untreated celiac subjects and in patients affected by inflammatory bowel disease: a personality \"trait\" or a reactive illness? Hepatogastroenterology 1996; 43:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/68\">",
"      Hadjivassiliou M, Chattopadhyay AK, Davies-Jones GA, et al. Neuromuscular disorder as a presenting feature of coeliac disease. J Neurol Neurosurg Psychiatry 1997; 63:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/69\">",
"      Cronin CC, Jackson LM, Feighery C, et al. Coeliac disease and epilepsy. QJM 1998; 91:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/70\">",
"      Hadjivassiliou M, Gibson A, Davies-Jones GA, et al. Does cryptic gluten sensitivity play a part in neurological illness? Lancet 1996; 347:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/71\">",
"      Hadjivassiliou M, Gr&uuml;newald RA, Chattopadhyay AK, et al. Clinical, radiological, neurophysiological, and neuropathological characteristics of gluten ataxia. Lancet 1998; 352:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/72\">",
"      Hadjivassiliou M, Gr&uuml;newald RA, Lawden M, et al. Headache and CNS white matter abnormalities associated with gluten sensitivity. Neurology 2001; 56:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/73\">",
"      Hadjivassiliou M, Gr&uuml;newald RA, Davies-Jones GA. Gluten sensitivity as a neurological illness. J Neurol Neurosurg Psychiatry 2002; 72:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/74\">",
"      Zelnik N, Pacht A, Obeid R, Lerner A. Range of neurologic disorders in patients with celiac disease. Pediatrics 2004; 113:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/75\">",
"      Lionetti E, Francavilla R, Maiuri L, et al. Headache in pediatric patients with celiac disease and its prevalence as a diagnostic clue. J Pediatr Gastroenterol Nutr 2009; 49:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/76\">",
"      Ruggieri M, Incorpora G, Polizzi A, et al. Low prevalence of neurologic and psychiatric manifestations in children with gluten sensitivity. J Pediatr 2008; 152:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/77\">",
"      Pynn&ouml;nen P, Isomets&auml; E, Aalberg V, et al. Is coeliac disease prevalent among adolescent psychiatric patients? Acta Paediatr 2002; 91:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/78\">",
"      Pynn&ouml;nen PA, Isomets&auml; ET, Aronen ET, et al. Mental disorders in adolescents with celiac disease. Psychosomatics 2004; 45:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/79\">",
"      Cakir D, Tosun A, Polat M, et al. Subclinical neurological abnormalities in children with celiac disease receiving a gluten-free diet. J Pediatr Gastroenterol Nutr 2007; 45:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/80\">",
"      Addolorato G, Di Giuda D, De Rossi G, et al. Regional cerebral hypoperfusion in patients with celiac disease. Am J Med 2004; 116:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/81\">",
"      Pynn&ouml;nen PA, Isomets&auml; ET, Verkasalo MA, et al. Gluten-free diet may alleviate depressive and behavioural symptoms in adolescents with coeliac disease: a prospective follow-up case-series study. BMC Psychiatry 2005; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/82\">",
"      Hadjivassiliou M, M&auml;ki M, Sanders DS, et al. Autoantibody targeting of brain and intestinal transglutaminase in gluten ataxia. Neurology 2006; 66:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/83\">",
"      Volta U, De Giorgio R, Granito A, et al. Anti-ganglioside antibodies in coeliac disease with neurological disorders. Dig Liver Dis 2006; 38:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/84\">",
"      Collin P, Reunala T, Rasmussen M, et al. High incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J Gastroenterol 1997; 32:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/85\">",
"      Seissler J, Schott M, Boms S, et al. Autoantibodies to human tissue transgutaminase identify silent coeliac disease in Type I diabetes. Diabetologia 1999; 42:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/86\">",
"      Damasiewicz-Bodzek A, Wielkoszy��ski T. Serologic markers of celiac disease in psoriatic patients. J Eur Acad Dermatol Venereol 2008; 22:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/87\">",
"      Abenavoli L, Proietti I, Leggio L, et al. Cutaneous manifestations in celiac disease. World J Gastroenterol 2006; 12:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/88\">",
"      Dieterich W, Laag E, Bruckner-Tuderman L, et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/89\">",
"      Lemberg D, Day AS, Bohane T. Coeliac disease presenting as dermatitis herpetiformis in infancy. J Paediatr Child Health 2005; 41:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/90\">",
"      Powell GR, Bruckner AL, Weston WL. Dermatitis herpetiformis presenting as chronic urticaria. Pediatr Dermatol 2004; 21:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/91\">",
"      Weston WL, Morelli JG, Huff JC. Misdiagnosis, treatments, and outcomes in the immunobullous diseases in children. Pediatr Dermatol 1997; 14:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/92\">",
"      Garioch JJ, Lewis HM, Sargent SA, et al. 25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/93\">",
"      Aine L, M&auml;ki M, Collin P, Keyril&auml;inen O. Dental enamel defects in celiac disease. J Oral Pathol Med 1990; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/94\">",
"      Wierink CD, van Diermen DE, Aartman IH, Heymans HS. Dental enamel defects in children with coeliac disease. Int J Paediatr Dent 2007; 17:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/95\">",
"      Priovolou CH, Vanderas AP, Papagiannoulis L. A comparative study on the prevalence of enamel defects and dental caries in children and adolescents with and without coeliac disease. Eur J Paediatr Dent 2004; 5:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/96\">",
"      Bucci P, Carile F, Sangianantoni A, et al. Oral aphthous ulcers and dental enamel defects in children with coeliac disease. Acta Paediatr 2006; 95:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/97\">",
"      Rasmusson CG, Eriksson MA. Celiac disease and mineralisation disturbances of permanent teeth. Int J Paediatr Dent 2001; 11:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/98\">",
"      Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. J Pediatr Gastroenterol Nutr 2009; 49:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/99\">",
"      Shaker JL, Brickner RC, Findling JW, et al. Hypocalcemia and skeletal disease as presenting features of celiac disease. Arch Intern Med 1997; 157:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/100\">",
"      Mustalahti K, Collin P, Siev&auml;nen H, et al. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/101\">",
"      Bottaro G, Cataldo F, Rotolo N, et al. The clinical pattern of subclinical/silent celiac disease: an analysis on 1026 consecutive cases. Am J Gastroenterol 1999; 94:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/102\">",
"      Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res 1999; 14:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/103\">",
"      Zanchi C, Di Leo G, Ronfani L, et al. Bone metabolism in celiac disease. J Pediatr 2008; 153:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/104\">",
"      Mora S, Barera G, Beccio S, et al. A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J Pediatr 2001; 139:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/105\">",
"      Mora S, Barera G, Beccio S, et al. Bone density and bone metabolism are normal after long-term gluten-free diet in young celiac patients. Am J Gastroenterol 1999; 94:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/106\">",
"      American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology 2003; 124:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/107\">",
"      Lubrano E, Ciacci C, Ames PR, et al. The arthritis of coeliac disease: prevalence and pattern in 200 adult patients. Br J Rheumatol 1996; 35:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/108\">",
"      Lepore L, Martelossi S, Pennesi M, et al. Prevalence of celiac disease in patients with juvenile chronic arthritis. J Pediatr 1996; 129:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/109\">",
"      Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/110\">",
"      Bardella MT, Fraquelli M, Quatrini M, et al. Prevalence of hypertransaminasemia in adult celiac patients and effect of gluten-free diet. Hepatology 1995; 22:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/111\">",
"      Lo Iacono O, Petta S, Venezia G, et al. Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease? Am J Gastroenterol 2005; 100:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/112\">",
"      Farre C, Esteve M, Curcoy A, et al. Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. Am J Gastroenterol 2002; 97:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/113\">",
"      Bonamico M, Pitzalis G, Culasso F, et al. [Hepatic damage in celiac disease in children]. Minerva Pediatr 1986; 38:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/114\">",
"      Ludvigsson JF, Elfstr&ouml;m P, Broom&eacute; U, et al. Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 2007; 5:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/115\">",
"      Davison S. Coeliac disease and liver dysfunction. Arch Dis Child 2002; 87:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/116\">",
"      Caprai S, Vajro P, Ventura A, et al. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. Clin Gastroenterol Hepatol 2008; 6:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/117\">",
"      Villalta D, Girolami D, Bidoli E, et al. High prevalence of celiac disease in autoimmune hepatitis detected by anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 2005; 19:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/118\">",
"      Demir H, Y&uuml;ce A, Caglar M, et al. Cirrhosis in children with celiac disease. J Clin Gastroenterol 2005; 39:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/119\">",
"      Ackerman Z, Eliakim R, Stalnikowicz R, Rachmilewitz D. Role of small bowel biopsy in the endoscopic evaluation of adults with iron deficiency anemia. Am J Gastroenterol 1996; 91:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/120\">",
"      Carroccio A, Iannitto E, Cavataio F, et al. Sideropenic anemia and celiac disease: one study, two points of view. Dig Dis Sci 1998; 43:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/121\">",
"      Volta U, De Franceschi L, Lari F, et al. Coeliac disease hidden by cryptogenic hypertransaminasaemia. Lancet 1998; 352:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/122\">",
"      Bardella MT, Vecchi M, Conte D, et al. Chronic unexplained hypertransaminasemia may be caused by occult celiac disease. Hepatology 1999; 29:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/123\">",
"      Mariani P, Mazzilli MC, Margutti G, et al. Coeliac disease, enamel defects and HLA typing. Acta Paediatr 1994; 83:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/124\">",
"      Ferguson R, Holmes GK, Cooke WT. Coeliac disease, fertility, and pregnancy. Scand J Gastroenterol 1982; 17:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/125\">",
"      Corazza GR, Di Sario A, Sacco G, et al. Subclinical coeliac disease: an anthropometric assessment. J Intern Med 1994; 236:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/126\">",
"      Collin P, Reunala T, Pukkala E, et al. Coeliac disease--associated disorders and survival. Gut 1994; 35:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/127\">",
"      Schuppan D, Hahn EG. Celiac disease and its link to type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001; 14 Suppl 1:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/128\">",
"      Acerini CL, Ahmed ML, Ross KM, et al. Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. Diabet Med 1998; 15:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/129\">",
"      Cronin CC, Feighery A, Ferriss JB, et al. High prevalence of celiac disease among patients with insulin-dependent (type I) diabetes mellitus. Am J Gastroenterol 1997; 92:2210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/130\">",
"      Talal AH, Murray JA, Goeken JA, Sivitz WI. Celiac disease in an adult population with insulin-dependent diabetes mellitus: use of endomysial antibody testing. Am J Gastroenterol 1997; 92:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/131\">",
"      Kordonouri O, Dieterich W, Schuppan D, et al. Autoantibodies to tissue transglutaminase are sensitive serological parameters for detecting silent coeliac disease in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/132\">",
"      Galli-Tsinopoulou A, Nousia-Arvanitakis S, Dracoulacos D, et al. Autoantibodies predicting diabetes mellitus type I in celiac disease. Horm Res 1999; 52:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/133\">",
"      Meddings JB, Jarand J, Urbanski SJ, et al. Increased gastrointestinal permeability is an early lesion in the spontaneously diabetic BB rat. Am J Physiol 1999; 276:G951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/134\">",
"      Funda DP, Kaas A, Bock T, et al. Gluten-free diet prevents diabetes in NOD mice. Diabetes Metab Res Rev 1999; 15:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/135\">",
"      Ventura A, Magazz&ugrave; G, Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in Celiac Disease. Gastroenterology 1999; 117:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/136\">",
"      Saukkonen T, Savilahti E, Reijonen H, et al. Coeliac disease: frequent occurrence after clinical onset of insulin-dependent diabetes mellitus. Childhood Diabetes in Finland Study Group. Diabet Med 1996; 13:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/137\">",
"      Westman E, Ambler GR, Royle M, et al. Children with coeliac disease and insulin dependent diabetes mellitus--growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999; 12:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/138\">",
"      Simmons JH, Klingensmith GJ, McFann K, et al. Celiac autoimmunity in children with type 1 diabetes: a two-year follow-up. J Pediatr 2011; 158:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/139\">",
"      Ch'ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin Med Res 2007; 5:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/140\">",
"      Sattar N, Lazare F, Kacer M, et al. Celiac disease in children, adolescents, and young adults with autoimmune thyroid disease. J Pediatr 2011; 158:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/141\">",
"      Cassio A, Ricci G, Baronio F, et al. Long-term clinical significance of thyroid autoimmunity in children with celiac disease. J Pediatr 2010; 156:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/142\">",
"      Richey R, Howdle P, Shaw E, et al. Recognition and assessment of coeliac disease in children and adults: summary of NICE guidance. BMJ 2009; 338:b1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/143\">",
"      Simmons JH, Klingensmith GJ, McFann K, et al. Impact of celiac autoimmunity on children with type 1 diabetes. J Pediatr 2007; 150:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/144\">",
"      Crowe SE. In the clinic. Celiac disease. Ann Intern Med 2011; 154:ITC5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/145\">",
"      Csizmadia CG, Mearin ML, Oren A, et al. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr 2000; 137:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/146\">",
"      Troncone R, Maurano F, Rossi M, et al. IgA antibodies to tissue transglutaminase: An effective diagnostic test for celiac disease. J Pediatr 1999; 134:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/147\">",
"      Basso D, Guariso G, Fasolo M, et al. A new indirect chemiluminescent immunoassay to measure anti-tissue transglutaminase antibodies. J Pediatr Gastroenterol Nutr 2006; 43:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/148\">",
"      Maglio M, Tosco A, Paparo F, et al. Serum and intestinal celiac disease-associated antibodies in children with celiac disease younger than 2 years of age. J Pediatr Gastroenterol Nutr 2010; 50:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/149\">",
"      Panetta F, Torre G, Colistro F, et al. Clinical accuracy of anti-tissue transglutaminase as screening test for celiac disease under 2 years. Acta Paediatr 2011; 100:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/150\">",
"      Korponay-Szab&oacute; IR, Szabados K, Pusztai J, et al. Population screening for coeliac disease in primary care by district nurses using a rapid antibody test: diagnostic accuracy and feasibility study. BMJ 2007; 335:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/151\">",
"      Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology 2005; 128:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/152\">",
"      Richter T, Bossuyt X, Vermeersch P, et al. Determination of IgG and IgA antibodies against native gliadin is not helpful for the diagnosis of coeliac disease in children up to 2 years old. J Pediatr Gastroenterol Nutr 2012; 55:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/153\">",
"      Prause C, Ritter M, Probst C, et al. Antibodies against deamidated gliadin as new and accurate biomarkers of childhood coeliac disease. J Pediatr Gastroenterol Nutr 2009; 49:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/154\">",
"      Vermeersch P, Geboes K, Mari&euml;n G, et al. Diagnostic performance of IgG anti-deamidated gliadin peptide antibody assays is comparable to IgA anti-tTG in celiac disease. Clin Chim Acta 2010; 411:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/155\">",
"      Rashtak S, Ettore MW, Homburger HA, Murray JA. Comparative usefulness of deamidated gliadin antibodies in the diagnosis of celiac disease. Clin Gastroenterol Hepatol 2008; 6:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/156\">",
"      Ghedira I, Sghiri R, Ayadi A, et al. [Anti-endomysium, anti-reticulin and anti-gliadin antibodies, value in the diagnosis of celiac disease in the child]. Pathol Biol (Paris) 2001; 49:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/157\">",
"      Mubarak A, Gmelig-Meyling FH, Wolters VM, et al. Immunoglobulin G antibodies against deamidated-gliadin-peptides outperform anti-endomysium and tissue transglutaminase antibodies in children &lt;2 years age. APMIS 2011; 119:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/158\">",
"      Barbato M, Maiella G, Di Camillo C, et al. The anti-deamidated gliadin peptide antibodies unmask celiac disease in small children with chronic diarrhoea. Dig Liver Dis 2011; 43:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/159\">",
"      Bonamico M, Mariani P, Thanasi E, et al. Patchy villous atrophy of the duodenum in childhood celiac disease. J Pediatr Gastroenterol Nutr 2004; 38:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/160\">",
"      Vogelsang H, H&auml;nel S, Steiner B, Oberhuber G. Diagnostic duodenal bulb biopsy in celiac disease. Endoscopy 2001; 33:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/161\">",
"      Bonamico M, Thanasi E, Mariani P, et al. Duodenal bulb biopsies in celiac disease: a multicenter study. J Pediatr Gastroenterol Nutr 2008; 47:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/162\">",
"      Levinson-Castiel R, Hartman C, Morgenstern S, et al. The role of duodenal bulb biopsy in the diagnosis of celiac disease in children. J Clin Gastroenterol 2011; 45:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/163\">",
"      Mubarak A, Wolters VM, Gerritsen SA, et al. A biopsy is not always necessary to diagnose celiac disease. J Pediatr Gastroenterol Nutr 2011; 52:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/164\">",
"      Kurppa K, Salminiemi J, Ukkola A, et al. Utility of the new ESPGHAN criteria for the diagnosis of celiac disease in at-risk groups. J Pediatr Gastroenterol Nutr 2012; 54:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/165\">",
"      Kurppa K, Ashorn M, Iltanen S, et al. Celiac disease without villous atrophy in children: a prospective study. J Pediatr 2010; 157:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/3/37946/abstract/166\">",
"      Tosco A, Salvati VM, Auricchio R, et al. Natural history of potential celiac disease in children. Clin Gastroenterol Hepatol 2011; 9:320.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5899 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37946=[""].join("\n");
var outline_f37_3_37946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6912852\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Infant feeding practices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Classic celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Atypical celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Silent/subclinical celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Latent celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27351026\">",
"      Potential celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      General population",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      High-risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Nongastrointestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Growth and development",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Neurologic disease and behavioral symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dental enamel defects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Metabolic bone disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Liver disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Subclinical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ASSOCIATED CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Autoimmune thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Whom to test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      How to test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15390478\">",
"      - Antibody testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15390455\">",
"      - Intestinal biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Whom to treat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6912852\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5899|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/17/30994\" title=\"figure 1\">",
"      Intestinal lesions celiac",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5899|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/30/24041\" title=\"picture 1\">",
"      Celiac disease Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?30/2/30753\" title=\"picture 2A\">",
"      Dermatitis herpetiformis AGA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/62/39905\" title=\"picture 2B\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/23/28031\" title=\"picture 3\">",
"      Dental enamel defects in a child with celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5899|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/31/22011\" title=\"table 1\">",
"      Celiac screening in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/53/42844\" title=\"table 2\">",
"      Prevalence of celiac disease in special populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/6/25707\" title=\"table 3\">",
"      NonGI sympt celiac",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/19/3387\" title=\"table 4\">",
"      Skin disorders associated with celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/38/41579\" title=\"table 5\">",
"      Oligosymptomatic celiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/38/23148\" title=\"table 6\">",
"      Antibody tests celiac",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/43/31414?source=related_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/38/4714?source=related_link\">",
"      Management of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7929?source=related_link\">",
"      Management of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/14/11492?source=related_link\">",
"      Patient information: Celiac disease in children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_3_37947="Percent pregnancy loss by maternal age at conception";
var content_f37_3_37947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70032&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Percent pregnancy loss by maternal age at conception",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Maternal age",
"      </td>",
"      <td class=\"subtitle1\">",
"       Spontaneous abortions (percentage)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ectopic pregnancies (percentage)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Stillbirths rate/1000",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       12-19",
"      </td>",
"      <td>",
"       13.3",
"      </td>",
"      <td>",
"       2.0",
"      </td>",
"      <td>",
"       5.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       20-24",
"      </td>",
"      <td>",
"       11.1",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"      <td>",
"       4.2",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25-29",
"      </td>",
"      <td>",
"       11.9",
"      </td>",
"      <td>",
"       1.6",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30-34",
"      </td>",
"      <td>",
"       15.0",
"      </td>",
"      <td>",
"       2.8",
"      </td>",
"      <td>",
"       4.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35-39",
"      </td>",
"      <td>",
"       24.6",
"      </td>",
"      <td>",
"       4.0",
"      </td>",
"      <td>",
"       5.0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40-44",
"      </td>",
"      <td>",
"       51.0",
"      </td>",
"      <td>",
"       5.8",
"      </td>",
"      <td>",
"       6.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &gt;=45",
"      </td>",
"      <td>",
"       93.4",
"      </td>",
"      <td>",
"       7.0",
"      </td>",
"      <td>",
"       8.2",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Anderson et al. Figures 2,4,5. The total spontaneous abortion rate is estimated using the assumption that only 80 percent of women with abortions in recognized pregnancies were hospitalized. Adapted from: Anderson FWJ, Johnson TRB. Maternal mortality at Y2K. Postgraduate Obstetrics and Gynecology 2000; 20:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37947=[""].join("\n");
var outline_f37_3_37947=null;
var title_f37_3_37948="Asthma adherence II";
var content_f37_3_37948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Identifying problems in taking medicines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\" colspan=\"3\" rowspan=\"1\">",
"        During the week, did you miss or were you late in taking your medicine because:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        1. You felt good and decided you didn't need your medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        2. You felt good and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        3. You were involved in an activity and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        4. You were interrupted and forgot.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        5. There was a planned change in your normal routine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        6. There was some unexpected change in your normal routine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        7. Your medicine caused you to be sick (side effects).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        8. You ran out of medicine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        9. You felt the medicine may not work as well if you used it too much.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        10. You felt that the medicine wasn't working.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        11. It was inconvenient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\" rowspan=\"1\">",
"        12. You were confused about what medicine you should take.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often",
"       </td>",
"       <td>",
"        Sometimes",
"       </td>",
"       <td>",
"        Never",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        Look back over your week's records and your answers to the questions above. Use this information to identify the problems you have most often in taking medicine as prescribed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37948=[""].join("\n");
var outline_f37_3_37948=null;
var title_f37_3_37949="Medications for narcolepsy";
var content_f37_3_37949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73910&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs used in the treatment of narcolepsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common side effects",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serious side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Excessive daytime sleepiness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methylphenidate",
"       </td>",
"       <td>",
"        10 to 30 mg twice per day",
"        <strong>",
"         or",
"        </strong>",
"        20 mg sustained-release every morning with 10 to 20 mg every afternoon",
"       </td>",
"       <td>",
"        Reduced appetite, nausea, headache, insomnia",
"       </td>",
"       <td>",
"        Abuse potential, psychosis, mania, seizures, cardiovascular effects*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dextroamphetamine",
"       </td>",
"       <td>",
"        5 to 30 mg twice per day",
"        <strong>",
"         or",
"        </strong>",
"        10 mg sustained-release every morning with 10 to 20 mg every afternoon",
"       </td>",
"       <td>",
"        Reduced appetite, nausea, headache, insomnia",
"       </td>",
"       <td>",
"        High abuse potential, psychosis, mania, seizures, cardiovascular effects*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amphetamine-dextroamphetamine",
"       </td>",
"       <td>",
"        10&nbsp;to 30 mg twice per day",
"        <strong>",
"         or",
"        </strong>",
"        20 mg sustained-release twice per day",
"       </td>",
"       <td>",
"        Reduced appetite, nausea, headache, insomnia",
"       </td>",
"       <td>",
"        High abuse potential, psychosis, mania, seizures, cardiovascular effects*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Modafinil",
"       </td>",
"       <td>",
"        100 to 400 mg every morning",
"        <strong>",
"         or",
"        </strong>",
"        200 mg twice per day",
"       </td>",
"       <td>",
"        Headache, nervousness, nausea, insomnia",
"       </td>",
"       <td>",
"        Severe rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Armodafinil",
"       </td>",
"       <td>",
"        150 to 250 mg every morning",
"        <strong>",
"         or",
"        </strong>",
"        125 mg (half of 250 mg tablet) twice per day",
"       </td>",
"       <td>",
"        Headache, nervousness, nausea, insomnia",
"       </td>",
"       <td>",
"        Severe rash",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium oxybate (gamma hydroxybutyrate)&nbsp;",
"       </td>",
"       <td>",
"        2.5 to 4.5 grams at bedtime",
"        <strong>",
"         and",
"        </strong>",
"        repeated 3 to 4 hours later",
"       </td>",
"       <td>",
"        Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking",
"       </td>",
"       <td>",
"        Abuse potential, confusion, severe&nbsp;sedation, coma^&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cataplexy",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine",
"       </td>",
"       <td>",
"        37.5 to 75 mg twice per day",
"        <strong>",
"         or",
"        </strong>",
"        37.5 to 150 mg extended release every morning",
"       </td>",
"       <td>",
"        Transient nausea, headache, insomnia, increase in blood-pressure when given in higher doses",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine",
"       </td>",
"       <td>",
"        20 to 80 mg every morning",
"       </td>",
"       <td>",
"        Nausea, dry mouth, insomnia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clomipramine",
"       </td>",
"       <td>",
"        10 to 150 mg as a single dose every morning or in divided doses",
"       </td>",
"       <td>",
"        Dry mouth, constipation, sweating, dizziness, somnolence, weight gain, orthostatic hypotension",
"       </td>",
"       <td>",
"        Cardiotoxicity, seizures, dangerous in overdose",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protriptyline",
"       </td>",
"       <td>",
"        5 to 60 mg as a single dose every morning or in divided doses",
"       </td>",
"       <td>",
"        Dry mouth, constipation, sweating, anxiety, disturbed nighttime sleep, orthostatic hypotension",
"       </td>",
"       <td>",
"        Cardiotoxicity, seizures, dangerous in overdose",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium oxybate (gamma hydroxybutyrate)",
"       </td>",
"       <td>",
"        2.5 to 4.5 grams at bedtime",
"        <strong>",
"         and",
"        </strong>",
"        repeated 3 to 4 hours later",
"       </td>",
"       <td>",
"        Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking",
"       </td>",
"       <td>",
"        Abuse potential, confusion, severe sedation, coma^",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Disrupted nighttime sleep",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zolpidem",
"       </td>",
"       <td>",
"        5 to 10 mg at bedtime",
"       </td>",
"       <td>",
"        Morning sedation, dizziness",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sodium oxybate (gamma hydroxybutyrate)",
"       </td>",
"       <td>",
"        2.5 to 4.5 grams at bedtime",
"        <strong>",
"         and",
"        </strong>",
"        repeated 3 to 4 hours later",
"       </td>",
"       <td>",
"        Morning sedation, nausea, dizziness, urinary incontinence, sleepwalking",
"       </td>",
"       <td>",
"        Abuse potential, confusion, severe sedation, coma^",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * See section on Adverse effects in UpToDate topic: Attention deficit hyperactivity disorder in children and adolescents: Pharmacotherapy.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Anti-cataplexy medications are also useful for problematic sleep paralysis or hypnagogic hallucinations.",
"      <br>",
"       &Delta; See section on Side effects in UpToDate topic: Tricyclic and tetracyclic drugs for treating depressed adults.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Some sleep disruption in narcolepsy may be caused by additional sleep disorders that require specific treatment (examples include obstructive sleep apnea or periodic limb movements of sleep).",
"        <br>",
"         ^ Combined use with alcohol, sedatives, or hypnotics is specifically contraindicated in US licensing information.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and expanded from: Scammell TE. The Neurobiology, diagnosis, and treatment of Narcolepsy. Ann Neurol 2003; 53:154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37949=[""].join("\n");
var outline_f37_3_37949=null;
var title_f37_3_37950="Mitochondrial inheritance--pedigree";
var content_f37_3_37950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73424&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Example of a pedigree showing mitochondrial inheritance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This pedigree illustrates a mitochondrial inheritance pattern. All children of affected mothers who are homoplasmic for a mitochondrial gene mutation&nbsp;are affected. Affected males do not pass the affected status to their&nbsp;descendants.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37950=[""].join("\n");
var outline_f37_3_37950=null;
var title_f37_3_37951="Mesh nebulizers";
var content_f37_3_37951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesh nebulizers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 232px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mesh nebulizers generate fine mists with more efficient drug delivery and minimal residual medication volume compared with conventional nebulizers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_3_37951=[""].join("\n");
var outline_f37_3_37951=null;
